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Abstract 
 
Disulfide bonds represent an important target for site-selective protein modification, 
particularly via the strategy of functional re-bridging. Reduction of interchain disulfide bonds, 
followed by their re-bridging allows proteins to be functionalised in a site-selective manner 
whilst retaining the stability and integrity offered by the original bridge. This work describes 
the design and development of two distinct pyridazinedione-based technologies that, through 
the conduit of functional disulfide re-bridging, enable the synthesis of antibody – drug 
conjugates with hitherto unmet levels of control and homogeneity.  
 
As proteins often contain multiple disulfide bonds that are critical to conformation and 
stability, reagents that allow functional disulfide re-bridging without disulfide scrambling 
(non-native disulfide re-bridging) in multiple disulfide containing systems are critical for the 
success of this method. The first presented technology is a molecule that is capable of both 
reducing and re-bridging disulfide bonds, enabling a rapid and efficient one-reagent protocol 
for the functionalisation of disulfide containing proteins, moreover, it does so in such a way 
that native disulfide configuration is retained via a high local concentration effect. This novel 
pyridazinedione scaffold has been shown to functionalise a variety of therapeutically relevant 
proteins, including the widely used mAb Herceptin™, enabling the synthesis of homogenous 
antibody – drug conjugates from a native mAb. 
 
Shifting focus from homogeneity to control over drug loading, the second presented 
technology is a single pyridazinedione-based molecule that contains four cysteine reactive 
centres and only one bioorthogonal reactive handle, which enables the generation of antibody 
conjugates with a loading of two modules. A loading of two is desirable for many reasons, 
especially in the context of large, hydrophobic payloads, which are increasingly popular for 
use in antibody-drug conjugates. A loading of two drugs per antibody has been shown to 
provide an optimal balance between efficacy and biophysical properties in many cases. A 
reliable method based on a native antibody scaffold without the use of enzymes or harsh 
oxidative conditions has hitherto not been achieved. The use of native antibodies has several 
advantages in terms of cost, practicality, accessibility and time. Thus, a novel, reliable method 
of furnishing antibody conjugates with a loading of two modules starting from a native 
antibody scaffold was developed. 
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Chapter 1: Introduction 
 
Proteins have some of the most dynamic and diverse roles of any macromolecule 
in biology. For instance, they facilitate complex biochemical pathways and 
reactions, transport molecules throughout systems and can act as receptors 
within a cell membrane.1 The human genome consists of 25,000 – 30,000 genes, 
however, due to alternative splicing and post-translational modifications (PTMs) 
the human proteome is much more complex; consisting of over 1,000,000 
proteins.1-4 Whilst proteins already boast a huge array of functions, chemical 
biologists seek to understand their function in greater detail and/or increase their 
versatility, through the conduit of protein modification. Through manipulating 
proteins, powerful new tools can be created for a variety of different purposes.5 
For example, to probe biological systems with a previously unattainable level of 
detail, to construct tools for advanced biosynthesis and for designing novel 
therapies for use against diseases.5, 6 
 
As proteins innately have, or are designed to have, unique and highly specific 
interactions with biological systems, they represent versatile platforms for 
creating novel therapeutics. To date, bioconjugates have been used successfully to 
treat many serious and life-threatening indications, including HIV,7 malaria8 and 
cancer.9 Furthermore, bioconjugates have seen use as diagnostic tools.10 
 
Protein modification, through various synthetic and biological strategies, is a well-
established field of research.11-14 However, selectively modifying proteins at a 
specific site remains a significant challenge. Proteins often consist of hundreds of 
amino acids, each of which potentially carry a reactive side chain. This means that 
any reactions required to achieve selective modification at a particular residue 
(this may be a natural or unnatural residue) must be capable of proceeding 
chemoselectively, i.e. in the presence of numerous other functional groups (e.g. 
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amines, carboxylic acids, thiols and alcohols), and regioselectively, i.e. in the 
presence of other competing residues of the same type. 
 
The use of synthetic methodologies to achieve site-selective protein modification 
on amino acids within a protein’s sequence has garnered much attention and the 
field has advanced rapidly over the years. A large number of distinct strategies 
have been developed, which can generally be categorised as (i) modification of 
unnatural amino acids; and (ii) modification of natural amino acids; each general 
category presents its own set of unique benefits and challenges. 
 
1.1 Chemical modification of proteins 
 
1.1.1 Unnatural amino acids 
 
Unnatural amino acids (UAAs) are powerful tools in the field of site-selective 
protein modification owing to their ability to grant unique bioorthogonal reactive 
handles directly into a protein’s peptidic backbone. The range of possible 
bioorthogonal handles available can include, but is not limited to, arylhalide, 
alkene, alkyne, tetrazene and azide functional groups (Figure 1). Furthermore, 
such handles can be installed with a high degree of accuracy at a specific point 
within a protein’s sequence using site-directed mutagenesis.15-17 The term 
bioorthogonal, initially coined by Bertozzi in 2004, denotes any kind of chemical 
reaction that can proceed within biological systems without interfering with 
native biochemical pathways.18 
 
Figure 1 Examples of UAAs featuring a range of bioorthogonal reaction handles; 
(from left to right) alkene, alkyne, arylhalide, arylazide and tetrazene. 
3 
 
Once installed, UAAs can undergo further chemical modification in a regio- and 
chemoselective manner though various synthetic processes such as palladium 
catalysed cross couplings,19 metatheses,20 copper-catalysed and copper-free 
azide-alkyne Huisgen cycloadditions (Scheme 1).21 Bernardes, Davis and co-
workers have demonstrated that these techniques can work successfully on a 
diverse portfolio of proteins to create many different diagnostic and therapeutic 
bioconjugates. However, the production of UAA containing proteins can be 
prohibitively expensive and presently remains highly challenging for large scale 
production of bioconjugates. This is due, in part, to the required optimisation of 
cell culture conditions and intricate mutagenesis techniques; the processes are 
specific to given targets.22, 23 These issues have been somewhat mitigated by Chin 
et al. in recent years by improving the efficiency and yields of mutagenesis 
techniques.24, 25 Specifically, by improving response to the amber stop codon, UAA-
bearing proteins were synthesised at previously unattainable yields.26 However, 
these strategies are still protein specific and, therefore, lack broad applicability. 
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Scheme 1 The construction of proteins containing bioorthogonal handles is 
made possible through the incorporation UAAs via site-directed mutagenesis. 
Handles such as alkynes, halides and tetrazene have been incorporated 
facilitating further bioorthogonal chemical modification.  
 
1.1.2 Naturally occurring amino acids 
  
Targeting of natural occurring amino acids (NAAs) involves taking advantage of 
the differential reactivity of a functional handle present on one of the 22 
proteinogenic amino acids (Figure 2). While this method limits the scope of 
bioorthogonal reactions that can be performed directly on the protein, there is an 
abundance of strategies that can still enable site-selective modification.27 As with 
UAAs, NAAs can be incorporated into proteins using site-directed mutagenesis to 
provide convenient handles for further chemical modification. However, 
incorporation of NAAs via site-directed mutagenesis is less challenging; i.e. the 
codons for NAAs already exist and so optimisation of cell culture conditions is less 
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complicated. The degree of selectivity offered by this method is thus reliant on the 
reactivity and natural abundance of the NAA that is being introduced, i.e. only the 
amino acid that is being introduced will be available for reaction as it is the only 
amino acid of that type being introduced or it is the only amino acid of that type 
that is available for bioconjugation (other residues of the same type may be buried 
in the protein structure and, therefore, not accessible). Moreover, the modification 
of NAAs offers a facile strategy for the modification of native proteins.   
 
The two NAAs that are most frequently targeted for bioconjugation are lysine and 
cysteine, on account of their high nucleophilicity under physiological conditions. 
Tyrosine and tryptophan can also be targeted but are typically less accessible due 
to often being buried within the hydrophobic interiors of proteins.28-30 
 
Figure 2 Some of the NAAs that serve as potential targets for protein 
modification; lysine and cysteine are the most common choices due their high 
nucleophilicity. Left to right: cysteine, serine, lysine; histidine, tyrosine and 
tryptophan. 
 
1.1.2.1 Lysine modification 
 
Lysine is a common choice for protein modification; the primary alkyl amine side 
chain is a functional group with high nucleophilicity.31 The relatively high natural 
abundance of lysine residues on proteins often also nullifies the need for 
incorporation of extra lysine residues.32, 33 The majority of Food and Drug 
Administration (FDA) approved bioconjugates have been synthesised using lysine 
modification strategies, most commonly through the use of amine-reactive 
succinimidyl esters.31 Lysine’s high natural abundance and high nucleophilicity 
make it well suited for instances when site-selectivity is not required.32,33  
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Under physiological conditions lysine has been shown to form irreversible amide 
linkages with N-hydroxysuccinimide (NHS) esters with no exogenous reagents. 
Moreover, lysine has been shown to react in good yields with isothiocyanates or 
isocyanates at higher pH (9.0-9.5). There is a plethora of strategies available for 
modification of lysines on the surface of proteins using a variety of reagents under 
a broad range of conditions (Scheme 2).34-37 
 
Scheme 2 Main reactions for the primary alkyl amine side chain of lysine. 
 
An early example of lysine modification was demonstrated by Tuls et al. through 
conjugation of a fluorescein isothiocyanate (FITC) to an oxidative cytochrome 
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P-450 enzyme.34 The isothiocyanate motif reacted readily with the primary amine 
side chain under basic pH to create a stable thiourea linkage. Interestingly, the 
authors found the modification took place at a specific lysine in the active site of 
the protein, reflected by a sharp loss in binding with adrenodoxin.34 More recently, 
reductive amination, a common strategy for installation of secondary amines, has 
seen use in the context of lysine modification. Gildersleeve et al. demonstrate the 
use of reductive amination to install a series of oligosaccharides onto bovine 
serum albumin (BSA).36 The technique serves as an especially convenient method 
for conjugation of sugars to lysine owing to the natural occurrence of the 
saccharide aldehyde groups, therefore mitigating any chemical preparation of 
either protein of conjugating reagent. Another example of lysine modification, that 
is currently applied in modern medicine, can be found in the synthesis of FDA 
approved drug Kadcyla™ (trastuzumab emtansine); an anti-HER2 monoclonal 
antibody, Herceptin™ (trastuzumab), linked to the microtubule assembly 
inhibiting drug maitansine (DM1) via lysine residues (Scheme 3).38 Surface lysines 
on the antibody react preferentially with an NHS ester on a succinimidyl-4-(N-
maleimidomethyl)cyclohexane-1-carboxylate linker leaving an exposed 
maleimide, through which the thiol-bearing DM1 drug is attached. The result of 
this modification method is a heterogeneous mixture of products with up to 106 
distinct species when targeting averaged drug-to-antibody ratio (DAR) of 3.0-
3.6.38 This is a direct consequence of there being 88 lysines on trastuzumab, 40 of 
which are solvent accessible for modification.39 
 
 
Scheme 3 The synthesis of FDA-approved ADC Kadcyla™ is achieved through 
reaction of surface lysine residues on native Herceptin™ via an NHS-ester 
bearing linker with the highly potent tubulin inhibitor emtansine. 
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It is a combination of lysine’s high natural abundance and frequent appearance on 
the solvent-accessible surface of proteins that gives rise to heterogeneous product 
generation, making the technique suboptimal for some applications.33, 40 
Furthermore, solvent-exposed lysines are present on the surface of almost all 
proteins in addition to exposed N-termini. Varied batch-to-batch product 
distribution can be particularly problematic in the production of bioconjugate 
therapeutics and imaging agents as it can lead to broad pharmokinetic profiles; 
resulting in a narrow therapeutic window.41, 42 Moreover, excessive lysine 
modification can result in a loss in solubility and rapid blood clearance rates when 
used to make therapeutics.43, 44 This is primarily due to exchange of the 
solubilising protonated ammonium of the lysine side chain for neutral moieties, 
resulting in a loss of polar surface area. Furthermore, the presence of lysines in 
key areas of proteins, for example in the complementarity determining region of 
antibodies, is not uncommon and, if modified can lead to significant decreases in 
binding affinity and, therefore, a potential loss in efficacy.45 Moreover, reactions 
at lysine residues often require very stringent control of pH or other conditions to 
slow the rate of reaction to ensure modification of only the most reactive lysine 
takes place.46, 47 It is in light of these factors that cysteine makes the most 
promising candidate for NAA modification. 
 
1.1.2.2 Cysteine modification 
 
Cysteine makes an attractive target for modification of NAAs; the highly reactive 
thiolate side chain under basic pH reaction conditions (i.e. generally far more 
reactive than lysine or other nucleophilic side-chains under analogous conditions) 
allows for rapid reaction in a chemoselective manner with various conjugating 
agents.48 This chemoselectivity is further increased due to the thiolate side chain 
being a ‘soft’ nucleophile; this means it has lower charge density than other 
nucleophiles, leading it to preferentially form more thermodynamically stable 
products. Moreover, free cysteine residues occur at only 0.2% abundance. Whilst 
total cysteine abundance is at 1.7% in the human proteome, the majority of 
cysteine residues exist in their oxidised form; disulfide bridges, which provide 
covalent support to a protein’s tertiary structure and assists in preserving them 
in a given conformation.49, 50 Cysteine modification has seen significant 
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development over the years having been shown to enable the synthesis of novel 
bioconjugates,51-54 label proteins,55 probe biochemical pathways and obtain 
structural information.56-60 Furthermore, there are now a wide range of 
commercially available reagents for cysteine modification from large suppliers, in 
addition to new reagents being developed by academic groups. There are several 
main methods that are applied for cysteine modification including; alkylation, 
disulfide formation and oxidation (Scheme 4).  
 
Site-selective reaction with cysteine is often achieved by incorporation of a single 
reactive cysteine into the protein structure at a solvent accessible site via site-
directed mutagenesis followed by chemoselective bioconjugation. Due to the 
extreme rarity of free cysteine occurring in native proteins and its differential 
reactivity, through inclusion into a protein’s sequence, a single cysteine can offer 
excellent selectivity. 
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Scheme 4 There is an abundance of possible reactions and transformations that 
can be performed on cysteine residues that either occur in a protein’s native 
sequence or are inserted via mutagenesis.13, 49, 61-63 
 
Davis et al. describe several strategies for the in situ conversion of single free 
cysteines into the alkene-bearing amino acid, dehydroalanine, which can then be 
functionalised further by nucleophilic addition. This has been performed on a 
range of single cysteine containing proteins, both engineered and native.13, 49, 61 
This is an example of the general strategy that was coined as the ‘tag and modify’ 
approach; where an amino acid ‘tag’, either natural or unnatural, is converted in 
situ into a reactive handle followed by a highly selective functionalisation. 
 
One of the most common classes of reagents used for alkylation of cysteines are 
maleimides. As good Michael acceptors, maleimides can react selectively and 
rapidly with cysteine thiols to form succinimide adducts, because of this feature 
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there are now many commercially available chemical probes with maleimide 
handles from leading suppliers (e.g. Sigma Aldrich). Further to this, 
bromomaleimides have been developed that react at comparable speeds, where 
the resulting thioether bond is reversible under certain conditions (vide infra, 
section 1.2.2).62 More recently, a novel class of pyridazinediones (PDs) have been 
developed by Chudasama et al. that can feature two thiol-reactive centres and two 
N-linked handles.63 Furthermore, they have shown exquisite selectivity for 
cysteine modification over lysine (vide infra, section 1.2.3).63 
 
The majority of cysteine residues found in the sequences of native proteins exist 
in their oxidised format (Scheme 5); a pair of cysteines forming a disulfide bridge. 
Considering the high thiol reactivity and their higher abundance,64 once reduced, 
they offer promising targets for site-selective modification of native proteins. 
 
 
Scheme 5 Cysteine has relatively low natural abundance; 1.7% total abundance; 
0.2% as free cysteine and 1.5% as the oxidised disulfide bond. 
 
1.2 Disulfide modification 
 
Disulfide bonds can be critical in providing structural integrity and 
conformational stability for a protein’s tertiary structure and, as a result, its 
biological activity. Many proteins contain disulfide bridges either buried within 
the protein’s hydrophobic interior (i.e. inaccessible for modification without 
denaturement) or on their solvent-accessible surface. As most proteins, including 
many therapeutically relevant ones, possess at least one solvent-accessible 
disulfide bridge they represent promising targets for site-selective 
modification.65-68  
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One of the more prominent examples of disulfide modification can be found in the 
synthesis of the FDA-approved antibody-drug conjugate (ADC), Adcetris™ 
(brentuximab vedotin) (Scheme 6). Reduction of disulfide bridges and subsequent 
conjugation of the liberated cysteines enabled conjugation of an anti-CD-30 
monoclonal antibody (brentuximab) to the highly cytotoxic drug 
monomethylauristatin E (MMAE).69 This method of inter-chain disulfide 
reduction and conjugation can give rise to a homogenous product if all the 
liberated thiols are reacted analogously, i.e. giving eight attachments per the 
antibody as brentuximab comprises four inter-chain disulfide bridges.70 However, 
when targeting typical DARs of 4 (as in the case of Adcetris™), a heterogeneous, 
statistical mixture of products is obtained. Whilst reduction of disulfide bonds did 
not lead to a significant change in the protein’s structure and conformation in this 
case, the antibody was less stable in vivo and no longer had antibody dependent 
cellular cytotoxicity (ADCC) associated with it, demonstrating the significance of 
the structural integrity and conformational support offered by disulfide bridges.71 
 
 
Scheme 6 Synthesis of FDA-approved ADC Adcetris™ is achieved through 
reduction of inter-chain disulfide bonds followed by conjugation to a maleimide 
linked drug (MMAE) giving an average DAR of 4.0 followed by careful re-
oxidation of remaining non-conjugated thiols. 
 
1.2.1 Functional disulfide re-bridging 
 
The issues associated with disulfide reduction, i.e. change in conformation/loss of 
activity can be somewhat mitigated through a technique known as functional 
disulfide re-bridging. The technique involves the reduction of accessible disulfide 
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bridges, followed by introduction of a linker, bearing either a chemical probe or 
functional handle (to enable further modification) that will restore the connection. 
This simultaneously results in the functionalisation of the protein whilst restoring 
the structural and conformational stability offered by the original covalent 
bridge.72 Over the past 10 years, since its inception by Brocchini et al.,68, 73 the 
strategy has seen significant development and has been successfully applied to 
many different disulfide bearing targets, often with significant therapeutic 
relevance.66, 67, 72, 74-76 
 
Scheme 7 Functional disulfide re-bridging enables functionalisation of proteins 
whilst retaining the structural stability offered by the native bridges; as such 
many strategies have been developed. 
   
The seminal work in the field of functional disulfide re-bridging was carried out 
by Brocchini et al. in 2006, in which an interferon α-2b was conjugated to a 
polyethylene glycol (PEG) chain.68 An enone-sulfonyl compound was synthesised 
that underwent in situ elimination to form a reactive species that reacts with a free 
thiol via a conjugate addition and elimination reaction. When applied to a reduced 
disulfide bond a second conjugate addition reaction with the other free thiol can 
take place, thereby re-connecting the cysteines with a three-carbon bridge 
(Scheme 8). This demonstrated the utility of functional disulfide re-bridging; the 
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native protein had been successfully site-selectively modified and in such a way 
that tertiary structure and biological activity were retained.68 
 
 
Scheme 8 Introduction of reduced disulfides to enone-sulfonyl reagent by 
Brocchini et al. resulted in first example of functional disulfide re-bridging.68 The 
reactive enone species is generated in situ followed by two conjugate additions. 
 
More recently, a photochemically driven thiol-yne reaction has been reported by 
Griebenow et al., which, similar to Brocchini’s strategy, leaves a saturated carbon 
bridge; in this case two carbons.77 Following reduction, a disulfide-bearing 
peptide was incubated with a commercially available alkyl alkyne with radical 
initiator lithium phenyl-2,4-6-trimethylphosphinate and irradiated with UV light 
(365 nm). This strategy results in a stable re-bridged peptide construct, however, 
the yield for this reaction was 3% and substitution for more strained alkynes saw 
improvement to only 22% in the best case.77 
 
1.2.2 Di-substituted maleimides 
 
Previous work in the Baker, Chudasama and Caddick groups has demonstrated 
functional disulfide re-bridging on a wide variety of disulfide containing peptides 
and large proteins using N-functionalised dibromomaleimides.65, 67 Unlike 
classical maleimides, once it has reacted with a thiol in its 3- or 4-position, a 
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dibromomaleimide retains the double bond due to the addition-elimination 
mechanism afforded by the presence of leaving groups (Scheme 9). This is as 
opposed to the 1,4-conjugate addition observed with a non-substituted 
maleimide. Through having two thiol-reactive centres and a versatile handle on 
the nitrogen, dibromomaleimides enable the formation of bis-thioether linked 
bioconjugates. Schumacher et al. initially demonstrated this class of molecule’s 
utility by increasing the in vivo stability of the peptide hormone somatostatin 
through PEGylation (attachment of a polyethylene glycol chain);78 the non-toxic, 
non-immunogenic and highly soluble polymer often sees use in drug delivery, 
owing to the fact it can improve resistance to enzymatic metabolism and decrease 
protein immunogenicity.46 A stepwise protocol was employed where the first step 
involved using tris(2-carboxyethyl)phosphine (TCEP) to reduce the disulfide 
bridge between the Cys3 and Cys14 residues; TCEP is a mild alkyl-phosphine 
reducing agent. The excess TCEP is then removed by ultrafiltration and the newly 
liberated thiols from the disulfide bond then undergo two addition-elimination 
reactions to freshly added N-PEG dibromomaleimide, which re-bridge across the 
two cysteines. This method allowed efficient and selective conjugation of a PEG 
chain to somatostatin; increasing its in vivo stability, without affecting its 
biological activity or conformation.15  
 
Scheme 9 3,4-Disubstituted maleimides enable functional disulfide re-bridging 
through two sequential addition-elimination reactions leaving an unsaturated 
rigid two-carbon bridge. 
 
Since their inception, the scope of dibromomaleimides has been expanded 
through variation of the leaving groups in the 3- and 4- positions, i.e. at the thiol-
reactive centres. Baker et al. attempted to overcome unwanted side-reactions, e.g. 
dibromomaleimide with TCEP, through the displacement of the bromo- groups 
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with thiophenol(Scheme 10, centre). This aided somewhat in reducing the large 
excess of maleimide required to affect re-bridging.78 Mono-bromomaleimides 
were also reintroduced for disulfide re-bridging; Richards et al. demonstrate a 
strategy in which a reduced disulfide is introduced to an excess of 
bromomaleimide followed by a photochemically driven [2+2] cycloaddition 
between the C3-C4 unsaturated bonds on two adjacent maleimides (Scheme 10, 
left). This strategy showed potential not just for functionalisation of proteins but 
also as a potential photo-switchable tool to manipulate a protein’s structure and 
effect conformational change.79 Further to this, the functional scope of di-
substituted maleimides was shown through the demonstration of a multimodal 
imaging strategy. A radiolabelled iodine was incorporated in to the triazole 
product resulting from a copper-catalysed azide-alkyne cycloaddition (CuAAC) 
between an alkyne-bearing dithioarylmaleimide and a fluorophore azide tag. The 
single-disulfide bearing peptide octreotide was then functionally re-bridged using 
the resultant multimodal imaging maleimide (Scheme 10, right).80 
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Scheme 10 Mono- and di-substituted maleimides have shown broad scope when 
applied to functional disulfide re-bridging.78-80 
 
Under certain conditions maleimides linkers have been shown to bind reversibly 
to cysteines, allowing them to be cleaved from proteins when exposed to high 
concentrations of other thiols, e.g. glutathione. 81 
 
Whilst di-substituted maleimides are a powerful tool in protein modification they 
have shortcomings in some areas: i) the five-membered ring is prone to hydrolysis 
under basic conditions (Scheme 11) (although this has been used beneficially to 
afford thiol stability in some cases), the rate of hydrolysis can be between minutes 
and days, depending on substituents;67 and ii) a maleimide re-bridged disulfide 
only has one point from which a functional handle can be easily constructed.  
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Scheme 11 Maleimide hydrolysis can occur under basic conditions. 
The high reactivity of dibromomaleimides can also make them incompatible with 
certain reagents used in chemical biology, often necessitating the use of a large 
excess of either reducing agent or re-bridging agent. Chudasama et al. have, in 
recent years, reported on a new class of PD-based reagents, which have several 
desirable attributes that make them a more optimised platform for functional 
disulfide re-bridging.63 
 
1.2.3 Pyridazinediones 
 
In addition to having two thiol-reactive centres, PDs can comprise two orthogonal 
functional handles, which can be used to carry out two chemoselective 
transformations to yield multi-functionalised adducts (Figure 3).  
 
Figure 3 Di-substituted maleimides (left) and PDs (right) both have two thiol 
reactive centres, however, PDs have two points of attachment for functional 
moieties or handles, furthermore, PDs are tolerant to a broader range of reagents 
and conditions. 
Furthermore, the 6-membered ring has been shown to be resistant to hydrolysis 
at a broad range of pH.63 Recent work in the Chudasama and Caddick groups has 
highlighted the impressive scope of this scaffold (Figure 4).82-84 The site-selective 
dual modification of proteins has been made possible using the ‘dual click’ strategy 
presented by Maruani et al (Figure 5).83  
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Figure 4 PDs have been shown to bear a range of orthogonal handles, of which a 
PD scaffold can bear two at once. A range of functional payloads have also been 
attached to antibodies and proteins demonstrating the scope of PDs in the field. 
 ‘Click’ chemistry is a general term that is used to describe reactions that proceed 
in high yields with minimal by-product formation and typically can proceed in 
benign solvent conditions.85, 86 Moreover, ‘click’ reactions usually feature a strong 
thermodynamic driving force that lead to the rapid and selective formation of a 
single product; they have seen widespread use in the field of protein modification 
due to their tendency to proceed via bioorthogonal reaction pathways.21, 48  
Through inclusion of a terminal alkyne handle on one nitrogen and of a 
cyclooctyne strained alkyne on the other, two distinct targets can be conjugated 
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via sequential copper-free strain promoted azide-alkyne cycloaddition (SPAAC) 
‘click’ on the strained alkyne and a CuAAC ‘click’ on the non-strained alkyne.83  
 
Figure 5 The ‘dual click’ strategy presented by Maruani et al. involves the use of 
orthogonal azide-alkyne cycloaddition reactions; a strained alkyne that can react 
under copper free conditions and an alkyl alkyne that reacts via a copper 
catalysed route.  
The Chudasama group have also presented work demonstrating the advantages 
of PDs over succinimide linkers formed from maleimide-cysteine additions.82 It 
has recently emerged that succinimide thiol linkages are unstable in blood serum 
due to thiol exchange with blood thiols (e.g. albumin).87 It was shown that if one 
of the nitrogen atoms on a PD is unsubstituted then the molecule does not react 
with thiols at physiological pH or higher. It was speculated that this was a 
consequence of such a structure existing as its enol tautomer, which is likely to be 
significantly deprotonated under physiological conditions, thus significantly 
reducing the electrophilicity of the PD core and, therefore, it’s susceptibility to 
thiol attack. Thus a novel strategy to unmask such an entity post-bioconjugation 
was developed (Scheme 12). This was done by reaction with a PD bearing a 
p-azidobenzyl group on the nitrogen, which when reacted with TCEP offered the 
desired thiol irreversible scaffold.82 
 
21 
 
 
Scheme 12 Chudasama and co-workers developed thiol irreversible linkers by 
removing a para-azidobenzyl group on a conjugated PD in situ to convert 
reversible linkers into irreversible ones. 
 
The broader functional applications of PDs were further demonstrated in the 
context of photo-dynamic therapy. Chudasama and Boyle et al. showed site-
selective functionalisation of Herceptin™ to bear 4 porphyrin moieties to act as 
photosensitisers, which upon being directed to the tumour could be activated 
through the topical application of low energy light. The resultant conjugates were 
appraised in vitro and were shown to exude excellent selectivity and efficacy.84  
 
1.3 Antibody-Drug Conjugates 
 
Functional-disulfide re-bridging is broadly applicable to protein modification in 
general. However, much of the presented work has been performed in the context 
of the site-selective modification of antibodies and their fragments for use as 
therapeutic tools, often referred to as ADCs. As such a brief introduction to the 
current state of ADC synthesis and use will be given. 
 
1.3.1 Antibodies 
 
Antibodies (often referred to as immunoglobulin [Ig]) are large (ca. 150 kDa) 
protein complexes that are produced as part of the body’s active immune response 
to invading pathogens. The Y-shaped complexes bind with excellent selectivity to 
their complementary antigens. This, combined with their inherent ADCC is why 
they have seen use as therapies on their own. However, their use as delivery 
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vehicles for cytotoxic drugs and imaging moieties has attracted much attention in 
previous years. 
 
The most common class of antibody used to construct ADCs is IgG (the sub-
classification G, its isotype, denotes the structure of the constant domain of the 
heavy chain), as they make up the greatest proportion of antibodies found in 
humans and are predominantly located in blood. More specifically the sub-type 
most commonly use is an IgG1; the general structural motif of which can be 
described as consisting of two distinct chains, the heavy chain and light chain 
(denoted by H and L, respectively) (Figure 6). The chains themselves can be divided 
into constant and variable regions, where changes in the variable region dictate 
the antibody’s complementarity to its given antigen. This structure means that 
IgG1s are bivalent, i.e. each antibody can bind two antigens.88 
 
 
Figure 6 Generic structure of an IgG1 antibody displaying its general regions; 4 
accessible disulfides and; 2 glycans; each of which represents a potential point of 
site-selective modification on native antibodies. 
 
1.3.2 Current methods of antibody modification 
 
The initial concept of delivering a toxic payload selectively to a tumour was 
conceived by Paul Ehrlich in 1913;89 where he described a “haptophoric” or “fixing 
group”, which could deliver a “toxophoric” or “injuring group” selectively to a 
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tumour. However, it was 45 years before an ADC was first created by Bernard et 
al.90 and not until the 1970’s that ADCs were first tested on animal models.91, 92 
The first ADCs using humanised monoclonal antibodies (mAbs) were reported in 
the 1990’s.43 Following this, the payloads used were developed to be more potent 
and selectivity of mAbs was improved.93 By 2000 the first FDA approved ADC, 
Mylotarg™ (gemtuzumab ozogamicin) was released;94 vindicating Ehrlich’s initial 
hypothesis of an entity that could deliver the cytotoxic potency of a chemotherapy 
drug with the reduced off-target toxicity of an antibody. 
 
Mylotarg™ has since been voluntarily withdrawn due to subsequent clinical trials 
showing no clinical benefit over conventional chemotherapy. However, two 
further ADCs have since seen approval; aforementioned Adcetris™ and Kadcyla™, 
which gained FDA approval in 2011 and 2013, respectively.69, 95-97 There are 
currently ca. 50 ADCs in clinical trials, showing the impressive rate of growth in 
this sector.98 
 
Kadcyla™ and Mylotarg™ were both constructed using lysine modification (vide 
supra, section 1.1.2.1), whereas Adcetris™ uses capping of reduced inter-chain 
disulfides (vide supra, section 1.2). All three exist as statistical heterogeneous 
mixtures of products, and while these remain the only entities to have gained FDA 
approval, the non-specific conjugation techniques used to create them are now 
seen as sub-optimal.  
  
 
Figure 7 Kadcyla™ and Adcetris™ remain the only two currently FDA-approved 
ADCs; both use non-specific methods of modification in their synthesis. 
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1.3.3 Engineered antibodies 
 
Many strategies have evolved in recent years that enable the site-selective 
modification of antibodies, due to recent advances in the field of protein 
engineering. These methods can be categorised into 3 main groups; (i) 
incorporation of cysteine into an antibody’s sequence by mutagenesis; (ii) 
enzymatic conjugation; and (iii) incorporation of UAAs. 
 
Engineered cysteines 
 
The most widely applied example of engineered cysteine use was first 
demonstrated by Junutula et al. (Genentech) where additional cysteine residues 
were incorporated into a mAb via site-directed mutagenesis.99 This enabled 
further site-selective attachment of functional moieties owing to the absence of 
other accessible free cysteines. This method is non-trivial, however, owing to the 
fact that the newly introduced cysteines can form disulfides with other available 
cysteines (e.g. forming mixed disulfides and protein dimers) that could disrupt the 
mAb’s activity.15, 100 This strategy of insertion of two additional cysteines into a 
mAb was coined THIOMAB™ by Genentech and has seen application in different 
mAbs including Herceptin™ (scheme 13).101 While cysteine residues can be 
successfully introduced, they cannot be readily accessed due them mostly existing 
in the form of mixed disulfides with glutathione. Due to the lack of a method to 
selectively reduce the engineered cysteines, an alternative strategy was devised 
for modification at these points. All accessible disulfide bridges must be reduced, 
followed by re-oxidation under mild conditions to restore the inter-chain disulfide 
bonds, affording a mAb with its native disulfide bridges intact but featuring two 
engineered cysteines free for further chemical modification. THIOMABs™ have 
been used to create antibody conjugates with several different functional moieties 
(including drugs), with the ratio of payload to antibody typically being 1.9 (±0.1) 
with varying degrees of homogeneity.50, 102 
 
25 
 
 
Scheme 13 THIOMAB™ technology enables site-selective incorporation of two 
cysteines into accessible points on a mAb’s surface. As these are typically capped 
with a disulfide protecting group they require deprotection via reduction, then 
the inter-chain disulfides must be re-oxidised. 
 
Enzymatic modification 
 
Another strategy for the site-selective modification of engineered antibodies is 
through the incorporation of an amino acid sequence that acts as a tag to direct 
enzymatic modification. This approach has been used to site-selectively attach 
drugs to antibodies. An example of such a strategy has been through the use of 
certain transglutaminases (TGs). TGs are useful tools in biosynthesis owing to 
their ability to form amide linkages between a lysine primary amine side chain 
and the amide group on a glutamine.103 Strop et al. demonstrated the use of a 
bacterial TG, isolated from Streptoverticillium mobaraense, which will only 
catalyse reactions of glutamines found in a ‘glutamine (Q)-tag’ (as in LLQG).104 The 
authors identified two optimal positions in an anti-M1S1 mAb sequence for 
inclusion of Q-tags. This enabled the use of the bacterial TG to catalyse conjugation 
of two monomethyl dolastatin (MMAD, a potent tubulin inhibitor) to the mAb’s 
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surface, resulting in the generation of ADCs with good biophysical properties and 
average DARs of 1.9.104 These ADCs showed better in vivo tolerance in comparison 
with analogous ADCs with higher drug loadings synthesised through the use of 
cysteine modification following reduction of inter-chain disulfides. 
 
Incorporation of UAAs 
 
Incorporation of UAAs also remains a viable strategy and has been used for the 
successful construction of ADCs. Axup et al. presented the synthesis of an MMAD-
Herceptin™ ADC with a DAR 2.0, through incorporation of the UAA 
p-acetylphenylalanine into the constant region of the mAb and a subsequent 
oxime-ligation reaction.15 This method enabled production of several ADCs with 
good homogeneity. Incorporation of UAAs sees continued use in the field but is 
still hampered with the aforementioned issues (vide supra, section 1.1.1). 
Furthermore the potential immunogenicity of UAAs is not yet fully understood 
and more studies are required to fully appraise the implications of their use in bio-
therapeutics. 
 
1.3.4 Site-selective modification of native antibodies 
 
Whilst the synthesis of near homogeneous ADCs is made possible through the use 
of engineered antibodies, it remains advantageous to carry out site-selective 
homogenous transformations on native mAbs. This is due to the increased overall 
costs associated with the optimisation of cell-culture conditions and site-directed 
mutagenesis that engineered mAb scaffolds necessitate. There are two main types 
of target available for the site-selective modification of antibodies; (i) glycans; and 
(ii) disulfide bridges. 
 
N-Glycan modification 
 
All antibodies possess N-glycosylated residues at a conserved position in their 
constant region, thus they serve as potential targets for site-selective 
modification. This is generally achieved through oxidation of the carbohydrate 
residues to produce aldehydes, which can then undergo further chemical 
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modification (scheme 14).105, 106 However, this strategy employs harsh oxidative 
conditions that can result in oxidation of other residues on the antibody; this over-
oxidation has been known to negatively affect the activity and half-life of resulting 
ADCs.107 Whilst these issues have been somewhat mitigated through the use of 
milder enzymatic oxidation strategies, the fact remains that glycan populations 
are heterogeneous due to the existence of different glycoforms amongst 
antibodies of the same type. Thus, ADCs synthesised through glycan modification 
can suffer from poor homogeneity.108  
 
 
Scheme 14 Native glycan targeting to yield aldehyde-modified mAb by oxidation 
followed by reductive amination or O-substituted oxime functionalization. 
 
Disulfide modification of antibodies 
 
Reduction of inter-chain disulfide bonds and subsequent reaction with the free 
thiols has also been put to use in the site-selective modification of antibodies. This 
is due in part to the inter-chain disulfides being the only solvent-accessible ones 
on the antibody; i.e. on an IgG1 there four accessible inter-chain disulfide bridges, 
offering eight thiols once reduced.  
 
Reaction at reduced disulfides can yield ADC species with a DAR of up to 8.0 as 
was the case in the early development of Adcetris™. Ultimately, however, it was 
discovered that a lower drug loading (averaging 4.0) provided the best balance 
between efficacy and pharmacokinetic properties. As such, carefully controlled 
stoichiometry of conjugating reagents was employed to ensure an average loading 
of 4.0, with homogeneity of up to 75%. Overall, due to a lack of control over 
selective disulfide reduction a heterogeneous mixture of products still arises. 
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In order to target more homogeneous ADCs with a DAR of 4.0, Badescu et al. 
(PolyTherics) considered the use of functional disulfide re-bridging.66 It was 
proposed that the use of a bis-sulfone reagent would allow, through a bis-
elimination-addition mechanism (vide supra, section 1.2.1), incorporation of a 
single cytotoxic drug into each accessible disulfide bridge. MMAE, another potent 
tubulin inhibitor, was chosen as the toxic payload and the resulting conjugates 
were shown to have improved efficacy and selectivity over the free drug alone in 
vitro and in vivo.66 
 
The field of functional disulfide re-bridging in the context of ADCs has also seen 
considerable advancements from the Chudasama, Baker and Caddick groups 
through the use of di-substituted maleimides and PDs (vide supra, section 1.2.1). 
Nunes et al. describe methods that target a DAR 4 ADC using Herceptin™ that has 
undergone functional disulfide re-bridging with disubstituted maleimides. A 
bisthioaryl maleimide bearing MMAE was incorporated into the interchain 
disulfide bonds of the mAb using a sequential reduction/re-bridging protocol 
(figure 8). The resultant species had an average DAR of 3.89, as characterised by 
HIC.67 Further to this, the utility of post-bioconjugation hydrolysis of the 
maleimide linkers was shown through dramatic increases in serum stability over 
conventional (non-hydrolysed) maleimides. The potency of the ADCs was 
assessed through in vitro assays against a HER2 positive cell line showing 
significantly reduced cell viability and increased cytotoxicity when compared to 
native Herceptin™.67 The homogeneity of conjugates produced using this strategy 
has since been improved by Morais et al., through the accelerated hydrolysis of 
maleimide linkers post-conjugation.109 The presented conjugates undergo 
hydrolysis in 1 h; a stark improvement over the 72 h achieved previously by Nunes 
et al. This improved rate of hydrolysis prevented unwanted side reactions and 
increased homogeneity.  
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Figure 8 Conjugates prepared by Robinson et al. (left) and Nunes et al. (right). 
Both feature the use of functional disulfide re-bridging to create DAR 4 ADCs. 
Stable thioether linkages are essential to ensure selective delivery to cancer cells. 
 
More recently, Robinson et al. described the use of PDs to synthesise 
Herceptin™-MMAE ADCs, targeting a DAR of 4.0 (figure 8).110 Two different MMAE 
PDs were used to produce conjugates; one with a valine-citrulline linker, one 
without. In both cases an average DAR of 4.0 was achieved with 90% homogeneity, 
characterised by both HIC and LCMS. Furthermore, the PD conjugates showed 
comparable serum stability to the maleimide conjugates prepared by Nunes et al., 
thereby mitigating the need for an extra hydrolysis step post-bioconjugation. The 
activity of the prepared ADCs was assessed through in vitro and in vivo studies.110 
The PD ADCs performed especially well in breast cancer xenograft mouse models; 
showing complete tumour regression in 18 days; a significant improvement over 
native Herceptin™ in the same study. 
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1.4 Aims 
 
In recognition of the aforementioned challenges associated with the modification 
of antibodies, the need for improved biochemical techniques that would increase 
the homogeneity and control of such modifications was identified. Furthermore, 
in order to make the field of bioconjugation, and specifically the synthesis of ADCs, 
more accessible to groups and companies that do not have access to more 
expensive mutagenesis techniques, simple chemical strategies are required.  
 
The work in this thesis centres on the development of two distinct technologies, 
both of which address hitherto unmet needs in the field. The first of which was 
designed to overcome two issues central to functional disulfide re-bridging in 
mAbs; to simplify the protocols used in functional disulfide re-bridging and to 
overcome incidence of non-native disulfide re-bridging in multi-disulfide systems, 
which can lead to a loss in activity. It was theorised that the creation of a single 
chemical entity that could both reduce and re-bridge a disulfide bond would 
circumvent both these issues (detailed further; vide infra, Chapter 2.0). 
 
The second technology was envisaged to meet the growing demand in the field for 
the capability to construct ADCs with a functional loading of two moieties per 
mAb, without the use of antibody engineering techniques. The loading of two 
moieties per mAb is especially desirable in the case of large hydrophobic payloads 
where a compromise between efficacy and pharmacokinetic profile is required 
and has until now not been achieved with control over homogeneity of products 
using chemical methods alone (detailed further; vide infra, Chapter 3.0). 
 
Both the presented technologies aim to use PD-based scaffolds to affect novel 
disulfide re-bridging on a variety of disulfide-containing systems. Specifically, 
however, they are both aimed at improving the control and homogeneity with 
which ADCs can be constructed from native mAbs. 
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Chapter 2: Reduction and re-bridging delivered 
by one reagent 
 
Whilst pyridazinediones represent an important step towards providing reagents 
for efficient and versatile modification of proteins, there are still areas in which 
significant barriers remain. A commonly used protocol for functional disulfide re-
bridging with pyridazinediones (as well as other bridging agents) is a stepwise 
procedure, whereby the disulfide bond on a protein is first reduced with TCEP; 
excess TCEP (and oxidised by-product) is then removed and the liberated 
cysteines are exposed to a pyridazinedione based conjugating reagent with two 
appropriate leaving groups at the thiol-reactive 4- and 5-positions.75, 83 This 
sequential protocol works very efficiently with templated single disulfide systems 
(e.g. the fragment antigen-binding [Fab] of Herceptin™, Somatostatin), but certain 
protein complexes that are not templated and/or held together by a single 
disulfide bond would fall apart if this sequential reduction/re-bridging protocol 
were employed. Moreover, when this stepwise protocol is applied to multi-
disulfide systems re-bridging of cysteines in a non-native configuration has been 
observed; this is especially likely when there are multiple disulfide bonds within 
close proximity to one another, e.g. in the hinge region of an IgG1 (Figure 9).67, 111 
Re-bridging in a non-native configuration can lead to significant changes in a 
protein’s configuration that can impact its stability and activity.112 Furthermore 
within a given bioconjugation reaction it can lead to a heterogeneous mixture of 
products. Whilst steps can be taken to avoid non-native disulfide re-bridging (e.g. 
running conjugation reactions at low temperature and modifying with a low 
concentration of TCEP and a high concentration of re-bridging reagent in situ to 
rapidly trap reduced disulfide bonds) these procedures are inefficient, reagent-
specific and cumbersome.83 Moreover, for many bridging reagents cross-
reactivity between the bridging reagent and reducing reagent is a major issue. 
Hence, it would be highly desirable to be able to perform functional disulfide re-
bridging rapidly and efficiently with a single reagent, and ideally if it facilitated 
functional re-bridging with native disulfide connectivity retained. Furthermore, 
such a reagent would eliminate the need to purify a protein post-reduction and/or 
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switch buffer, reducing the number of steps and associated costs of the 
conjugation. 
 
 
Figure 9 Left: SDS-PAGE analysis showing native Herceptin™ (lane 1) and 
Herceptin that has been re-bridged to give a mixture of native and non-natively 
re-bridged products (lane 2). Re-bridging in the native configuration gives rise to 
the full antibody band (top band) and non-native re-bridging gives rise to the 
half antibody band (lower band observed in lane 2).  
 
 
2.1 A one-reagent procedure to create homogenous 
functional disulfide bridged proteins 
 
Recently, Chudasama, Caddick et al. have shown dibromopyridazinediones to be 
viable candidates for functional disulfide re-bridging and that the resulting 
bisthioether is stable in blood plasma-mimicking conditions.83 Whilst this 
approach, as well as others, offer advances in this growing field of disulfide 
labelling, a common limitation is the requirement for reduction and re-bridging in 
distinct steps. As highlighted above, this is mainly due to the incompatibility of the 
bridging and reducing agents. This introduces inefficiencies in terms of cost, time 
and practicality. Whilst one-pot in situ methods have been employed, this is only 
at the expense of using a vast excess of reducing and bridging agents to 
compensate for the reaction between the two reagents.83 
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The aim of this project is to develop a system that can, with a single reagent, 
convert a range of single and multi-disulfide systems into functional bioconjugates 
whilst retaining their native disulfide configuration. The proposal is to synthesise 
a molecule that can single-handedly reduce and conjugate across a disulfide bond 
in a rapid manner. In order to achieve this, a suitable molecule needed to be 
designed, which had to feature both a reduction and re-bridging moiety, this 
would turn the previously step-wise protocol into a one-reagent/one-addition 
procedure. Furthermore, it was theorised that immediately following reduction, 
by having the re-bridging moiety so close in space to the reduction moiety, the 
newly liberated thiol groups would be immediately exposed to a high local 
concentration of the conjugating molecule core (i.e. minimising reduced disulfide 
residency time and, thereby, the associated risk of non-native disulfide re-
bridging) and rapidly undergoing functional re-bridging. During the course of 
previous studies within in the Chudasama and Caddick groups, 
dithiophenolpyridazinediones have been observed to be unreactive towards 
commonly used disulfide reducing agent TCEP.63, 75, 83 In light of this, TCEP 
moieties were a logical choice for incorporation into a 
dithiophenolpyridazinedione. More specifically, the TCEP functional moieties 
were to be tethered onto the thiophenol groups of the 
dithiophenolpyridazinedione since these groups would be extruded during an 
addition-elimination reaction with a thiol following disulfide reduction (Figure 
10). 
 
 
Figure 10 Proposed structure for dithioaryl(TCEP)pyridazinedione 7; a 
molecule that can both reduce and subsequently conjugate across a disulfide 
bridge 
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2.2 Results and discussion 
 
2.2.1 Synthesis of dithioaryl(TCEP)pyridazinedione 
 
The synthesis of target pyridazinedione 7 started through bis-alkylation of di-tert-
butyl hydrazine-1,2-dicarboxylate 1 using caesium carbonate with bromoethane 
in N,N-dimethylformamide (DMF) at 21 °C for 48 h to give di-tert-butyl 1,2-
diethylhydrazine-1,2-dicarboxylate (2)(Scheme 15). The first alkylation, to give 
the mono-N-alkylated product proceeded rapidly (within 3-5 h), whereas the 
second, to give the desired bis-alkylated product, required significantly longer (ca. 
40 h); the reaction progress was tracked by TLC. The bis-alkylation to give 
diethylhydrazine 2 proceeded with an 88% yield.  
 
Scheme 15 Bis-alkylation of di-Boc protected hydrazine 1 to give diethyl 
analogue 2.  
Following this, TFA cleavage of the Boc groups of diethylhydrazine 2, followed by 
reaction with dibromomaleic anhydride under reflux in AcOH afforded diethyl 
dibromopyridazinedione 3 in an overall yield of 73% (Route A, Scheme 16). An 
alternative route for the formation of dibromopyridazinedione 3 where the 
deprotection and pyridazinedione formation steps are combined in a single-pot 
and the use of TFA avoided was also developed (Route B, Scheme 16). 
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Scheme 16 Formation of pyridazinedione 3 was achieved through TFA 
deprotection of hydrazine 2 and subsequent treatment of the crude hydrazine 
with dibromomaleic anhydride in AcOH, refluxed for 2 h (Route A). Subsequent 
optimisation of the synthesis revealed deprotection of the hydrazine and 
pyridazinedione formation could both take place under reflux in AcOH (Route B). 
Dibromopyridazinedione 3 was then reacted with 4-aminothiophenol in DCM 
with triethylamine at 21 °C for 2 h to form dithioarylpyridazinedione 4 in 66% 
yield (Scheme 17).  
 
Scheme 17 Dibromopyridazinedione 3 was treated with 4-aminothiophenol and 
triethylamine in DCM 
Following this a TCEP derivative (6), for attachment to the pyridazinedione core, 
was prepared through methyl esterification of two out of the three carboxylic acid 
groups give di-methylated species 6 (Scheme 18). 
 
Scheme 18 TCEP·HCl was prepared for incorporation into final pyridazinedione 
scaffold 7 through methyl esterification of two out of the three carboxylic acid 
groups to give di-methylated TCEP analogue 6.  
To do this, TCEP·HCl 5 was treated with acidic resin Amberlyst® 15 in MeOH for 
1 h at 21 °C to give a mixture of the mono-, di- and tri-methylated products. 
Gratifyingly, the three products were easily separated on silica using FCC, 
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affording dimethyl-TCEP analogue 6 as a colourless oil in a 17% yield. Finally the 
TCEP derivative 6, now bearing only one carboxylic acid group, was coupled via 
an amide bond formation to the 4-amino groups on dithioarylpyridazinedione 4. 
1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) was used to activate the carboxylic acid on TCEP 
analogue 6, with DIPEA as base, prior to addition of the bis-aniline bearing 
dithioarylpyridazinedione 4; the reaction was performed in DMF at 21 °C for 12 h 
and afforded target dithioaryl(TCEP)pyridazinedione 7 in a yield of 18% (Scheme 
19).  
 
Scheme 19 Synthesis of dithioaryl(TCEP)pyridazinedione 7. The thioaryl moiety 
was chosen for several reasons; it is reactive towards alkyl thiols; it is resistant 
to cross reactivity with TCEP; the 4-amino group served as a convenient point 
through the synthesis could be continued. 
2.2.2 Proof of concept with single-disulfide containing systems 
 
With dithioaryl(TCEP)pyridazinedione 7 in-hand, it’s suitability as a 
bioconjugation reagent for both disulfide reduction and functional re-bridging 
was appraised. To do this, dithioaryl(TCEP)pyridazinedione 7 was incubated with 
a selection of biologically relevant disulfide containing proteins, i.e. the Fab 
(fragment antigen-binding) arm of Herceptin™, somatostatin, and octreotide. 
 
2.2.2.1 Reaction of dithioaryl(TCEP)pyridazinedione 7 with Herceptin™ Fab 
fragment 
 
To appraise the utility of dithioaryl(TCEP)pyridazinedione 7 it’s suitability for the 
functional re-bridging of the Fab of Herceptin™ was examined. To do this, the 
single–disulfide containing Fab fragment was incubated in borate buffer solution 
(BBS) at pH8 with EDTA (0.5 mM) at 37 °C for 1 h with 1.25, 2, 5, and 10 
equivalents of dithioaryl(TCEP)pyridazinedione 7 (scheme 20). A range of 
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equivalents were used to test the lower limit possible for 
dithioaryl(TCEP)pyridazinedione 7 to effect full re-bridging; 1.25 eq represents 
the lowest possible number that ensured a minimum ratio of 1:1 within the 
experimental degree of error. In each case significant conversion to the desired 
product was observed; the N,N’-diethylpyridazinedione core had been inserted 
into the one disulfide bond on the Fab fragment as assessed by LS-MS (Figure 11). 
In the acquired MS data, only one species is observed both before and after 
reaction showing a clear gain in mass corresponding to the mass of one diethyl-
PD ring. The use of only 1.25 eq of dithioaryl(TCEP)pyridazinedione 7 was an 
especially significant result as conventional means of functional disulfide re-
bridging typically require large excesses of either re-bridging or reduction 
components effect full conversion. 
 
Scheme 20 Insertion of pyridazinedione core into the single disulfide bond 
present on a Herceptin™ Fab fragment through incubation with 
dithioaryl(TCEP)pyridazinedione 7. 
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(a)
 
(b)
 
Figure 11 (a) deconvoluted MS data for native Fab fragment of Herceptin™ (b) 
deconvoluted MS data for Fab fragment of Herceptin™ reacted with 
dithioaryl(TCEP)pyridazinedione 7 (1.25 eq.). 
 
2.2.2.2 Reaction of dithioaryl(TCEP)pyridazinedione 7 with octreotide 
 
Octreotide is a peptide used in the treatment various conditions including growth 
hormone producing tumours.113 It is a mimetic of somatostatin and has higher 
activity; it was chosen on the basis that it had only one disulfide bridge and that 
previous work on the peptide in the Caddick and Baker groups had provided 
insight to the peptide’s characteristics with regards to its reactivity and solubility. 
In view of the optimisation on Fab and previous studies, the unmodified peptide 
was incubated with 1.25 equivalents of dithioaryl(TCEP)pyridazinedione 7, as this 
was the previously discovered lowest number of equivalents used to effect re-
bridging in a single disulfide system, in a 57.5:40:2.5 mixture of phosphate buffer 
(PB) (pH 6.2)/MeCN/DMF (peptide buffer) at 37 °C for 1 h (scheme 21). The 
octreotide underwent conversion to the desired product; the N,N’-
diethylpyridazinedione core had been inserted into the one disulfide in the 
peptide as confirmed by LC-MS (Figure 11), which again showed a clear increase 
in the observed mass of the peptide corresponding to one PD ring. 
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Scheme 21 Insertion of pyridazinedione core into the single disulfide bond 
present in octreotide through incubation with dithioaryl(TCEP)pyridazinedione 
7. 
 
(a) 
 
(b) 
 
Figure 11 (a) deconvoluted MS data for unmodified octreotide, peak at m/z 
1039.6 corresponds to [M+Na]+ (b) deconvoluted MS data for octreotide reacted 
with dithioaryl(TCEP)pyridazinedione 7 (1.25 eq.). 
 
2.2.2.3 Reaction of dithioaryl(TCEP)pyridazinedione 7 with somatostatin 
The peptide somatostatin, an endocrine system regulatory hormone, was also 
chosen on the basis that it contained only one disulfide bond and on the familiarity 
that the Chudasama and Caddick groups have with reacting the peptide. In view 
of previous optimisation, the native peptide was incubated with 1.25 equivalents 
of dithioaryl(TCEP)pyridazinedione 7 in peptide buffer at 37 °C for 1 h (scheme 
22). Gratifyingly, somatostatin underwent complete conversion to the desired 
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product; the N,N’-diethylpyridazinedione core had been inserted into the one 
disulfide in the peptide as confirmed by MALDI-TOF-MS (Figure 12). 
 
 
Scheme 22 Insertion of pyridazinedione core into the single disulfide bond 
present in a somatostatin through incubation with 
dithioaryl(TCEP)pyridazinedione 7. 
 
(a) 
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(b) 
 
Figure 12 (a) MS data for unmodified somatostatin, peak at m/z 1663 
corresponds to [M+Na]+ (b) deconvoluted MS data for somatostatin reacted with 
dithioaryl(TCEP)pyridazinedione 7 (1.25 eq.), peak at m/z 1830 corresponds to 
[M+Na]+. 
2.2.2.4 Summary of results with single disulfide systems 
 
Gratifyingly, in each case, dithioaryl(TCEP)pyridazinedione 7 was shown to 
reduce and functionally re-bridge the singly accessible disulfide of somatostatin, 
octreotide and Herceptin™ Fab. Moreover, only a small excess of 
dithioaryl(TCEP)pyridazinedione 7, 1.25 equivalents, was required to effect 
complete conversion. Over the course of these studies it was also noted that 
dithioaryl(TCEP)pyridazinedione 7 could be stored with near complete stability 
over six months at -18 °C under argon. This was assessed by 31P NMR, showing 
less than 10% oxidation after six months. 
 
2.2.3 Competition studies 
 
It was previously rationalised that a molecule with both reducing and re-bridging 
functions would minimise the residency time of the cysteines liberated from 
disulfide reduction due to the aforementioned high local concentration effect. This 
is especially in view of no reduced protein being observed upon incubation of the 
above peptides and proteins with dithioaryl(TCEP)pyridazinedione 7. To appraise 
42 
 
this further, an analogous pyridazinedione with comparable thiol reactivity (to 
that of dithioaryl(TCEP)pyridazinedione 7), which if incorporated into a peptide 
would give a product of distinct mass to that observed with reagent 7, was 
designed and synthesized; pyridazinedione 10. 
 
2.2.3.1 Synthesis of pyridazinedione 10 
 
Synthesis of the pyridazinedione 10 started with bis-alkylation of di-tert-butyl 
hydrazine-1,2-dicarboxylate 1 using caesium carbonate with 1-bromopropane in 
DMF at 21 °C for 48 h to give di-tert-butyl 1,2-dipropylhydrazine-1,2-
dicarboxylate 8 in a 78% yield (Scheme 23).  
 
Scheme 23 Alkylation of di-Boc hydrazine 1 was achieved through treatment 
with 1-bromopropane and caesium carbonate to give bis-alkylated product 8. 
Following this, TFA cleavage of the Boc groups of dipropylhydrazine 8, followed 
by reaction with dibromomaleic anhydride under reflux in AcOH afforded 
dipropyl dibromopyridazinedione 9 in an overall yield of 78%.  
 
Scheme 24 Bromo groups were displaced with 4-acetimidothiphenol to create 
pyridazinedione 10, which would feature comparable thiol-reactivity to that of 
pyridazinedione 7. 
Dibromopyridazinedione 9 was then reacted with 4-acetimidothiophenol in DCM 
with triethylamine at 21 °C for 2 h to form dithioarylpyridazinedione 10 in 40% 
yield (Scheme 24).  
 
2.2.3.2 Application to Herceptin™ Fab fragment 
 
In comparison to pyridazinedione 7, dipropyl pyridazinedione 10 lacks the 
reducing function and it bears two N-propyl groups in place of the ethyl groups. 
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The mass difference of having two propyl groups in place of two ethyl groups is 
detectable by mass spectrometry.  
 
Scheme 25 Reaction of a Herceptin™ Fab fragment with 
dithioaryl(TCEP)pyridazinedione 7; the Fab fragment was first incubated with 
dipropyl pyridazinedione 10 and subsequently incubated with 7. 
By having an excess of pyridazinedione 10 present in solution, incorporation of 
the diethyl pyridazinedione core from pyridazinedione 7, would validate the high 
local concentration hypothesis i.e. the effective concentration of pyridazinedione 
7 would be higher than that of competing pyridazinedione 10. In the competition 
experiment, the Fab of Herceptin™ was incubated with 1, 2 and 5 equivalents of 
dipropyl pyridazinedione 10 in BBS with EDTA at pH 8 prior to incubation with 2 
equivalents of diethyl pyridazinedione 7 (Scheme 25). Validating our hypothesis, 
re-bridging was only observed with the dithioaryl(TCEP)pyridazinedione 7, i.e. 
only the N,N’-diethylpyridazinedione core from the parent scaffold of 7 was 
incorporated. The control reaction of reducing the Fab prior to adding a mixture 
of pyridazinediones 7 and 10 afforded a mixture of bioconjugates, confirming the 
validity of the competition studies; i.e. dipropyl pyridazinedione 10 did indeed 
have comparable thiol reactivity; this was validated by LC-MS (figure 13). 
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(b) 
 
Figure 13 (a) deconvoluted MS data for Fab fragment of Herceptin reacted with 
dithioaryl(TCEP)pyridazinedione 7 in the presence of dipropyl pyridazinedione 
10 (ratio of 7:10 = 2:5). (b) Deconvoluted MS data for reduction of Fab fragment 
of Herceptin and subsequent reaction with dithioaryl(TCEP)pyridazinedione 7 
and dipropyl pyridazinedione 10 (1:1 ratio 0.5 eq.:0.5 eq); the three species 
observed are unmodified Fab, Fab modified with the diethyl species and Fab 
modified with the dipropyl species at m/z 47565, 47746 and 47776, 
respectively. 
 
2.2.4 Multi-disulfide system 
 
With the knowledge of the use of dithioaryl(TCEP)pyridazinedione 7 resulting in 
a high local concentration of the specific pyridazinedione incorporated into the 
parent scaffold of pyridazinedione 7, the use of this reagent was appraised in the 
context of a multi-disulfide system, i.e. to apprise if it minimised non-native 
disulfide re-bridging. 
 
Scheme 26 Reaction of a Herceptin™ full antibody with 
dithioaryl(TCEP)pyridazinedione 7 was chosen as a way to appraise the utility of 
the technology, as the modification of full antibodies to produce homogeneous 
bioconjugates is seen as a significant challenge. Control reactions with 
conventional pyridazinedione 4 (not containing integrated reducing agent) were 
also carried out. 
To do this, the multi-disulfide system of Herceptin™ was chosen as the model 
system. Herceptin™ is an antibody comprising four disulfide bonds – whose 
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disulfide bonds can be re-bridged in a non-native configuration on attempted 
functional disulfide re-bridging using traditional methods.111 Although the 
incidence of non-native disulfide re-bridging can be minimised, the leading 
strategy is reagent specific.83 It was rationalised that the use of 
dithioaryl(TCEP)pyridazinedione 7 would ensure minimisation of non-native 
disulfide re-bridging in a general sense (Scheme 26). To this end, 
pyridazinediones 4 (with no internal reducing agent function) and 7 (with 
reducing agent function) were reacted with Herceptin™ under the appropriate 
reaction conditions, i.e. reaction with dithioarylpyridazinedione 4 required pre-
reduction of Herceptin™ with TCEP. Gratifyingly, no non-native disulfide re-
bridging was observed by SDS-PAGE for reagent 7, with complete re-bridging of 
all disulfides confirmed by UV-Vis (Figure 14, lane 4). Analogous reagent 4, with 
no inherent reducing capability, afforded an appreciable amount of non-natively 
re-bridged product (Figure 14, lane 2). Even when dithioarylpyridazinedione 4 
was used in excess and TCEP was added in small portions multiple times (6 × 0.33 
eq. per disulfide every 30 mins), i.e. to minimise the number of open disulfides at 
any given time, non-native re-bridging was still observed (Figure 14, lane 3). 
Although the degree of non-native re-bridging was far less pronounced, the 
reaction protocol is highly cumbersome and inefficient. Reaction of 
dithiopyridazinedione 4 at 37 °C also afforded a mixture of products (Figure 14, 
lane 5). Furthermore, reaction of dibromopyridazinedione 3 at 4 °C and 37 °C also 
afforded a mixture of correctly and incorrectly re-bridged modified Herceptin™ 
conjugates. All re-bridged samples analysed by SDS-PAGE were subjected to pre-
incubation with TCEP, thereby ensuring that any non-re-bridged interchain 
disulfides would be shown through fragmentation. An example of a fully reduced 
mAb is shown in Figure S61.  
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Figure 14 Appraisal of the use of pyridazinediones 4 (in situ 4°C (pre-reduced, 
portion-wise reduction), 37 °C) and 7 for functional re-bridging of Herceptin™ 
(lane 4). 
Providing a reagent that can functionally re-bridge the disulfide bonds of 
Herceptin™ without non-native disulfide re-bridging is a major contribution in 
view of the desire to create homogenous conjugates in the field of antibody–drug 
conjugates.11 Use of Herceptin™, in view of its clinical validation alone and as the 
antibody component of FDA-approved ADC Kadcyla™,114, 115 provides direct 
applicability of the chemistry to this exciting area of targeted therapy. 
 
2.2.5 Extension of technology to incorporate a “click” handle 
 
To make this approach modular and expand its scope, an analogue of 
pyridazinedione 7 was synthesised, which contained an alkyne handle for further 
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chemical functionalisation, i.e. alkyne-pyridazinedione 15. The alkyne group 
enables further chemical modification through the use of CuAAC ‘click’ chemistry. 
 
2.2.5.1 Synthesis of alkyne-bearing dithioaryl(TCEP)pyridazinedione 
analogue 15 
 
For the synthesis of an alkyne-bearing analogue of 
dithioaryl(TCEP)pyridazinedione, an analogous route to that described for 
dithioaryl(TCEP)pyridazinedione 7 was followed, with the exception of the use of 
asymmetric N-substituents on the pyridazinedione core. Initially, mono-alkylation 
was carried out by treating a large excess of di-tert-butyl hydrazine-1,2-
dicarboxylate 1 with caesium carbonate and bromoethane in DMF at 21 °C for 18 
h to give di-tert-butyl 1-ethylhydrazine-1,2-dicarboxylate 11 in a 41% yield. The 
other major product from this reaction is the di-alkylated hydrazine, which is a 
common feedstock molecule within the Chudasama group and, therefore, is not 
undesired. Alkylation of the mono-ethyl hydrazine product 11 was achieved 
through treatment with caesium carbonate and propargyl bromide in DMF at 
21 °C for 72 h to give di-tert-butyl 1-ethyl-2-(prop-2-yn-1-yl)hydrazine-1,2-
dicarboxylate 12 in a 35% yield (Scheme 27). This yield was lower than desired; 
the reaction had only reached 35% conversion even after 3 days, this is likely due 
to the poor nucleophilicity of the remaining non-alkylated nitrogen. 
 
Scheme 27 Two separate alkylations were performed on di-Boc hydrazine to 
create alkyne-bearing Boc protected hydrazine 12. 
The pyridazinedione formation (Scheme 28), involving TFA cleavage of the Boc 
groups of dipropylhydrazine 12, followed by reaction with dibromomaleic 
anhydride under reflux in AcOH afforded dipropyl dibromopyridazinedione 13 in 
an overall yield of 43%.  
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Scheme 28 Hydrazine 12 was treated first with TFA for deprotection followed 
by reflux with dibromomaleic anhydride to give alkyne-bearing 
dibromopyridazinedione 13. 
The alkyne-bearing dibromopyridazinedione product 13 was subsequently 
treated with 4-aminothiophenol with triethylamine in DCM at 21 °C to give alkyne-
bearing thioarylpyridazinedione 14 in a 95% yield (scheme 29). 
 
Scheme 29 Dibromopyridazinedione 13 was treated with 4-aminothiophenol 
and triethylamine in DCM to give alkyne-bearing dithioarylpyridazinedione 14.  
Finally, amide coupling to dimethyl-esterified TCEP analogue 6 was carried out 
through treatment with HATU and triethylamine in DMF at 21 °C for 12 h to give 
the alkyne-bearing dithioaryl(TCEP)pyridazinedione 15 in a 32% yield (scheme 
30).   
 
Scheme 30 Final alkyne-bearing analogue 15 was created through amide 
coupling of TCEP analogue 6 to pyridazinedione 14. 
 
 
2.2.5.2 Application to Herceptin™ 
 
The appraisal of this molecule was carried on the Fab fragment of Herceptin™ as 
this would allow extensive analysis by UV-Vis, MS, SDS-PAGE and ELISA (for 
binding). The optimised conditions for the insertion of 
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dithioaryl(TCEP)pyridazinedione 7, were applied to the alkyne bearing analogue 
15 for the functional re-bridging of the Fab of Herceptin™ to form conjugate 16. 
The efficiency of reduction and re-bridging was translated cleanly from reagent 7 
to alkyne analogue 15.  
 
Scheme 31 Application of alkyne bearing pyridazinedione 15 for disulfide 
reduction and re-bridging as well as “click” functionalisation of the product with 
various azides to form bioconjugates 16a-c.  
Finally, conjugate 16 was functionalised by “click” modification using doxorubicin, 
AlexaFluor488™ and sulfo-cyanine5 azides (see Scheme 31); three biologically 
relevant functional moieties. In all cases, complete conversion was observed to 
afford functionalised conjugates 16a-c, thus demonstrating how the platform may 
be used for efficient introduction of functional modalities as well as reduction and 
re-bridging. The “click” reactions were carried out in BBS with copper (II) sulfate, 
tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) and sodium ascorbate for 
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1.5 h at 21 °C. Samples were analysed by LC-MS, showing only one species in each 
case (figure 15). 
 
 
Figure 15 Deconvoluted MS data for “click” functionalised conjugates 16a-c.  
 
Finally, pyridazinedione 15 was also used to re-bridge Herceptin™ mAb under the 
same conditions as those used for pyridazinedione 7. The compound was shown 
to successfully re-bridge the full antibody system and was amenable to further 
“click” functionalisation with doxorubicin azide to create a homogeneous ADC 
(Scheme 32). The creation of homogeneous ADCs from native antibody scaffolds 
was a significant achievement and a hitherto unmet need in the field. Such 
technology opens the ability to readily functionalise multi-disulfide containing 
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systems to groups and researchers, for whom custom protein expression or 
antibody engineering is too expensive or impractical. 
 
Scheme 32 Incubation with pyridazinedione 15 to give alkyne-bearing 
bioconjugate, 17, followed by further chemical modification via a CuAAC reaction 
to give doxorubicin-bearing ADC 18. 
 
2.2.6 Activity of bioconjugates 
 
It was important that the bioconjugates obtained through reaction with 
pyridazinedione 15 retained the binding activity offered by their native 
counterparts, as it is indicative of how the bioconjugates could perform as 
therapeutics. The Herceptin™ fab fragment (16a-c) (Figure 16) and full antibody 
(18) (Figure 17) bioconjugates were all submitted to analysis by enzyme linked 
immunosorbent assay (ELISA). ELISA is a biochemical assay used to measure the 
52 
 
strength with which a protein, typically an antibody, binds to a complementary 
fragment (or antigen) (a fully detailed protocol is given in Chapter 5: 
Experimental). For all modified Fab fragments (bioconjugates 16a-c) and the 
modified mAb (bioconjugate 18), no loss in activity was observed, i.e. the curves 
generated for the tested conjugates closely fit those of the native analogues, 
therefore indicating that, relative to the native proteins, no binding activity has 
been lost. 
 
Figure 16 Binding activity of Fab-Her bioconjugates 16a, 16b and 16c against 
untreated Fab fragment of Herceptin™. 
 
 
Figure 17 Binding activity of bioconjugate 18 against native unmodified 
Herceptin™. 
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2.3 Conclusion 
 
In conclusion, an important step towards delivering on next-generation functional 
disulfide re-bridging has been demonstrated. This technology allows for reduction 
and functional re-bridging by the use of a single reagent. The technology was 
demonstrated on a series of single disuflide bearing systems. Furthermore, this 
strategy has been shown to result in a high local concentration of bridging agent, 
which has been exploited for the functional re-bridging of a multi-disulfide system 
(i.e. Herceptin™) whilst retaining native disulfide configuration. Finally, facile 
“click” functionalisation and retention of binding affinity, using our strategy, has 
been demonstrated on a full antibody Herceptin™ and its Fab fragment. This has 
resulted in the construction of a DAR 4 ADC from a native antibody scaffold, a 
hitherto unmet need. 
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Chapter 3: Controlled loadings on native mAb 
scaffolds  
 
Whilst a large number of reagents and strategies have been developed to create 
new ADCs, novel approaches for site-specific conjugation continue to attract 
considerable interest.48, 72 This is especially important as it is coming to light that 
specific requirements are essential for each particular ADC to operate at its 
optimum. Specifically, much attention has been given to the generation of ADCs 
with controlled drug loadings due to the varied physical properties of payloads 
requiring different degrees of drug loading. Whilst engineered antibodies have 
worked well in meeting the demand for these tailor-made antibody conjugates, 
e.g. by using engineered cysteine residues, UAAs, selenocysteine or enzymatic 
conjugation, there is a requirement for methods that are based on native antibody 
modification (vide supra, section 1.3).48 This is to ensure that technologies to make 
these “designer” ADCs are more accessible and cost-effective; engineered 
approaches often require significant optimisation on each antibody scaffold they 
are applied to, as well as not being accessible to a broad range of scientists. 
 
It has recently come to light that in various tailor-made ADCs, one of the most 
desirable ratios of drugs to antibody is two. The reason for this is that for certain 
hydrophobic drugs, a loading of two is preferable as it provides a good balance 
between efficacy and pharmacokinetic profile (higher payload loading tends to 
result in a too rapid clearance and lower loadings reduce efficacy). This is an issue 
that has been especially prominent in the construction of pyrrolobenzodiazepine–
protein conjugates. Pyrrolobenzodiazepines (PBDs) are a class of compound 
containing a substituted aromatic A-ring, a diazepine B-ring and a pyrrolidine C-
ring, with a chiral centre at the carbon connecting the B and C rings (Figure 18). 
Overall this grants PBDs the ideal 3-dimesional shape to fit within the DNA minor 
groove, making them well suited for use as anti-tumour agents. Moreover, the PBD 
motif typically features an electrophilic imine (N10-C11) which reacts 
preferentially with the C2-NH2 group on the nucleotide base guanine. This feature 
was exploited to create DNA cross-linking agents by constructing PBD dimers that 
would feature two of the alkylating imine moieties capable of producing both 
inter-strand and intra-strand cross-links in addition to mono-alkylated products 
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(figure 19). Due to the greater variety of possible adducts and better adduct 
stability, PBD dimers typically offer greater cytotoxicity than their monomer 
counterparts.116, 117  
 
 
Figure 18 The core template of PBD drugs, the alkylating capability is offered by 
the electrophilic imine between N10-C11. 
 
Due to the significant cytotoxicity of PBD dimers, they have seen use as payloads 
in ADCs. Seattle Genetics have two PBD dimer-based ADCs in early and late stage 
clinical development; SGN-CD33A and SGN-CD70A (in Phase I and Phase III 
clinical trials, respectively). Both of which have a targeted DAR of 2 (average 1.9), 
which has been shown to be optimal for providing the best balance between 
efficacy and pharmacokinetic profile.118, 119 Higher loadings of the drug, while 
synthetically feasible, produce conjugates with undesirable physicochemical 
properties due to the high hydrophobicity and large size of the PBD dimers, in 
spite of attempts to offset this through the use of solubilising groups as linkers e.g. 
PEG chains. For both SGN-CD33A and SGN-CD70A a DAR 2 is achieved through the 
use of two serine-to-cysteine point mutations on the heavy chains (one on each 
chain) to give two free solvent-accessible thiols that can attack PBD dimer 
maleimide-based linkers. 
 
 
Figure 19 Example of PBD dimer, featuring two electrophilic imines; increased 
ability to cross link DNA strands comes at the cost of larger hydrophobic surface 
area. 
Whilst the challenge of producing lower loadings of hydrophobic drug conjugates 
has been addressed to some extent through the use of the above methods and 
similar antibody engineering strategies in the field e.g. THIOMABS™, they are not 
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readily accessible and there are issues associated with the methodology (e.g. 
potential for non-native disulfide re-bridging and the inefficiency of having to 
reduce, carefully re-oxidise and then conjugate).48, 98, 120, 121 Thus, there is a need 
for a reliable method of constructing antibody conjugates with a loading of two 
entities starting from a native antibody construct. This is especially in the context 
of: (i) the rapid progression in the development of further hydrophobic drugs 
being used and developed in the field;117, 118, 122-125 and (ii) the major attempts on 
native antibodies (i.e. based on the selective reduction of the Fab or hinge 
disulfides of an IgG1)111, 126, 127 proving to lack broad applicability, as evidenced by 
the lack of uptake in the field, or having to employ harsh oxidation conditions or 
enzymes under highly specific conditions. 
 
3.1 A reagent that enables a controlled loading of two 
entities per mAb  
 
While much progress has been made in the synthesis of DAR 4 ADCs, i.e. through 
the use of the integrated reduction-enabled PDs (vide supra, section 2.0), 
dibromomaleimides and other methods (vide supra, section 1.2), the construction 
of DAR 2 conjugates from native antibody scaffolds remains a hitherto unmet 
need. Given their recent successes in functional disulfide re-bridging of mAbs,48, 
75, 82, 83 DiBrPDs were chosen as a platform on which to base a technology that 
could enable the controlled assembly of a DAR 2 ADC. It was envisaged that 
conjugation of two bis-DiBrPDs (each containing a single functional modality) 
with an appropriate linker length could “tie up” two pairs of the four disulfides on 
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an IgG1 to allow the formation of a conjugate with an overall loading of two 
functional modules (Figure 20). 
 
 
Figure 20 The envisaged molecule would feature four cysteine-reactive centres 
and one functional handle; thereby, upon introduction to a reduced mAb, each 
molecule would ‘tie-up’ two disulfide bonds. A flexible tether was essential to 
ensure mAb would not be conformationally constricted. 
 
3.2 Results and discussion  
 
The study commenced with the design and synthesis of an appropriately spaced 
bis-dibromopyridazinedione, bis-diBrPD 19. Given the aim to react a pair of 
disulfides using bis-diBrPD 19 it was rationalised from the outset that the linker 
length would be key. If too short, the bis-PD could not react with a pair of disulfides 
as it could not span the appropriate length; too long and it would increase the 
likelihood of undesirable intermolecular reaction(s) by losing the high local 
concentration effect – thus resulting in inefficient bridging of bis-diBrPD 19 across 
a pair of disulfides. In an effort to avoid these issues a linker was designed based 
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on the spacing of the disulfides on an IgG1 for which a crystal structure has been 
obtained (~16.1 Å = maximum linear distance) (Figure 21).128  
 
 
Figure 21 Image of crystal structure for an IgG1 hinge region with inter-Fab 
(Red - 13.4 Å) disulfide and hinge-Fab (Green - 16.1 Å) disulfide distances 
highlighted. The bis-DiBrPD was designed to be long and flexible enough to cause 
minimum hindrance of mAb. 
 
To ensure flexibility, and improve water solubility of the bis-DiBrPD, a PEG spacer 
was used to link together the PD bioconjugation sites. A single alkyne was installed 
on the bis-PD scaffold to eventually allow a loading of two modules, through the 
use of click chemistry, post-conjugation of bis-DiBrPD 19 on a full antibody. The 
click handle was also positioned by design to be close to a PD-disulfide bridging 
site to minimise exposure of the clicked entity.83 The length of the PEG linker was 
chosen to give the final bis-DiBrPD a maximum linear distance of ~25 Å as this 
was anticipated to be a suitable separation between the bridging sites when taking 
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into account the resolution of the measurement,128 given the flexibility of this 
region of the antibody, and the PEG chain not being structurally linear (figure 22).  
 
 
Figure 22 The proposed structure of bis-DiBrPD 19, which features four 
cysteine reactive centres on the PD end groups, a flexible PEG linker and a single 
functional handle (terminal alkyne) – and its substituent components. 
 
3.2.1 Synthesis of bis-DiBrPD 
 
Synthesis of bis-DiBrPD 19 began with assembly of asymmetric DiBrPD 20 using 
a protocol analogous to those used to synthesise previously mentioned PDs (vide 
supra section 2.1). Methyl hydrazine 21 was reacted with di-tert-butyl 
dicarbonate, triethylamine and 4-(dimethylamino)pyridine in DCM at 20 °C for 
72 h to afford tri-tert-butyl 2-methylhydrazine-1,1,2-tricarboxylate 22 as a yellow 
oil in quantitative yield. Selective mono-deprotection of the non-methyl 
substituted nitrogen was carried out through reaction of tri-tert-butyl 2-
methylhydrazine-1,1,2-tricarboxylate 22 with magnesium perchlorate in MeCN at 
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20 °C for 1 h, which yielded di-tert-butyl 1-methylhydrazine-1,2-dicarboxylate 23 
as a white solid in an 89% yield (scheme 33).84 
 
 
Scheme 33 Methyl hydrazine was prepared for selective alkylation through 
triple Boc-protection followed by selective removal of one of the Boc groups 
from the N-diBoc nitrogen using magnesium perchlorate. 
 
Di-tert-butyl 1-methylhydrazine-1,2-dicarboxylate 23 then underwent an 
alkylation with tert-butyl bromoacetate with caesium carbonate in DMF at 20 °C 
for 16 h to give di-tert-butyl 1-(2-(tert-butoxy)-2-oxoethyl)-2-methylhydrazine-
1,2-dicarboxylate 24 as a colourless oil in a 98% yield (scheme 34).  
 
 
Scheme 34 Alkylation of hydrazine with tert-butyl bromoacetate 
 
The PD precursor 24 then underwent Boc-deprotection with TFA in DCM at 20 °C 
for 2 h. The crude product was then refluxed with dibromomaleic anhydride in 
acetic acid for 16 h to give 2-(4,5-dibromo-2-methyl-3,6-dioxo-3,6-
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dihydropyridazin-1(2H)-yl)acetic acid 25 (scheme 35). With DiBrPD 25 in hand 
synthesis of the second DiBrPD 27 was undertaken. 
 
 
Scheme 35 N-Boc and t-butyl ester removal with TFA followed by DiBrPD 
formation with dibromomaleic anhydride 
 
Di-tert-butyl hydrazine-1,2-dicarboxylate 1 was alkylated with propargyl 
bromide and TBAB in a mixture of toluene and aqueous sodium hydroxide at 20 °C 
for 16 h to afford di-tert-butyl-1-(prop-2-yn-1-yl)hydrazine-1,2-dicarboxylate 25 
as a white solid in a yield of 83% (scheme 36).83 This yield was a significant 
improvement over the yield obtained from the previous mono-alkylation strategy 
used in the synthesis of the asymmetric dithioaryl(TCEP)pyridazinedione 15 (vide 
supra, Section 2.2.5). The biphasic reaction, adapted from a literature protocol, 
uses TBAB as a phase transfer catalyst that prevents over alkylation, resulting in 
a relatively high yield of the desired mono-alkylated hydrazine.129 
 
 
Scheme 36 Selective mono-alkylation of di-Boc hydrazine with propargyl 
bromide. 
 
The alkyne-bearing hydrazine 25 was then alkylated further with tert-butyl 
bromoacetate and caesium carbonate in DMF at 20 °C for 16 h, which gave di-tert-
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butyl 1-(2-(tert-butoxy)-2-oxoethyl)-2-(prop-2-yn-1-yl)hydrazine-1,2-
dicarboxylate 26 as a colourless oil in a 97% yield (Scheme 37).83  
 
 
Scheme 37 Alkylation alkyne hydrazine with tert-butyl bromoacetate. 
 
The bis-substituted di-Boc hydrazine 26 underwent Boc-deprotection with TFA in 
DCM followed by reaction with dibromomaleic anhydride under reflux in acetic 
acid, which afforded the second DiBrPD, 2-(4,5-dibromo-3,6-dioxo-2-(prop-2-yn-
1-yl)-2,3-dihydropyridazin-1(6H)-yl) acetic acid 27 as a white solid in a 65% yield 
(Scheme 28). 
 
 
Scheme 28 N-Boc and tert-butyl ester removal with TFA followed by DiBrPD 
formation with dibromomaleic anhydride. 
 
The PEG linker that would tether the two DiBrPDs, 20 and 27, was prepared 
through dropwise addition of Boc-anhydride in 1,4-dioxane over 2 h to a stirring 
solution of the bis-amine PEG, 3,3'-((oxybis(ethane-2,1-
diyl))bis(oxy))bis(propan-1-amine) in 1,4-dioxane. After a further 30 min at 20°C, 
the mono-Boc protected product, tert-butyl (3-(2-(2-(3- 
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aminopropoxy)ethoxy)ethoxy)propyl)carbamate 28, was given as a colourless oil 
in a 75% yield (Scheme 39). 
 
 
Scheme 39 Mono N-Boc protection of bis-amine PEG in dioxane. 
 
To couple the first bis-DiBrPD 20 to PEG linker 28, the two species were reacted 
with 1,1’-carbonyldiimidazole (CDI) in DMF at 20 °C for 12 h to afford Boc-
protected PEG-DiBrPD 29 as a yellow gum in an 8% yield (scheme 40). Whilst this 
yield was disappointingly low, the synthesis was continued in interest of 
expediting the testing of the final product. In future work, a reagent screen of 
conditions and other carboxylic acid-activating reagents would be desirable. 
 
 
Scheme 40 Amide coupling between DiBrPD 20, and mono-Boc PEG using CDI to 
make Boc-PEG-DiBrPD 29. 
 
The Boc-protected PEG-DiBrPD 29 then underwent deprotection through 
reaction with TFA in DCM at 21 °C for 30 mins. After removal of all volatiles, the 
crude deprotected product was taken through to form the second amide bond via 
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reaction with DiBrPD 27 with HATU and DIPEA in DMF at 21°C for 16 h to afford 
final product, bis-DiBrPD 19 as a yellow gum in a 30% yield (scheme 41). 
 
 
Scheme 41 Deprotection of Boc-PEG-DiBrPD 29, followed by coupling of crude 
amine to second DiBrPD 27 with HATU to give final product bis-DiBrPD 19. 
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3.2.2 Conjugation of Herceptin™ with bis-DiBrPD 19 and click 
functionalisation 
 
Following the successful synthesis of DiBrPD 19, its ability to conjugate a mAb had 
to be appraised. The clinically relevant IgG1 antibody Herceptin™ was chosen as a 
platform upon which to assess the technology. Herceptin™ was reduced with TCEP 
following pre-incubation with bis-DiBrPD 19 in BBS with EDTA at pH 8 for 1 h at 
37 °C to give bioconjugate 30 (scheme 42). Gratifyingly, following purification, the 
sample was analysed via UV-vis, SDS-PAGE gel and LC-MS to show a 
pyridazinedione-to-antibody ratio (PDAR) of 4.0 with complete functional re-
bridging confirmed by SDS-PAGE (Figure 23). Further to this conjugate 30 was 
incubated with excess TCEP, which showed no change in fragmentation profile as 
assessed by SDS-PAGE, further confirming that all disulfides were re-bridged. This 
result supported the original hypothesis, as it suggested each bis-diBrPD had re-
bridged two disulfides; i.e. only such a result could have yielded the observed SDS-
PAGE profile and PDAR. Despite the challenges of using mass spectrometry for 
characterisation of full antibody conjugates,130 especially for disulfide modified 
conjugates,131 mass spectrometry data for conjugate 30 was obtained which 
further verified two additions of bis-diBrPD 19 to Herceptin™. The observed mass, 
146,328 Da (Expected mass: 146,320 Da.) showed addition of two bis-DiBrPD 19 
molecules for one mAb (Figure 24). The MS data clearly shows one major species, 
66 
 
representing a single mAb with two bis-PDs conjugated to it; the raw data shows 
a small amount of half mAb arising from non-native disulfide re-bridging  
 
Scheme 42 Pre-incubation with bis-DiBrPD 19, followed by reduction with TCEP 
yielded conjugate 30, with all four disulfide bonds ‘tied-up’ with two molecules 
of bis-DiBrPD 19, giving a PDAR of 4.0. 
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Figure 23 Left) UV-Vis data for conjugate 30. (Right) SDS-PAGE gel; M.) 
Molecular weight marker; 1) Unmodified Herceptin™; 2) Conjugate 30; 3) 
Conjugate 30 treated with TCEP·HCl; 4) Herceptin™ reduced with TCEP·HCl 
displaying heavy chain and light chain fragments. 
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Figure 24 (a) non-deconvoluted and (b) deconvoluted MS data for conjugate 30 
(deglycosylated). 
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Fluorophore conjugation 
 
 
Scheme 43 “Click” functionalisation, via CuAAC, of conjugate 30 with AF488 
azide to give FAR 2 species conjugate 31. 
 
As conjugate 30 was in possession of two alkyl alkyne handles it was theorised 
that a copper click reaction to a fluorophore azide would yield a conjugate with a 
FAR of 2.0 (Scheme 43). Thus, conjugate 30 was reacted with a large excess (20 
eq) of AlexaFluor488™ azide with copper (II) sulfate, THPTA and sodium 
ascorbate in BBS pH 8 at 21 °C for 1.5 h to afford conjugate 31, which was 
characterised by SDS-PAGE and UV-Vis spectroscopy. An excess of azide was used 
to ensure all pendant alkynes were reacted. Analysis showed the conjugate had a 
loading (FAR) of 2.0, furthermore the result was highly reproducible (n=7) 
reporting FAR in the range 1.9-2.1 by UV-Vis spectroscopy (Figure 25). Following 
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the copper click no degradation of the mAb was observed as monitored by SDS-
PAGE. 
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Figure 25 (Left) UV-Vis data for conjugate 31. (Right) SDS-PAGE gel; M.) 
Molecular weight marker; 1) Unmodified Herceptin™; 2) Conjugate 31. 
 
To ensure the binding capability of the antibody remained unperturbed by the 
conjugation and subsequent click functionalisation, conjugate 31 was submitted 
to an ELISA study. The conjugate was found to have retained binding capability 
completely (with respect to the native mAb) (Figure 26a). Finally, as the 
effectiveness of the platform is dependent on the ability of the resultant 
conjugates to deliver the payloads selectively to the internal cellular environment 
of cancer cells, the ability of the conjugates to be internalised also had to be 
assessed. As such, their internalisation into a HER2 positive cell line was assessed 
via confocal microscopy (Figure 26b). Internalisation can be effectively assessed 
through incubation of appropriate cells with the conjugates at two different 
temperatures; 4 °C and 37 °C. At the lower temperature, the conjugates can be 
seen bound to the cell membrane, incubation at a higher temp allows the receptor-
mediated internalisation to take place as it is an active process. If movement of the 
conjugates from the membrane to the cytoplasm can be observed following 
incubation at 37 °C, it can be concluded that the activity of the antibody has not 
been retarded following modification. Gratifyingly, the conjugate was shown to be 
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internalised rapidly, showing the mechanism of the native mAb had not been 
negatively affected by the conjugation or click procedures. 
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Figure 26 a) ELISA for conjugate 31 against native unmodified Herceptin™ mAb, 
showing binding affinity was unaffected by conjugation and “click”” 
functionalisation. b) Internalisation analysis by confocal microscopy – movement 
of conjugates from membrane to cytoplasm was observed at 37 °C. 
 
Drug conjugation 
 
Given that the intended end purpose of the bis-DiBrPD platform was to enable the 
synthesis of DAR 2 ADCs, it was prudent to demonstrate the utility of the platform 
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with a clinically relevant chemotherapy drug. Doxorubicin was chosen at it offered 
an acceptable balance between toxicity (and associated risk to scientists involved 
with the project) and relevance; more hydrophobic (and toxic) payloads such as 
MMAE/PBD dimers would have required use of specialised facilities certified for 
handling of such materials. 
 
 
Scheme 44 “Click” functionalisation, via CuAAC, of conjugate 30 with 
doxorubicin azide to give a DAR 2 ADC, conjugate 32. 
 
The DAR 2 doxorubicin ADC was assembled per the protocol established for 
conjugate 31. Following a copper click of doxorubicin azide to conjugate 30, a 
Herceptin™ – doxorubicin ADC with a loading of 2.0, conjugate 32, was achieved 
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(Scheme 44). The drug loading and re-bridging were assessed by SDS-PAGE gel 
and UV-Vis spectroscopy (Figure 27). 
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Figure 27 (Left) UV-Vis data for conjugate 32. (Right) SDS-PAGE gel; M.) 
Molecular weight marker; 1) Unmodified Herceptin™; 2) conjugate 32. 
 
3.2.3 Extension of strategy to loadings of four  
 
In order to demonstrate the utility of the bis-DiBrPD platform and expand its 
utility, it was decided that synthesis of an antibody conjugate with a loading of 
four would showcase the flexibility of the strategy, i.e. for cases when a loading of 
four moieties is appropriate. This would also serve as further proof of the disulfide 
pair functional re-bridging hypothesis as well as provide a novel conjugation 
strategy for making antibody conjugates with a loading of four. To this end, a 
second bis-DiBrPD was synthesised; while conceptually similar to bis-DiBrPD 19, 
the new iteration would feature two functional handles instead of one, i.e. once 
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installed on a mAb scaffold bis-DiBrPD 33 would furnish an antibody with four 
points of attachment (Figure 28). 
 
 
Figure 28 Proposed structure of bis-DiBrPD 34, designed to conjugate in the 
same modes as bis-DiBrPD 19 but to feature two functional handles instead of 
one, enabling synthesis of DAR 4 ADCs. 
 
In light of the success of bis-DiBrPD 19, both in its ability to successfully re-bridge 
a Herceptin™ mAb and in that the binding and internalisation ability of the 
resulting conjugates was undisturbed, bis-DiBrPD 33 was designed to match its 
properties as closely as possible (Figure 28).  
 
3.2.3.1 Synthesis of bis-DiBrPD 33 
 
Due to the symmetrical nature of bis-DiBrPD 33 the synthesis was technically 
simpler. DiBrPD 27 was coupled to both ends of bis-amine PEG 3,3'-
((oxybis(ethane-2,1-diyl))bis(oxy))bis(propan-1-amine) with DCC in DMF at 
21 °C for 12 h giving bis-DiBrPD 33 as a yellow gum in an 18% yield (scheme 45). 
 
 
Scheme 45 Preparation of bis-DiBrPD 33 via amide coupling of DiBrPD 27 to 
both ends of bis-amine PEG with DCC. 
 
3.2.3.2 Conjugation to Herceptin and subsequent click functionalisation 
 
Conjugation to Herceptin was performed under analogous conditions for 
conjugate 30. Herceptin™ was reduced with TCEP following pre-incubation with 
bis-DiBrPD 33 in BBS with EDTA at pH 8 for 1 h at 37 °C to give conjugate 34 
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(Scheme 46). Following purification, the sample was analysed via UV-Vis and SDS-
PAGE gel to show a PDAR of 3.9 with complete functional re-bridging (Figure 29).  
 
 
Scheme 46 Pre-incubation with bis-DiBrPD 33, followed by reduction with TCEP 
yielded conjugate 34, with all four disulfide bonds ‘tied-up’ with two molecules 
of bis-DiBrPD 33, giving a PDAR of 4.0. 
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Figure 29 (Left) UV-Vis data for conjugate 34. (Right) SDS-PAGE gel; M) 
Molecular weight marker; 1) Untreated Herceptin™; 2) conjugate 34. Artefact in 
SDS-PAGE gel observed in both samples (ca. 35 kDa). 
 
As conjugate 34 was in possession of four alkyl alkyne handles, it was theorised 
that a copper click reaction to a fluorophore azide would yield a conjugate with an 
FAR of 4.0. Thus, conjugate 34 was reacted with a large excess (40 eq) of 
AlexaFluor488™ azide with copper (II) sulfate, THPTA and sodium ascorbate in 
BBS pH 8 at 21 °C for 1.5 h to afford conjugate 35 (Scheme 47), which was 
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characterised by SDS-PAGE and UV-Vis spectroscopy (Figure 30). An excess of 
azide was used again to ensure all pendant alkynes were reacted. Analysis showed 
the conjugate had a loading (FAR) of 4.0. Following the copper click no 
degradation of the mAb was observed as monitored by SDS-PAGE. 
 
Scheme 47 “Click” functionalisation, via CuAAC, of conjugate 34 with 
AlexaFluor488™ azide to give a FAR 4 species, conjugate 35. 
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Figure 30 (Left) UV-Vis data for conjugate 35 modified with AF488-azide. 
(Right) SDS-PAGE gel; M) Molecular weight marker; 1) Unmodified Herceptin™; 
2) Conjugate 35. 
 
Finally, to assess that the higher loading of fluorophores had not disturbed the 
activity of the mAb scaffold, conjugate 35 was submitted to ELISA study and its 
internalisation assessed as per conjugate 31 (Figure 31). Gratifyingly, both the 
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conjugates binding capability and internalisation were unaffected by the 
functionalisation procedure. 
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Figure 31 a) ELISA for conjugate 35 against native unmodified Herceptin™ mAb, 
showing binding affinity was unaffected by conjugation and “click”” 
functionalisation. b) Internalisation analysis by confocal microscopy – movement 
of conjugates from membrane to cytoplasm was observed at 37 °C. 
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3.3 Conclusion 
 
In conclusion, a strategy for enabling the controlled, reproducible loading of two 
modules onto a native antibody scaffold has been produced. This was enabled by 
the successful synthesis and application of an entity, containing one “click” handle 
and four cysteine reactive centres, which functionally re-bridges two pairs of 
disulfide bonds on an IgG1. Subsequent reaction of the formed conjugate with an 
azide-fluorophore and azide-drug showed that the controlled loading of two 
modules was feasible and reproducible. The strategy, starting from the same 
branch point, was also readily adapted for the formation of a conjugate with a 
loading of four modules. Furthermore, all final conjugates were shown to retain 
binding by ELISA and internalisation by study with confocal microscopy. Given the 
practical simplicity and effectiveness of the bis-DiBrPD conjugation strategy to 
facilitate the loading of two modules starting from a native antibody scaffold, it 
will likely find application in multiple fields where the controlled loading of lower 
than four entities is desirable (e.g. antibody conjugates bearing highly 
hydrophobic modules) and especially in laboratories where antibody engineering 
techniques are not accessible, too expensive or not practical. 
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Chapter 4: Conclusions 
 
In conclusion, two technologies have been developed that enable the construction 
of ADCs with previously unmet degrees of homogeneity. The first, 
dithioaryl(TCEP)pyridazinedione, features a molecule that has two cysteine-
reactive centres, through which phosphine reducing agents are linked. This 
enables a strategy to both reduce and re-bridge disulfide containing proteins, 
allowing for the creation of protein conjugates (that are ready for further chemical 
modification) with a single reagent. Moreover, due to a high local concentration 
effect, in multi-disulfide containing systems only re-bridging in the native 
configuration is observed. This allowed for the construction of homogeneous 
ADCs using only biochemical techniques on native mAb scaffolds, a hitherto unmet 
need in the field. The activity of the resultant ADC, which featured doxorubicin as 
a payload, the activity of which was shown to be unperturbed by the modification 
as shown by ELISA. 
 
The second technology, bis-DiBrPDs, feature two DiBrPDs connected via a flexible 
PEG linker, which can re-bridge mAbs in such a way that all four accessible 
disulfides are ‘tied up’ whilst only installing two chemical handles. By varying the 
terminal PD groups on these molecules a loading of two or four functional moieties 
per mAb can be achieved. The length of the bis-DiBrPDs was designed to span the 
maximum distance between any two accessible disulfide bonds on a mAb, thus the 
conformational freedom of the mAbs would not be hampered. This technology 
was used to synthesise a series of antibody conjugates that with a functional 
loading of two, exemplified with a fluorophore (AlexaFluor488™) and a drug 
(doxorubicin). The resulting conjugates were shown to have precise loadings, as 
assessed by UV-Vis, SDS-PAGE, and LC-MS. Furthermore, the activity of the 
conjugates was shown by ELISA (binding) and confocal microscopy (cell 
internalisation). 
 
Both reported technologies represent significant breakthroughs within the field 
of ADCs. They are both biochemical techniques that provide companies and 
research groups around the globe the means to create ADCs with previously 
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unmet levels of control. Thus, mitigating the need for more expensive protein 
engineering techniques such as mutagenesis and protein expression. 
 
4.1 Outlook 
 
Given the success of the technologies presented in this work, it is prudent to 
appraise their future in the field, both in their commercial and academic 
applications.  
 
4.1.1 Dithioaryl(TCEP)pyridazinedione 
 
The key success of the dithioaryl(TCEP)pyridazinedione, and its analogues, lie in 
the streamlining of the functional disulfide re-bridging protocol and in its ability 
to re-bridge multi-disulfide systems whilst maintaining the native disulfide 
configuration. While this has been applied, with great success, to the IgG1 mAb 
Herceptin™, there are many proteins that see use in therapeutic settings that 
remain challenging targets for disulfide functionalisation. 
 
Insulin 
 
Insulin is a vital endocrine peptide hormone, which comprises two small peptide 
chains of 21 and 30 amino acids. It plays a major role in glucose regulation as well 
as other critical biological mechanisms and, defects in insulin secretion result in 
diabetes type I and II, thus efficient preparation and use of insulin is key to its 
ever-growing role in replacement therapy. Over the last decade, recombinant 
production, conversion of porcine insulin and high-yielding total syntheses have 
made the preparation of this peptide relatively inexpensive.132 Unfortunately, to 
date, even state-of-the-art regimes of replacement therapy are insufficient to 
simulate hormone levels that match the physiological profile and, since all insulin 
analogues must be administered subcutaneously, patient compliance is poor. 
Thus, there is great demand for stable, longer lasting analogues that would allow 
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for less frequent dosing structures, which in turn, will lead to better patient 
compliance and welfare. 
 
 
Figure 32 The structure of the endocrine hormone insulin, featuring three 
disulfide bridges; one intra-chain and two inter-chain. 
 
The challenges associated with insulin use as a therapeutic lie in that it has a poor 
pharmacokinetic profile with low physicochemical stability, inherent 
immunogenicity and short plasma half-life.133, 134 Additionally, the hormone 
becomes inactive and highly immunogenic upon partial unfolding.135 The chemical 
modification of insulin to create stable and long acting analogues has generated a 
significant amount of research. 
 
 In most approaches lysines were non-specifically targeted to increase the 
hydrodynamic radius. This resulted in low-yielding and heterogenous mixtures of 
products.46, 134, 136 Moreover, activity of the protein was abrogated as the 
interaction of the hormone with its receptor is governed by ionic interactions, 
which are inhibited through reaction with charged amino acids.  
 
Attempts to functionalise the two interchain and one intrachain disulfide have met 
varying success. Upon reduction of the disulfides, they rapidly scramble, the 
hormone unfolds and loses biological activity.137 Furthermore, the thiol groups of 
insulin are highly reactive and disulfide exchange is often observed. Modifying 
insulin via its disulfide bonds represents a significant challenge yet would allow 
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for functionalisation of the hormone whilst retaining and potentially stabilising 
the conformation associated with its native, most active disulfide configuration. A 
direct parallel can be made between the intricate 3-disulfide system of insulin and 
IgG1 antibodies 4-disulfide architecture. Indeed, when attempting to natively 
modify IgG1’s essential disulfides, scrambling is almost always observed.48 
  
Dithioaryl(TCEP)pyridazinedione was successfully applied to the full IgG1 mAb 
Herceptin™, resulting in successful re-bridging to produce homogenous ADCs. A 
similar strategy could be used to great effect to functionalise insulin with a broad 
range of modules. Moreover, the unique “built-in” reduction function would allow 
for re-bridging of the protein in its native configuration, thus retaining its 
conformational stability and associated activity. After optimisation of the 
conditions, re-bridged insulin conjugates could be covalently modified further 
with a diverse portfolio of biologically-relevant adducts with the intention of 
prolonging half-life and serum stability. To this end, PEG chains of varying sizes, 
including high molecular weight (20–60 kDa) dendritic PEG chains to prevent 
glomerular filtration of the insulin conjugates, could be attached. Other sought-
after targets for insulin conjugation would be biotin, albumin, and albumin-binder 
proteins, which have also been shown to improve serum stability. Work could 
then be conducted to assess the activity of the insulin conjugates and their viability 
for use as therapeutics. 
 
4.1.2 bis-DiBrPDs 
 
In this work the scope of the presented bis-DiBrPDs are limited to controlled 
loadings of two and four of the same functional moiety. Whilst the use of 
asymmetric bis-DiBrPDs was exploited to allow loadings of two by tying using a 
methyl dummy handle (PD 20) on one end, the same position could be used by a 
functional handle that could react in an orthogonal mode to the PD on the other 
end. This would allow the construction of ADCs bearing two distinct functional 
moieties, with two of each moiety; a highly significant achievement as a controlled 
dual-functionalisation of such a large protein scaffold has hitherto not been 
achieved. An example of the reactive handles that would be applicable could be 
borrowed from Maruani et al.’s aforementioned “dual click” strategy, featuring 
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one strained alkyne, for a SPAAC ‘click’ reaction and a terminal alkyne, for a 
CuAAC.83 
 
 
Figure 33 A proposed structure for a bis-DiBrPD bearing orthogonally reactive 
functional handles. 
 
4.1.3 Combination of technologies: bis-dithioaryl(TCEP)PDs 
 
Dithioaryl(TCEP)pyridazinedione, while capable of producing homogeneous 
ADCs is limited to loadings of four, or eight if two handle per pyridazinedione are 
used. Whereas, the bis-DiBrPDs are not capable of the same consistent 
homogeneous native re-bridging seen with dithioaryl(TCEP)pyridazinediones. 
Individually, the reported technologies have significant utility, however if the two 
technologies were combined, i.e. a bis-thioaryl(TCEP)PDs linked by a flexible PEG, 
the synthesis of homogenous ADCs could be achieved with modular loadings of 
two or four. While the synthesis of such a molecule would be difficult, due to its 
size and complexity, its capability and versatility (with respect to drug loading) 
would be of great value in the creation of new ADCs. 
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Chapter 5: Experimental 
 
5.1 Experimental for Chapter 2 
 
General Experimental  
All reagents were purchased from Aldrich, AlfaAesar or Lumiprobe and were used as 
received. Where described below Pet. refers to petroleum ether (40–60 °C). All reactions 
were monitored by thin-layer chromatography (TLC) on pre-coated SIL G/UV254 silica 
gel plates (254 m) purchased from VWR. Flash column chromatography was carried out 
with Kiesegel 60M 0.04/0.063 mm (200–400 mesh) silica gel. 1H and 13C NMR spectra 
were recorded at ambient temperature on a Bruker Avance 300 instrument operating at 
a frequency of 300 MHz for 1H and 75 MHz for 13C, a Bruker Avance 500 instrument 
operating at a frequency of 500 MHz for 1H and 125 MHz for 13C, and a Bruker Avance 600 
instrument operating at a frequency of 600 MHz for 1H and 150 MHz for 13C in CDCl3 or 
CD3OD (as indicated below). The chemical shifts () for 1H and 13C are quoted relative to 
residual signals of the solvent on the ppm scale. 1H NMR peaks are reported as singlet (s), 
doublet (d), triplet (t), quartet (q), m (multiplet), br (broad) and doublet of quartets (dq). 
Coupling constants (J values) are reported in Hertz (Hz) and are H-H coupling constants 
unless otherwise stated. Signal multiplicities in 13C NMR were determined using the 
distortionless enhancement by phase transfer (DEPT) spectral editing technique. Infrared 
spectra were obtained on a Perkin Elmer Spectrum 100 FTIR Spectrometer operating in 
ATR mode with frequencies given in reciprocal centimetres (cm-1). Melting points were 
measured with a Gallenkamp apparatus and are uncorrected. All reagents containing 
phosphine were stored at ‒18 °C under argon. All bioconjugation reactions were carried 
out in duplicate. 
Protein LC-MS for Figures S14-S24, S32-S36 
LC-MS was performed on protein samples using a Thermo Scientific uPLC connected to 
MSQ Plus Single Quad Detector (SQD). Column: Hypersil Gold C4, 1.9 μm, 2.1 × 50 mm. 
Wavelength: 254 nm. Mobile Phase: 99:1 Water (0.1% formic acid): MeCN (0.1% formic 
acid) to 1:9 Water (0.1% formic acid): MeCN (0.1% formic acid) gradient over 4.5 min. 
Flow Rate: 0.3 mL/min. MS Mode: ES+. Scan Range: m/z = 500–2000. Scan time: 1.5 s. 
Data obtained in continuum mode. The electrospray source of the MS was operated with 
a capillary voltage of 3.5 kV and a cone voltage of 50 V. Nitrogen was used as the nebulizer 
and desolvation gas at a total flow of 600 L/h. Ion series were generated by integration of 
the total ion chromatogram (TIC) over the 3.0–5.0 min range. Total mass spectra for 
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protein samples were reconstructed from the ion series using the pre-installed ProMass 
software using default settings for large proteins in m/z range 500–1500.  
Peptide MALDI-TOF MS for Figure S25 
Samples were prepared by diluting with matrix (α-cyano-4-hydroxy-cinnamic acid in 
water-acetonitrile (2:8, v/v)), 0.5% formic acid. 3 μL of sample was spotted onto the 
MALDI target plate and allowed to dry. Samples were analysed using a Waters MALDI 
micro MX (Waters, UK) with a nitrogen laser in positive reflectron mode using source TLF 
delay (500 ns), an accelerating voltage of 120 V, pulse 2500 and detector 2000. 
Acquisition was between 500–30000 Da with 100 shots/spectrum. 
UV-Vis spectroscopy 
UV-vis spectroscopy was used to determine protein concentrations and pyridazinedione 
to antibody ratios (PAR) using a nanodrop ND-1000 spectrophotometer (Figure S26–29) 
and a Varian Cary 100 Bio UV-Visible spectrophotometer (Figure S30, S31, S41 and S42), 
operating at room temperature. Sample buffer was used as blank for baseline correction. 
SDS-PAGE gels 
Non-reducing glycine-SDS-PAGE at 12% acrylamide gels were performed following 
standard lab procedures. A 6% stacking gel was used and a broad-range MW marker (10–
250 kDa, Prestained PagerulerPlus Protein Standards, Bio-Rad) was co-run to estimate 
protein weights. Samples (15 μL at ~12 μM construct) were mixed with loading buffer (3 
μL, composition for 6 × SDS: 1 g SDS, 3 mL glycerol, 6 mL 0.5 M Tris buffer pH 6.8, 2 mg 
bromophenol blue in 10 mL) and heated at 75 °C for 3 min. The gels were run at 30 mA 
for 50 min in 1 × SDS running buffer. The gels were stained with Coomassie dye. 
85 
 
5.1.1 Synthesis of compounds 
 
Di-tert-butyl 1,2-diethylhydrazine-1,2-dicarboxylate (2) 
 
To a solution of di-tert-butyl hydrazine-1,2-dicarboxylate 1 (1.0 g, 4.3 mmol) and caesium 
carbonate (5.6 g, 17.2 mmol) in DMF (20 mL) was added bromoethane (1.1 g, 10.1 mmol) 
and the reaction mixture stirred at 21 °C for 24 h. After this time, the reaction mixture 
was diluted with EtOAc (50 mL) and washed with deionised water (4 × 20 mL) and brine 
(2 × 20 mL). The organic phase was then concentrated in vacuo and the crude residue 
purified by flash column chromatography (50% EtOAc:Pet.). The appropriate fractions 
were combined and concentrated in vacuo to afford di-tert-butyl 1,2-diethylhydrazine-
1,2-dicarboxylate 2 (1.1 g, 3.8 mmol, 88%) as a colourless oil as a mixture of rotamers. 1H 
NMR (300 MHz, CDCl3) δ 3.57–3.33 (m, 4H), 1.50–1.39 (m, 18H), 1.16 (t, J = 7.2 Hz, 6H); 
13C NMR (75 MHz, CDCl3) δ 155.1 (C), 80.6 (C), 46.37 (CH2), 44.37 (CH2), 28.35 (CH3), 
28.27 (CH3), 13.56 (CH3), 12.95 (CH3); IR (thin film) 2980, 2927, 2881, 1698 cm-1; LRMS 
(ES+) 288 (100, [M+H]+); HRMS (ES+) calcd for C16H32N2O [M+H]+ 288.2049, observed 
288.2054. 
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Figure S1. 1H and 13C NMR data for di-tert-butyl 1,2-diethylhydrazine-1,2-dicarboxylate 
(2). 
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4,5-Dibromo-1,2-diethyl-1,2-dihydropyridazine-3,6-dione (Pyridazinedione 3)1 
 
 
To a 1:1 solution of CH2Cl2:TFA (5 mL:5 mL) was added di-tert-butyl 1,2-
diethylhydrazine-1,2-dicarboxylate 2 (348 mg, 1.21 mmol) and the reaction mixture 
stirred at 21 °C for 1 h. The reaction mixture was then concentrated in vacuo, taking care 
to ensure all the TFA was removed by use of toluene to form an azeotrope. The crude 
residue was then dissolved in AcOH (10 mL), to which was added 3,4-dibromomaleic 
anhydride (310 mg, 1.21 mmol) and the reaction mixture heated under reflux for 2 h. The 
reaction mixture was then concentrated in vacuo and the crude residue was purified by 
flash column chromatography (30–50 % EtOAc:Pet.). The appropriate fractions were then 
combined and concentrated in vacuo to afford 4,5-dibromo-1,2-diethyl-1,2-
dihydropyridazine-3,6-dione (288 mg, 0.88 mmol, 73%) as a pale yellow solid. 1H NMR 
(600 MHz, CDCl3) δ 4.17 (q, J = 7.0 Hz, 4H), 1.28 (t, J = 7.0 Hz, 6H); 13C NMR (150 MHz, 
CDCl3) δ 153.3 (C), 136.1 (C), 42.4 (CH2), 13.2 (CH3); IR (solid) 2979, 2937, 1630, 1574 
cm-1; LRMS (EI) 328 (50, [M81Br81Br]+), 326 (100, [M81Br79Br]+), 324 (50, [M79Br79Br]+); 
HRMS (EI) calcd for C8H10Br2N2O2 [M79Br79Br]+ 323.9104, observed 323.9097. 
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Figure S2. 1H and 13C NMR data for 4,5-dibromo-1,2-diethyl-1,2-dihydropyridazine-3,6-
dione (Pyridazinedione 3). 
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4,5-Bis((4-aminophenyl)thio)-1,2-diethyl-1,2-dihydropyridazine-3,6-dione 
(Pyridazinedione 4) 
 
To a solution of 4,5-dibromo-1,2-diethyl-1,2-dihydropyridazine-3,6-dione 3 (193 mg, 
0.60 mmol) and 4-aminothiophenol (89 mg, 0.71 mmol) in CH2Cl2 (20 ml) was added NEt3 
(166 µL, 1.20 mmol) and the reaction mixture stirred at 21 °C for 2 h. The reaction mixture 
was then washed with deionised water (3 × 15 mL), the organic phase was concentrated 
in vacuo and the crude residue purified by flash column chromatography (40–60% 
EtOAc:Pet.). The appropriate fractions were combined and concentrated in vacuo to give 
4,5-bis((4-aminophenyl)thio)-1,2-diethyl-1,2-dihydropyridazine-3,6-dione 4 (163 mg, 
0.39 mmol, 66%) as an orange-red crystalline solid. m.p. 158–162 °C; 1H NMR (300 MHz, 
CDCl3) δ 7.18–7.08 (m, 4H), 6.62–6.52 (m, 4H), 3.98 (q, J = 7.0 Hz, 4H), 3.75 (br. s, 4H), 
1.17 (t, J = 7.0 Hz, 4H); 13C NMR (75 MHz, CDCl3) δ 156.4 (C), 146.8 (C), 142.3 (C), 134.1 
(C), 120.4 (CH), 115.6 (CH), 41.0 (CH2), 12.7 (CH3); IR (solid) 3420, 3247, 2975, 1708, 
1653, 1596, 1495, 1397 cm-1; LRMS (ES+) 415 (100, [M+H]+); HRMS (ES+) calcd for 
C20H22N4O2S2 [M+H]+ 415.1262, observed 415.1272.  
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Figure S3. 1H and 13C NMR data for 4,5-bis((4-aminophenyl)thio)-1,2-diethyl-1,2-
dihydropyridazine-3,6-dione (Pyridazinedione 4). 
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3-(Bis(3-methoxy-3-oxopropyl)phosphanyl)propanoic acid (6)138 
 
To a solution of tris(2-carboxyethyl)phosphine hydrochloride 5 (1.0 g, 3.5 mmol) in 
MeOH (15 mL), was added Amberlyst® 15 beads (1.0 g), which had been freshly pre-
washed with MeOH (10 mL) for 10 mins, filtered and then dried. The reaction mixture 
was stirred at 21 °C for 1 h. The reaction mixture was then filtered to remove the 
Amberlyst® beads, the filtrate was concentrated in vacuo and the crude residue purified 
by flash column chromatography (1–2% MeOH:CH2Cl2). The appropriate fractions were 
collected and concentrated in vacuo to give 3-(bis(3-methoxy-3-
oxopropyl)phosphanyl)propanoic acid 6 (170 mg, 0.61 mmol, 17%) as a clear oil. 1H NMR 
(600 MHz, CDCl3) δ 3.70 (s, 6H), 2.62–2.36 (m, 6H), 1.76 (t, J = 7.9 Hz, 6H); 13C NMR (150 
MHz, CDCl3) δ 173.8 (C), 173.7  (C), 52.0 (CH3), 30.7 (CH2), 30.5 (CH2), 21.5 (CH2) (d, JC-P = 
13.1 Hz), 21.3 (CH2) (d, JC-P = 13.2 Hz); LRMS (ES-) 277 (100, [M-H]-); HRMS (ES-) calcd 
for C11H19O6P [M-H]- 277.0841, observed 277.0838. 
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Figure S4. 1H and 13C NMR data for 3-(bis(3-methoxy-3-
oxopropyl)phosphanyl)propanoic acid (6). 
93 
 
Tetramethyl 3,3',3'',3'''-((((((1,2-diethyl-3,6-dioxo-1,2,3,6-tetrahydropyridazine-
4,5-diyl)bis(sulfanediyl))bis(4,1-phenylene))bis(azanediyl))bis(3-oxopropane-
3,1-diyl))bis(phosphanetriyl))tetrapropionate (Pyridazinedione 7) 
 
To a solution of 6 (31 mg, 0.11 mmol) in DMF (3 ml) was added HATU (42 mg, 0.11 mmol) 
and the reaction stirred at 21 °C for 15 mins. Following this, 4,5-bis((4-
aminophenyl)thio)-1,2-diethyl-1,2-dihydropyridazine-3,6-dione 3 (12 mg, 0.03 mmol) 
was added and the reaction mixture stirred for a further 5 mins. After this, N,N-
diisopropylethylamine (DIPEA) (20 µL, 0.11 mmol) was added and the reaction mixture 
stirred at 21 °C for 12 h. Following this, the reaction mixture was diluted with EtOAc (20 
mL), and washed with deionised water (3 × 10 mL) and brine (3 × 10 mL). The organic 
phase was then concentrated in vacuo and the crude residue purified by flash column 
chromatography (0–2% MeOH:CH2Cl2). The appropriate fractions were then combined 
and concentrated in vacuo to give pyridazinedione 7 (6 mg, 0.01 mmol, 18%) as a yellow 
gum. 1H NMR (600 MHz, CDCl3) δ 7.80 (s, 2H), 7.45 (d, J = 8.4 Hz, 4H), 7.16 (d, J = 8.3 Hz, 
4H), 4.04 (q, J = 7.0 Hz, 4H), 3.69 (s, 12H), 2.50 (s, 12H), 1.91–1.67 (m, 12H), 1.22 (t, J = 
7.0 Hz, 6H); 13C NMR (150 MHz, CDCl3) δ 174.0 (C), 173.9 (C), 170.9 (C), 156.0 (C), 138.1 
(C), 132.2 (C), 127.1 (C), 120.1 (C), 52.1 (CH3), 41.2 (CH2) , 33.9 (CH2), 30.6 (d, JC-P =16.5, 
CH2), 22.3 (d, JC-P=13.5, CH2), 21.6 (d, JC-P=13.5, CH2), 12.9 (CH3); IR (thin film) 3325, 2953, 
1725, 1614, 1593, 1527, 1494, 1409, 1367; LRMS (ES+) 951 (100, [M(O)+H]+); HRMS 
(ES+) calcd for C42H56O13P2S2 [M(O)+H]+ 951.2839, observed 951.2887. 
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Figure S5. 1H and 13C NMR data for tetramethyl 3,3',3'',3'''-((((((1,2-diethyl-3,6-dioxo-
1,2,3,6-tetrahydropyridazine-4,5-diyl)bis(sulfanediyl))bis(4,1-
phenylene))bis(azanediyl))bis(3-oxopropane-3,1-
diyl))bis(phosphanetriyl))tetrapropionate (Pyridazinedione 7). 
  
95 
 
Di-tert-butyl 1,2-dipropylhydrazine-1,2-dicarboxylate (8) 
 
To a solution of di-tert-butyl hydrazine-1,2-dicarboxylate 1 (1.0 g, 4.3 mmol) and caesium 
carbonate (5.6 g, 17.2 mmol) in DMF (20 mL) was added bromopropane (1.1 g, 9.5 mmol) 
and the reaction mixture stirred at 21 °C for 24 h. After this time, the reaction mixture 
was diluted with EtOAc (50 mL) and washed with deionised water (4 × 20 mL) and brine 
(2 × 20 mL). The organic phase was then concentrated in vacuo and the crude residue 
purified by flash column chromatography (50% EtOAc:Pet.). The appropriate fractions 
were combined and concentrated in vacuo to afford di-tert-butyl 1,2-dipropylhydrazine-
1,2-dicarboxylate (1.1 g, 3.36 mmol, 78%) as a colourless oil as a mixture of rotamers. 1H 
NMR (600 MHz, CDCl3) δ 3.50–3.17 (m, 4H), 1.61 (s, 4H), 1.51–1.38 (m, 18H), 0.90 (t, J = 
7.4 Hz, 6H); 13C NMR (150 MHz, CDCl3) δ 156.0 (C), 155.3 (C), 154.9 (C), 80.9 (C), 80.7 (C), 
80.7 (C), 80.6 (C), 53.5 (CH2), 51.8 (CH2), 51.7 (CH2), 28.4 (CH3), 28.3 (CH3), 22.0 (CH3), 
21.3 (CH3), 21.1 (CH3), 11.7 (CH3), 11.6 (CH3), 11.5 (CH3); IR (thin film) 2974, 2934, 2877, 
1707 cm-1; LRMS (ES+) 317 (100, [M+H]+); HRMS (ES+) calcd for C16H32N2O [M+H]+ 
317.2440, observed 317.2425. 
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Figure S6. 1H and 13C NMR data for di-tert-butyl 1,2-dipropylhydrazine-1,2-
dicarboxylate (8). 
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4,5-Dibromo-1,2-dipropyl-1,2-dihydropyridazine-3,6-dione (9) 
 
To a 1:1 solution of CH2Cl2:TFA (5 mL:5 mL) was added di-tert-butyl 1,2-
dipropylhydrazine-1,2-dicarboxylate (8) (150 mg, 0.47 mmol) and the reaction mixture 
stirred at 21 °C for 1 h. The reaction mixture was then concentrated in vacuo, taking care 
to ensure all the TFA was removed by use of toluene as an azeotrope. The crude residue 
was then dissolved in AcOH (10 mL), to which was added 3,4-dibromomaleic anhydride 
(121 mg, 0.47 mmol) and the reaction mixture heated under reflux for 2 h. The reaction 
mixture was then concentrated in vacuo and the crude residue was purified by flash 
column chromatography (30–50 % EtOAc:Pet.). The appropriate fractions were then 
combined and concentrated in vacuo to afford 4,5-dibromo-1,2-dipropyl-1,2-
dihydropyridazine-3,6-dione (130 mg, 0.37 mmol, 78%) as a pale yellow gum. 1H NMR 
(300 MHz, CDCl3) δ 4.04 (t, J = 7.2 Hz, 4H), 1.67 (dq, J = 7.5 Hz, 4H), 0.93 (t, J = 7.5 Hz, 6H); 
13C NMR (75 MHz, CDCl3) δ 153.6 (C), 135.9 (C), 48.5 (CH2), 21.5 (CH2), 11.0 (CH3); LRMS 
(EI) 356 (50, [M81Br81Br+H]+), 354 (100, [M81Br79Br+H]+), 352 (50, [M79Br79Br+H]+); 
HRMS (EI) calcd for C10H14Br2N2O2 [M79Br79Br]+ 351.9422, observed 351.9420. 
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Figure S7. 1H and 13C NMR data for 4,5-dibromo-1,2-dipropyl-1,2-dihydropyridazine-
3,6-dione (9). 
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N,N'-(((3,6-Dioxo-1,2-dipropyl-1,2,3,6-tetrahydropyridazine-4,5-
diyl)bis(sulfanediyl))bis(4,1-phenylene))diacetamide (Pyridazinedione 10) 
 
To a solution of 4-acetimidothiophenol (169 mg, 1.01 mmol) and 4,5-dibromo-1,2-
dipropyl-1,2-dihydropyridazine-3,6-dione 9 (136 mg, 0.37 mmol) in  CH2Cl2 (20 mL) was 
added NEt3 (212 µL, 1.47 mmol) and the reaction mixture stirred at 21 °C over 72 h. The 
reaction mixture was then washed with deionised water (3 × 15 mL) and the organic 
phase concentrated in vacuo. The crude residue was then purified by flash column 
chromatography (2% MeOH:CH2Cl2), and the appropriate fractions combined and 
concentrated in vacuo to give N,N'-(((3,6-dioxo-1,2-dipropyl-1,2,3,6-
tetrahydropyridazine-4,5-diyl)bis(sulfanediyl))bis(4,1-phenylene))diacetamide 10 (78 
mg, 0.15 mmol, 40%) as a bright red crystalline solid. m.p. 147–150 °C;  1H NMR (600 
MHz, CDCl3) δ 7.40 (d, J = 8.2 Hz, 4H), 7.15 (d, J = 8.5 Hz, 4H), 3.94 (t, J = 7.3 Hz, 4H), 2.18 
(s, 4H), 1.62 (dq, J = 7.3 Hz, 6H), 0.89 (t, J = 7.4 Hz, 6H); 13C NMR (150 MHz, CDCl3) δ 168.5 
(C), 156.5 (C), 137.9 (C), 132.1 (C), 127.3 (CH), 120.2 (CH), 120.1 (CH), 47.0 (CH2), 24.8 
(CH2), 21.1 (CH2), 11.0 (CH3); IR (solid) 3314, 2966, 2929, 2876, 1694, 1632, 1592, 1527, 
1493 cm-1; LRMS (ES+) 527 (100, [M+H]+); HRMS (ES+) calcd for C26H30N4O4S2 [M+H]+ 
527.1787, observed 527.1798. 
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Figure S8. 1H and 13C NMR data for N,N'-(((3,6-dioxo-1,2-dipropyl-1,2,3,6-
tetrahydropyridazine-4,5-diyl)bis(sulfanediyl))bis(4,1-phenylene))diacetamide 
(Pyridazinedione 10). 
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Di-tert-butyl 1-ethylhydrazine-1,2-dicarboxylate (11) 
 
To a solution of di-tert-butyl hydrazine-1,2-dicarboxylate 1 (7.0 g, 30.13 mmol) and 
caesium carbonate (4.0 g, 12.06 mmol) in DMF (50 mL) was added bromoethane (644 µL, 
6.03 mmol) and the reaction mixture left to stir at 21 °C for 18 h. After this time, the 
reaction mixture was diluted with EtOAc (75 mL) and washed with deionised water (3 × 
40 mL) and brine (3 × 30 mL). The organic phase was then concentrated in vacuo, and 
cold hexane was added to the crude residue to precipitate out and recover the excess di-
tert-butyl hydrazine-1,2-dicarboxylate as a white solid through recrystallisation and 
filtration. The filtrate was then concentrated further in vacuo and purified by flash column 
chromatography (5–15% EtOAc:Pet.). The appropriate fractions were combined and 
concentrated in vacuo to give di-tert-butyl 1-ethylhydrazine-1,2-dicarboxylate (642 mg, 
2.46 mmol, 41%) as a white crystalline solid (rotamers present in solution NMR). m.p. 
54–57 °C  1H NMR (600 MHz, CDCl3) δ 6.15 (br. d, 1H), 3.49 (br. s, 2H), 1.48-1.45 (m, 18H), 
1.14 (t, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 155.3 (C), 81.2 (C), 81.0 (C), 45.8 (CH2), 
44.1 (CH2), 28.4 (CH3), 28.3 (CH3), 12.7 (CH3); IR (solid) 3313, 2978, 2934, 1706 cm-1; 
LRMS (ES+) 261 (100, [M+H]+); HRMS (ES+) calcd for C12H24N2O4 [M+H]+ 261.1814, 
observed 261.1813. 
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Figure S9. 1H and 13C NMR data for di-tert-butyl 1-ethylhydrazine-1,2-dicarboxylate 
(11). 
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Di-tert-butyl 1-ethyl-2-(prop-2-yn-1-yl)hydrazine-1,2-dicarboxylate (12) 
 
To a solution of di-tert-butyl 1-ethylhydrazine-1,2-dicarboxylate (11) (642 mg, 2.47 
mmol) and caesium carbonate (2.0 g, 6.14 mmol) in DMF (20 mL) was added propargyl 
bromide (1 mL, 19.4 mmol) and the reaction mixture stirred at 21 °C for 72 h. The reaction 
mixture was then diluted with EtOAc (30 mL) and washed with deionised water (3 × 20 
mL) and brine (3 × 20 mL). The organic phase was then concentrated in vacuo and 
purified by flash column chromatography (60% EtOAc:Pet.). The appropriate fractions 
were collected and concentrated in vacuo to give di-tert-butyl 1-ethyl-2-(prop-2-yn-1-
yl)hydrazine-1,2-dicarboxylate (259 mg, 0.87 mmol, 35%) as a colourless oil as a mixture 
of rotamers. 1H NMR (600 MHz, CDCl3) δ 4.70–4.26 (m, 1H), 4.04–3.89 (m, 1H), 3.71–3.35 
(m, 2H), 2.25 (s, 1H), 1.53–1.41 (m, 18H), 1.30–1.14 (m, 3H); 13C NMR (150 MHz, CDCl3) δ 
155.6 (C), 154.9 (C), 154.5 (C), 82.0 (C), 81.7 (C), 81.6 (C), 81.2 (C), 81.1 (C), 81.0 (C), 79.5 
(C), 79.0 (C), 78.7 (C), 72.7 (C), 72.4 (C), 72.2 (C), 46.6 (CH2), 44.7 (CH2), 41.6 (CH3), 39.6 
(CH3), 39.4 (CH3), 28.4 (CH3), 28.3 (CH3), 28.3 (C), 28.2 (C), 13.7 (CH3), 13.1 (CH3), 13.0 
(CH3); IR (solid) 3262, 2977, 2934, 2126, 1709 cm-1; LRMS (ES+) 299 (100, [M+H]+); 
HRMS (ES+) calcd for C15H26N2O4 [M+H]+ 299.1971, observed 299.1963. 
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Figure S10. 1H and 13C NMR data for di-tert-butyl 1-ethyl-2-(prop-2-yn-1-yl)hydrazine-
1,2-dicarboxylate (12). 
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4,5-Dibromo-1-ethyl-2-(prop-2-yn-1-yl)-1,2-dihydropyridazine-3,6-dione (13) 
 
To a 1:1 solution of CH2Cl2:TFA (5 mL: 5 mL) was added di-tert-butyl 1-ethyl-2-(prop-2-
yn-1-yl)hydrazine-1,2-dicarboxylate 12 (259 mg, 0.87 mmol) and the reaction mixture 
stirred at 21 °C for 1 h. The reaction mixture was then concentrated in vacuo, taking care 
to ensure all the TFA was removed by use of toluene as an azeotrope. The crude residue 
was then dissolved in AcOH (10 mL), to which was added 3,4-dibromomaleic anhydride 
(222 mg, 0.87 mmol) and the reaction mixture heated under reflux for 2 h. The reaction 
mixture was then concentrated in vacuo and the crude residue purified by flash column 
chromatography (60% EtOAc:Pet.). The appropriate fractions were then combined and 
concentrated in vacuo to give 4,5-dibromo-1-ethyl-2-(prop-2-yn-1-yl)-1,2-
dihydropyridazine-3,6-dione (124 mg, 0.37 mmol, 43%) as a pale yellow gum. 1H NMR 
(600 MHz, CDCl3) δ 4.89 (s, 2H), 4.29 (q, J = 7.1 Hz, 2H), 2.42 (t, J = 2.5 Hz, 1H), 1.32 (t, J = 
7.1 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 153.6 (C), 152.9 (C), 137.3 (C), 135.2 (C), 75.6 
(C), 75.0 (C), 43.0 (CH2), 37.1 (CH2), 13.2 (CH3); IR (thin film) 3243, 2985, 2123, 1639, 
1576 cm-1; LRMS (EI) 338 (50, [M81Br81Br+H]+), 336 (100, [M81Br79Br+H]+), 334 (50, 
[M79Br79Br+H]+); HRMS (EI) calcd for C9H8Br2N2O2 [M79Br79Br]+ 333.8953, observed 
333.8950.  
106 
 
Figure S11. 1H and 13C NMR data for 4,5-dibromo-1-ethyl-2-(prop-2-yn-1-yl)-1,2-
dihydropyridazine-3,6-dione (13). 
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4,5-Bis((4-aminophenyl)thio)-1-ethyl-2-(prop-2-yn-1-yl)-1,2-dihydropyridazine-
3,6-dione (14) 
 
To a solution of 4,5-dibromo-1-ethyl-2-(prop-2-yn-1-yl)-1,2-dihydropyridazine-3,6-
dione 13 (124 mg, 0.37 mmol) and 4-aminothiophenol (185 mg, 1.49 mmol) in  CH2Cl2 
(15 mL), was added triethylamine (215 µL, 1.49 mmol), and the reaction mixture was left 
to stir at 21 °C for 18 h. The reaction mixture was then washed with deionised water (3 × 
10 mL), and the organic phase was concentrated in vacuo and the crude residue purified 
by flash column chromatography (2–5% MeOH:CH2Cl2). The appropriate fractions were 
then combined and concentrated in vacuo to give 4,5-bis((4-aminophenyl)thio)-1-ethyl-
2-(prop-2-yn-1-yl)-1,2-dihydropyridazine-3,6-dione 14 (150 mg, 0.35 mmol, 95%) as an 
orange crystalline solid. m.p. 161–164 °C;  1H NMR (600 MHz, CDCl3) δ 7.17–7.12 (m, 4H), 
6.62–6.56 (m, 4H), 4.71 (d, J = 2.5 Hz, 2H), 4.07 (q, J = 7.1 Hz, 1H), 3.77 (br. s, 4H), 2.31 (t, 
J = 2.5 Hz, 1H), 1.20 (t, J = 7.1 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 156.8 (C), 156.0 (C), 
146.9 (C), 143.7 (C), 141.0 (C), 134.12 (C), 134.1 (C), 120.1 (C), 120.0 (C), 115.6 (C), 115.5 
(C), 76.5 (C), 74.0 (CH), 41.5 (CH2), 36.2 (CH2), 12.7 (CH3); IR (solid) 3450, 3359, 3275, 
2128, 1619, 1595, 1517, 1495 cm-1; LRMS (ES+) 425 (100, [M+H]+); HRMS (ES+) calcd for 
C21H20N4O2S2 [M+H]+ 425.1106, observed 425.1107.  
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Figure S12. 1H and 13C NMR data for 4,5-bis((4-aminophenyl)thio)-1-ethyl-2-(prop-2-
yn-1-yl)-1,2-dihydropyridazine-3,6-dione (14). 
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Tetramethyl 3,3',3'',3'''-((((((1-ethyl-3,6-dioxo-2-(prop-2-yn-1-yl)-1,2,3,6-
tetrahydropyridazine-4,5-diyl)bis(sulfanediyl))bis(4,1-
phenylene))bis(azanediyl))bis(3-oxopropane-3,1-
diyl))bis(phosphanetriyl))tetrapropionate (Pyridazinedione 15) 
 
To a solution of 3-(bis(3-methoxy-3-oxopropyl)phosphanyl)propanoic acid 6 (170 mg, 
0.61 mmol) in DMF (10 mL), was added HATU (232 mg, 0.61 mmol) and the reaction 
mixture stirred at 21 °C for 15 mins. After this time, to the reaction mixture was added 
4,5-bis((4-aminophenyl)thio)-1-ethyl-2-(prop-2-yn-1-yl)-1,2-dihydropyridazine-3,6-
dione (118 mg, 0.28 mmol) and the reaction mixture stirred for a further 5 mins. 
Following this, to the reaction mixture was added N,N-diisopropylethylamine (DIPEA) 
(195 µL, 1.12 mmol), and the mixture left to stirr at 21 °C for 12 h. After this time, the 
reaction mixture was diluted with EtOAc (20 mL) and washed with deionised water (3 × 
10 mL) and brine (3 × 10 mL). The organic phase was then concentrated in vacuo and the 
crude residue purified by flash column chromatography (0–2% MeOH:CH2Cl2). The 
appropriate fractions were then combined and concentrated in vacuo to give 
pyridazinedione 15 (84 mg, 0.09 mmol, 32%) as a yellow oil. 1H NMR (600 MHz, CDCl3) δ 
7.53–7.41 (m, 3H), 7.25–7.02 (m, 5H), 6.59 (d, J = 8.4 Hz, 2H), 4.82–4.65 (m, 3H), 4.21–
3.94 (m, 4H), 3.80–3.59 (m, 12H), 2.99–1.74 (m, 24H), 1.33–1.16 (m, 6H); 13C NMR (150 
MHz, CDCl3) δ 174.0 (C), 156.7 (C), 155.8 (C), 147.3 (C), 137.9 (C), 134.2 (C), 132.0 (CH), 
120.0 (CH), 115.7 (CH), 76.3 (C), 74.2 (CH), 52.5 (CH2), 52.1 (CH2), 41.7 (CH2), 36.3 (CH2), 
30.5 (CH2), 29.8 (CH2), 26.3 (CH3), 23.8 (CH2), 21.4 (CH2), 12.8 (CH3); IR (thin film) 3212, 
2925, 2852, 2120, 1734, 1687, 1624, 1531, 1494 cm-1; LRMS (ES+) 944 (100, [M+H]+); 
HRMS (ES+) calcd for C43H54N4O12P2S2 [M+H]+ 944.2655, observed 944.2651.   
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Figure S13. 1H and 13C NMR data for tetramethyl 3,3',3'',3'''-((((((1-ethyl-3,6-dioxo-2-
(prop-2-yn-1-yl)-1,2,3,6-tetrahydropyridazine-4,5-diyl)bis(sulfanediyl))bis(4,1-
phenylene))bis(azanediyl))bis(3-oxopropane-3,1-
diyl))bis(phosphanetriyl))tetrapropionate (Pyridazinedione 15). 
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5.1.2 Bioconjugation Reactions for Chapter 2 
 
Trastuzumab Fab fragment (Fab fragment) preparation83 
Preparation of Fab fragment using sequential digests with pepsin and papain 
Immobilized pepsin (0.15 mL) was washed with digestion buffer (20 mM sodium acetate 
trihydrate, pH 3.1) four times and trastuzumab (0.5 mL, 6.41 mg⋅mL-1 in digestion buffer) 
was added. The mixture was incubated for 5 h at 37 °C whilst shaking (1100 rpm). The 
resin was separated from the digest using a filter column, and washed with digest buffer 
(50 mM phosphate, 1 mM EDTA, 150 mM NaCl, pH 6.8) three times. The digest was 
combined with the washes and the volume adjusted to 0.5 mL.  
After this, immobilized papain (0.5 mL, 0.25 mg⋅mL-1) was activated with 10 mM DTT (in 
digest buffer: 50 mM phosphate, 1 mM EDTA, 150 mM NaCl, pH 6.8) whilst shaking (1100 
rpm) for 1 h at 37 °C. The resin was washed with digest buffer (without DTT) four times 
and the 0.5 mL of Herceptin-F(ab’)2 added. The mixture was incubated for 16 h at 37 °C 
whilst shaking (1100 rpm). Then the resin was separated from the digest using a filter 
column, and washed with BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 8.0) 
three times. The digest was combined with the washes and the buffer was exchanged 
completely for BBS using diafiltration columns (GE Healthcare, 10000 MWCO) and the 
volume adjusted to 0.5 mL. The digest was analysed by SDS-PAGE and LCMS to reveal 
formation of a single trastuzumab Fab fragment: observed mass 47585. The 
concentration of the Fab fragment was determined by UV/VIS using a molecular 
extinction coefficient of 280 = 68590 M-1⋅cm-1. [Fab-Her fragment] 2.6 mg⋅mL-1 (0.5 mL), 
62%. 
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Bioconjugation reactions involving Fab fragment of Herceptin 
Control for untreated Fab fragment of Herceptin for experiments using 
pyridazinediones 7 and 10 
(a) 
 
 
(b) 
 
 
 (c) 
 
Figure S14. (a) TIC, (b) non-deconvoluted and (c) deconvoluted MS data for untreated 
Fab fragment of Herceptin for experiments using pyridazinediones 7 and 10. 
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Reaction of Fab fragment of Herceptin with pyridazinedione 7 (1.25 eq.)   
 
Pyridazinedione 7 (0.56 µL, 2.0 mM in DMF, 1.25 eq) was added to Fab fragment of 
Herceptin (30 µL, 1.4 mg/mL, 30 µM) in BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM 
EDTA, pH 8.0). The reaction mixture was incubated at 37 °C for 1 h. Excess reagents were 
removed by repeated diafiltration into deionised water using VivaSpin sample 
concentrators (GE Healthcare, 10,000 MWCO). The samples were analysed by LCMS. 
Expected mass: 47,751 Da. Observed mass: 47,755 Da. 
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 (c) 
 
Figure S15. (a) TIC, (b) non-deconvoluted and (c) deconvoluted MS data for Fab 
fragment of Herceptin reacted with pyridazinedione 7 (1.25 eq.). 
Reaction of Fab fragment of Herceptin with pyridazinedione 7 (2 eq.)   
 
Pyridazinedione 7 (0.9 µL, 2.0 mM in DMF, 2 eq) was added to Fab fragment of Herceptin 
(30 µL, 1.4 mg/mL, 30 µM) in BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 
8.0). The reaction mixture was incubated at 37 °C for 1 h. Excess reagents were removed 
by repeated diafiltration into deionised water using VivaSpin sample concentrators (GE 
Healthcare, 10,000 MWCO). The samples were analysed by LCMS. Expected mass: 47,751 
Da. Observed mass: 47,743 Da. 
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(b) 
 
(c) 
 
Figure S16. (a) TIC, (b) non-deconvoluted and (c) deconvoluted MS data for Fab 
fragment of Herceptin reacted with pyridazinedione 7 (2 eq.). 
Reaction of Fab-Her fragment with pyridazinedione 7 (5 eq.)   
 
Pyridazinedione 7 (2.3 µL, 2.0 mM in DMF, 5 eq) was added to Fab fragment of Herceptin 
(30 µL, 1.4 mg/mL, 30 µM) in BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 
8.0). The reaction mixture was incubated at 37 °C for 1 h. Excess reagents were removed 
by repeated diafiltration into deionised water using VivaSpin sample concentrators (GE 
Healthcare, 10,000 MWCO). The samples were analysed by LCMS. Expected mass: 47,751 
Da. Observed mass: 47,753 Da. 
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 (a) 
 
 
(b) 
  
(c) 
 
Figure S17. (a) TIC, (b) non-deconvoluted and (c) deconvoluted MS data for Fab 
fragment of Herceptin reacted with pyridazinedione 7 (5 eq.). 
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Reaction of Fab fragment of Herceptin with pyridazinedione 7 (10 eq.)   
 
Pyridazinedione 7 (4.5 µL, 2.0 mM in DMF, 10 eq) was added to Fab fragment of Herceptin 
(30 µL, 1.4 mg/mL, 30 µM) in BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 
8.0). The reaction mixture was incubated at 37 °C for 1 h. Excess reagents were removed 
by repeated diafiltration into deionised water using VivaSpin sample concentrators (GE 
Healthcare, 10,000 MWCO). The samples were analysed by LCMS. Expected mass: 47,751 
Da. Observed mass: 47,750 Da. 
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Figure S18. (a) TIC, (b) non-deconvoluted and (c) deconvoluted MS data for Fab 
fragment of Herceptin reacted with pyridazinedione 7 (10 eq.). 
Reduction of Fab fragment of Herceptin and subsequent reaction with 
pyridazinedione 10 
 
TCEP (4.5 µL, 2.0 mM, 10 eq) was added to the Fab fragment of Herceptin (30 µL, 
1.4 mg/mL, 30 µM) in BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 8.0). 
The reaction was incubated at 37 °C for 1 h. Excess reagents were removed by repeated 
diafiltration into fresh BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 8.0) 
using VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO). Pyridazinedione 10 
(4.5 µL, 2.0 mM, 10 eq) was subsequently added to the reaction mixture and incubated at 
37 °C for 1 h. Excess reagents were removed by repeated diafiltration into deionised 
water using VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO). The samples 
were analysed by LCMS. Expected mass: 47,779 Da. Observed mass: 47,782 Da. 
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Figure S19. (a) TIC, (b) non-deconvoluted and (c) deconvoluted MS data for Fab 
fragment of Herceptin reacted with pyridazinedione 10. 
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Reaction of Fab fragment of Herceptin with pyridazinedione 7 (2 eq.) in the 
presence of pre-incubated pyridazinedione 10 (1 eq.)   
 
Pyridazinedione 7 (0.9 µL, 2.0 mM in DMF, 2 eq) was added to Fab fragment of Herceptin 
(30 µL, 1.4 mg/mL, 30 µM) in BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 
8.0), which had been pre-incubated at 37 °C for 0.5 h with pyridazinedione 10 (0.45 µL, 
2.0 mM in DMF, 1 eq). The reaction mixture was incubated further at 37 °C for 1 h. Excess 
reagents were removed by repeated diafiltration into deionised water using VivaSpin 
sample concentrators (GE Healthcare, 10,000 MWCO). The samples were analysed by 
LCMS. Expected mass: 47,751 Da. Observed mass: 47,745 Da. 
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Figure S20. (a) TIC, (b) non-deconvoluted and (c) deconvoluted MS data for Fab 
fragment of Herceptin reacted with pyridazinedione 7 in the presence of 
pyridazinedione 10 (ratio  of 7:10 = 2:1). 
Reaction of Fab fragment of Herceptin with pyridazinedione 7 (2 eq.) in the 
presence of pre-incubated pyridazinedione 10 (2 eq.)   
 
Pyridazinedione 7 (0.9 µL, 2.0 mM in DMF, 2 eq) was added to Fab fragment of Herceptin 
(30 µL, 1.4 mg/mL, 30 µM) in BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 
8.0), which had been pre-incubated at 37 °C for 0.5 h with pyridazinedione 10 (0.9 µL, 2.0 
mM in DMF, 2 eq). The reaction mixture was incubated further at 37 °C for 1 h. Excess 
reagents were removed by repeated diafiltration into deionised water using VivaSpin 
sample concentrators (GE Healthcare, 10,000 MWCO). The samples were analysed by 
LCMS. Expected mass: 47,751 Da. Observed mass: 47,749 Da. 
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Figure S21. (a) TIC, (b) non-deconvoluted and (c) deconvoluted MS data for Fab 
fragment of Herceptin reacted with pyridazinedione 7 in the presence of 
pyridazinedione 10 (ratio  of 7:10 = 2:2). 
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Reaction of Fab fragment of Herceptin with pyridazinedione 7 (2 eq.) in the 
presence of pre-incubated pyridazinedione 10 (5 eq.)   
 
Pyridazinedione 7 (0.9 µL, 2.0 mM in DMF, 2 eq) was added to Fab fragment of Herceptin 
(30 µL, 1.4 mg/mL, 30 µM) in BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 
8.0), which had been pre-incubated at 37 °C for 0.5 h with pyridazinedione 10 (2.3 µL, 2.0 
mM in DMF, 5 eq). The reaction mixture was incubated further at 37 °C for 1 h. Excess 
reagents were removed by repeated diafiltration into deionised water using VivaSpin 
sample concentrators (GE Healthcare, 10,000 MWCO). The samples were analysed by 
LCMS. Expected mass: 47,751 Da. Observed mass: 47,751 Da. 
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Figure S22. (a) TIC, (b) non-deconvoluted and (c) deconvoluted MS data for Fab 
fragment of Herceptin reacted with pyridazinedione 7 in the presence of 
pyridazinedione 10 (ratio  of 7:10 = 2:5). 
Reduction of Fab fragment of Herceptin and subsequent reaction with 
pyridazinedione 10 and pyridazinedione 7 (1:1 ratio 0.5 eq.:0.5 eq) 
 
TCEP (4.5 µL, 2.0 mM, 10 eq) was added to the Fab fragment of Herceptin (30 µL, 
1.4 mg/mL, 30 µM) in BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 8.0). 
The reaction was incubated at 37 °C for 1.0 h. Excess reagents were removed by repeated 
diafiltration into fresh BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 8.0) 
using VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO). Pre-mixed 
pyridazinediones 7 and 10 ([1.1 µL, 0.2 mM in DMF, 0.5 eq] each) were subsequently 
added to the reaction mixture and incubated at 37 °C for 1.0 h. Excess reagents were 
removed by repeated diafiltration into deionised water using VivaSpin sample 
concentrators (GE Healthcare, 10,000 MWCO). The samples were analysed by LCMS. 
Expected mass: 47,751 Da [Fab fragment reacted with pyridazinedione 7] and 47,779 Da 
[Fab fragment reacted with pyridazinedione 10]. Observed mass:47,585 Da [unreacted 
Fab fragment], 47,746 Da [Fab fragment reacted with pyridazinedione 7] and 47,776 Da 
[Fab fragment reacted with pyridazinedione 10]. 
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 (a) 
(b) 
(c) 
(d)
 
Figure S23. (a) TIC, (b) non-deconvoluted, (c) deconvoluted MS data over range 20,000–
80,000 Da and (d) deconvoluted data over range 46,500–48,500 Da for reduction of Fab 
fragment of Herceptin and subsequent reaction with pyridazinedione 7 and 
pyridazinedione 10 (1:1 ratio 0.5 eq.:0.5 eq). 
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Reaction of Octreotide peptide with pyridazinedione 7 (1.25 eq.)   
 
Pyridazinedione 7 (0.56 µL, 2.0 mM in DMF, 1.25 eq) was added to octreotide (30 µL, 30 
µg/mL, 30 µM) in peptide buffer (40% MeCN, 2.5% DMF, 57.5% phosphate buffer [50 mM, 
pH 6.2]). The reaction mixture was incubated at 37 °C for 1 h. The samples were analysed 
by LCMS. Expected mass: 1185 Da. Observed mass: 1184 Da. 
 (a) 
 
 
(b) 
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(c) 
(d) 
 
(e) 
 
(f) 
Figure S24. (a) TIC, (b) non-deconvoluted and (c) deconvoluted MS data for native 
octreotide; (d) TIC, (e) non-deconvoluted and (f) deconvoluted MS data for modified 
octreotide. 
Reaction of Somatostatin peptide with pyridazinedione 7(1.25 eq.)   
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Pyridazinedione 7 (0.56 µL, 2.0 mM in DMF, 1.25 eq) was added to somatostatin (30 µL, 
30 µg/mL, 30 µM) in peptide buffer (40% MeCN, 2.5% DMF, 57.5% phosphate buffer [50 
mM, pH 6.2]) The reaction mixture was incubated at 37 °C for 1 h. The samples were 
analysed by MALDI-TOF. Expected mass: 1,804 Da. Observed mass: 1,808 Da [M+H]+, 
1,830 Da [M+Na] +, 1,847 Da [M+K] +. 
(a) 
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(b) 
 
(c) 
 
  
130 
 
(d) 
 
 
 
Figure S25. (a) MS data for native Somatostatin (1100–2000 m/z), (b) MS data for 
native Somatostatin (1580–2000 m/z), (c) MS data for modified Somatostatin (1100–
2000 m/z) and (d) MS data for modified Somatostatin (1650–2000 m/z). 
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In situ reduction of Herceptin mAb and reaction with pyridazinedione 4 at 4 °C (25 
eq.)   
 
TCEP.HCl (2.3 µL, 20 mM in deionised water, 50 eq.) was added to Herceptin (30 µL, 4.4 
mg/mL, 30 µM) in BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 8.0) which 
had been pretreated and stored at 4 °C for 1 h previously with pyridazinedione 4 (5.6 µL, 
4 mM in DMF, 25 eq.). The reaction mixture was then stored at 4 °C for 15 h. Excess 
reagents were removed by repeated diafiltration into deionised water using VivaSpin 
sample concentrators (GE Healthcare, 10,000 MWCO). The samples were analysed by 
SDS-PAGE gel (see Figure S37. [lane 2]) and UV-vis spectroscopy was used to determine 
a PAR of 4.2. PAR was calculated according to that previously described.3  
 
Figure S26.  UV-vis data for Herceptin modified with pyridazinedione 4 at 4 °C in situ. 
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Portion-wise in situ reduction of Herceptin mAb and reaction with pyridazinedione 
4 at 4 °C (25 eq.)   
 
TCEP.HCl (1.2 µL, 0.2 mM in deionised water, 1.34 eq. [0.33 eq. per disulfide]) was added 
once every 0.5 h for 2.5 h (6 additions in total) to Herceptin (30 µL, 4.4 mg/mL, 30 µM) in 
BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 8.0) which had been 
pretreated and stored at 4 °C for 1 h previously with pyridazinedione 4 (5.6 µL, 4 mM in 
DMF, 25 eq.). The reaction mixture was then stored at 4 °C for 15 h. Excess reagents were 
removed by repeated diafiltration into deionised water using VivaSpin sample 
concentrators (GE Healthcare, 10,000 MWCO). The samples were analysed by SDS-PAGE 
gel (see Figure S37. [lane 3]) and UV-vis spectroscopy was used to determine a PAR of 
4.0. PAR was calculated according to that previously described.3 
 
Figure S27.  UV-vis data for Herceptin modified with pyridazinedione 4 in situ with 
portion-wise addition of TCEP.HCl. 
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Reaction of Herceptin mAb with pyridazinedione 7 at 4 °C (8 eq.)   
 
Pyridazinedione 7 (1.9 µL, 4.0 mM in DMF, 8 eq.) was added to Herceptin (30 µL, 4.4 
mg/mL, 30 µM) in BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 8.0) which 
had been stored at 4 °C for 1 h previously. The reaction mixture was then stored at 4 °C 
for 15 h. Excess reagents were removed by repeated diafiltration into deionised water 
using VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO). The samples were 
analysed by SDS-PAGE gel (see Figure S37. [lane 4]) and UV-vis spectroscopy was used to 
determine a PAR of 4.0. PAR was calculated according to that previously described.3 
 
Figure S28.  UV-vis data for Herceptin modified with pyridazinedione 7 at 4 °C. 
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In situ reduction of Herceptin mAb and reaction with pyridazinedione 4 at 37 °C (25 
eq.)   
 
TCEP.HCl (2.3 µL, 20 mM in deionised water, 50 eq.) was added to Herceptin (30 µL, 4.4 
mg/mL, 30 µM) in BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 8.0) which 
had been pretreated and stored at 37 °C for 1 h previously with pyridazinedione 4 (5.6 
µL, 4.0 mM in DMF, 25 eq). The reaction mixture was then stored at 37 °C for 2 h. Excess 
reagents were removed by repeated diafiltration into deionised water using VivaSpin 
sample concentrators (GE Healthcare, 10,000 MWCO). The samples were analysed by 
SDS-PAGE gel (see Figure S37. [lane 5]) and UV-vis spectroscopy was used to determine 
a PAR of 4.2. PAR was calculated according to that previously described.3 
 
Figure S29.  UV-vis data for Herceptin modified with pyridazinedione 4 at 37 °C in situ. 
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In situ reduction of Herceptin mAb and reaction with pyridazinedione 3 at 37 °C (25 
eq.)   
 
TCEP.HCl (2.3 µL, 20 mM in deionised water, 50 eq.) was added to Herceptin (30 µL, 4.4 
mg/mL, 30 µM) in BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 8.0) which 
had been pretreated and stored at 37 °C for 1 h previously with pyridazinedione 3 (5.6 
µL, 4.0 mM in DMF, 25 eq). The reaction mixture was then stored at 37 °C for 2 h. Excess 
reagents were removed by repeated diafiltration into deionised water using VivaSpin 
sample concentrators (GE Healthcare, 10,000 MWCO). The samples were analysed by 
SDS-PAGE gel (see Figure S38. [lane 3]) and UV-vis spectroscopy was used to determine 
a PAR of 4.1. PAR was calculated according to that previously described.3 
 
Figure S30.  UV-vis data for Herceptin modified with pyridazinedione 3 at 37 °C in situ. 
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In situ reduction of Herceptin mAb and reaction with pyridazinedione 3 at 4 °C (25 
eq.)   
 
TCEP.HCl (2.3 µL, 20 mM in deionised water, 50 eq.) was added to Herceptin (30 µL, 4.4 
mg/mL, 30 µM) in BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 8.0) which 
had been pretreated and stored at 4 °C for 1 h previously with pyridazinedione 3 (5.6 µL, 
4 mM in DMF, 25 eq.). The reaction mixture was then stored at 4 °C for 15 h. Excess 
reagents were removed by repeated diafiltration into deionised water using VivaSpin 
sample concentrators (GE Healthcare, 10,000 MWCO). The samples were analysed by 
SDS-PAGE gel (see Figure S38. [lane 2]) and UV-vis spectroscopy was used to determine 
a PAR of 3.9. 
 
Figure S31.  UV-vis data for Herceptin modified with pyridazinedione 3 at 4 °C in situ. 
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Control for untreated Fab fragment of Herceptin for experiments using 
pyridazinedione 15 
During the course of this study the LC-MS device used (Thermo Scientific uPLC connected 
to MSQ Plus Single Quad Detector) underwent servicing and recalibration, this caused a 
slight change in observed mass for the untreated Fab fragment of Herceptin. 
(a) 
 
 
(b) 
 
(c) 
 
Figure S32. (a) TIC, (b) non-deconvoluted and (c) deconvoluted MS data for untreated 
Fab fragment of Herceptin for experiments using pyridazinedione 15. 
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Reaction of Fab fragment of Herceptin with pyridazinedione 15 (1.25 eq) (Synthesis 
of bioconjugate 16) 
 
Pyridazinedione 15 (0.57 µL, 2.0 mM in DMF, 1.25 eq) was added to Fab fragment of 
Herceptin (30 µL, 1.4 mg/mL, 30 µM) in BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM 
EDTA, pH 8.0). The reaction mixture was incubated at 37 °C for 1 h. Excess reagents were 
removed by repeated diafiltration into deionised water using VivaSpin sample 
concentrators (GE Healthcare, 10,000 MWCO). The samples were analysed by LCMS. 
Expected mass: 47,785 Da. Observed mass: 47,787 Da. 
 (a) 
 
 
(b) 
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 (c) 
 
Figure S33. (a) TIC, (b) non-deconvoluted and (c) deconvoluted MS data for 
bioconjugate 16. 
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Reaction of Fab-Her bioconjugate 16 with Cy5-azide (Synthesis of bioconjugate 
16a) 
 
Cy5-azide (1.0 µL, 2.0 mM in water, 2 eq), CuSO4 (1.0 µL, 2.0 mM in water, 2 eq), tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA) (1.0 µL, 10 mM in water, 10 eq) and 
sodium ascorbate (5.0 µL, 0.10 M in water, 500 eq) were added in series to bioconjugate 
16 (20 µL, 2.4 mg/mL, 50 µM) in BBS (25 mM sodium borate, 25 mM NaCl, pH 8.0). The 
reaction mixture was stored at 21 °C for 1.5 h. The excess reagents were then removed by 
repeated diafiltration into fresh PBS with 2 mM EDTA (to remove residual copper ions) 
using VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO). Following this, the 
buffer salts were removed by repeated diafiltration into deionised water using VivaSpin 
sample concentrators (GE Healthcare, 10,000 MWCO). The samples were then analysed 
by LCMS. Expected mass: 48,615 Da. Observed mass: 48,613 Da. 
 (a) 
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(b) 
 
(c) 
 
Figure S34. (a) TIC, (b) non-deconvoluted and (c) deconvoluted MS data for 
bioconjugate 16a. 
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Reaction of Fab-Her bioconjugate 16 with Doxorubicin-azide3 (Synthesis of 
bioconjugate 16b) 
 
Doxorubicin-azide3 (1.0 µL, 2.0 mM in water, 2 eq), CuSO4 (1.0 µL, 2.0 mM in water, 2 eq), 
tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) (1.0 µL, 10 mM in water, 10 eq) and 
sodium ascorbate (5.0 µL, 0.10 M in water, 500 eq) were added in series to bioconjugate 
16 (20 µL, 2.4 mg/mL, 50 µM) in BBS (25 mM sodium borate, 25 mM NaCl, pH 8.0). The 
reaction mixture was stored at 21 °C for 1.5 h. The excess reagents were then removed by 
repeated diafiltration into fresh PBS with 2 mM EDTA (to remove residual copper ions) 
using VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO). Following this, the 
buffer salts were removed by repeated diafiltration into deionised water using VivaSpin 
sample concentrators (GE Healthcare, 10,000 MWCO). The samples were then analysed 
by LCMS. Expected mass: 48,587 Da. Observed mass: 48,586 Da. 
 (a) 
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(b) 
 
(c) 
 
Figure S35. (a) TIC, (b) non-deconvoluted and (c) deconvoluted MS data for 
bioconjugate 16b. 
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Reaction of Fab-Her bioconjugate 16 with AlexaFluor 488®-azide (Synthesis of 
bioconjugate 16c) 
 
AlexaFluor 488®-azide (1.0 µL, 2.0 mM in water, 2 eq), CuSO4 (1.0 µL, 2.0 mM in water, 2 
eq), tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) (1.0 µL, 10 mM in water, 10 eq) 
and sodium ascorbate (5.0 µL, 0.10 M in water, 500 eq) were added in series to 
bioconjugate 16 (20 µL, 2.4 mg/mL, 50 µM) in BBS (25 mM sodium borate, 25 mM NaCl, 
pH 8.0). The reaction mixture was stored at 21 °C for 1.5 h. The excess reagents were then 
removed by repeated diafiltration into fresh PBS with 2 mM EDTA (to remove residual 
copper ions) using VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO). 
Following this, the buffer salts were removed by repeated diafiltration into deionised 
water using VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO). The samples 
were then analysed by LCMS. Expected mass: 48,442 Da. Observed mass: 48,447 Da. 
 (a) 
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(b) 
 
(c) 
 
Figure S36. (a) TIC, (b) non-deconvoluted and (c) deconvoluted MS data for 
bioconjugate 16c. 
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SDS-PAGE gel for Herceptin modification with pyridazinediones 4 and 7 
 
Figure S37. Comparison of traditional methods for Herceptin modification against the 
use of pyridazinedione 7. M) Molecular weight marker. 1) Untreated Herceptin. 2) In 
situ reduction of Herceptin mAb and reaction with pyridazinedione 4 at 4 °C (25 eq.). 3) 
Portion-wise in situ reduction of Herceptin mAb and reaction with pyridazinedione 4 at 
4 °C (25 eq.). 4) Reaction of Herceptin mAb with pyridazinedione 7 at 4 °C (8 eq.). 5) In 
situ reduction of Herceptin mAb and reaction with pyridazinedione 4 at 37 °C (25 eq.) 
SDS-PAGE gel for Herceptin modification with pyridazinedione 3 
 
Figure S38. Further demonstration of traditional methods for Herceptin modification. 
M) Molecular weight marker. 1) Untreated Herceptin. 2) In situ reduction of Herceptin 
mAb and reaction with pyridazinedione 3 at 4 °C (25 eq.). 3) In situ reduction of 
Herceptin mAb and reaction with pyridazinedione 3 at 37 °C (25 eq.). 
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SDS-PAGE gel for Fab fragment of Herceptin and conjugates 16, 16a, 16b and 16c 
 
Figure S39 Distribution of Fab-Her bioconjugates 16, 16a, 16b and 16c against 
unmodified Fab-Her fragment. M) Molecular weight marker. 1) Unmodified Fab-Her 
fragment. 2) Bioconjugate 16. 3) Bioconjugate 16a. 4) Bioconjugate 16b. 5) 
Bioconjugate 16c. 
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Activity by enzyme-linked immunosorbent assay (ELISA)83 
Binding affinity to HER2 receptor was determined by ELISA. A 96-well plate was coated 
overnight at 4 °C with HER2 (100 μL of a 0.25 μg⋅mL-1 solution in PBS), including coating 
one row of wells with PBS only for negative controls. Next, coating solutions were 
removed and each well washed with PBS twice. Then, the wells were coated with a 1% 
BSA solution in PBS (200 μL) for 1 h at 21 °C. Then, the wells were washed with PBS three 
times. Solutions Fab fragment bioconjugates 16a, 16b and 16c in PBS with the following 
dilution series: 23 nM, 7.8 nM, 2.6 nM, 0.86 nM, 0.29 nM and 0.10 nM were prepared. 
Wells were coated with the dilution series solutions, including a PBS only and unmodified 
Fab fragment at 23 nM in the absence of HER2 as negative controls, and incubated for 2 h 
at room temperature. Then, the solutions were removed and the wells washed with 0.1% 
Tween 20 in PBS twice and with PBS three times. Detection antibody (100 μL of anti-
human IgG, Fab-specific-HRP solution, prepared by taking 4 μL of a 1:5000 diluted 
solution and further diluting with 20 mL of PBS) was added and incubated for 1 h at room 
temperature. Then, the solutions were removed and the wells washed with 0.1% Tween 
20 in PBS twice and with PBS three times. Finally, an OPD solution (100 μL of 0.5 mg⋅mL-
1 OPD in phosphate-citrate buffer with sodium perborate, prepared by dissolving 1 
capsule in 100 mL water) was added to each well. After ca. 2 min the reaction was stopped 
through addition of 4 M HCl (50 μL). Absorbance was measured at 490 nm. Absorbance 
was corrected by subtracting average of negative controls. See Figure S40 
 
Figure S40. Binding activity of Fab-Her bioconjugates 16a, 16b and 16c against 
untreated Fab fragment of Herceptin. 
  
149 
 
Reaction of Herceptin mAb with pyridazinedione 15 at 4 °C (8 eq.) for the synthesis 
of bioconjugate 17 
 
Pyridazinedione 15 (1.9 µL, 4.0 mM in DMF, 8 eq.) was added to Herceptin (30 µL, 4.4 
mg/mL, 30 µM) in BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 8.0) which 
had been stored at 4 °C for 1 h previously. The reaction mixture was then stored at 4 °C 
for 16 h. Excess reagents were removed by repeated diafiltration into deionised water 
using VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO). The samples were 
analysed by SDS-PAGE gel (see Figure S43. [lane 2]) and UV-vis spectroscopy was used to 
determine a PAR of 4.1. PAR was calculated according to that previously described.3 
 
Figure S41.  UV-vis data for Herceptin modified with pyridazinedione 15  at 4 °C. 
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Reaction of bioconjugate 17 with Doxorubicin-azide83 for the synthesis of 
bioconjugate 18 
 
Doxorubicin-azide (1.0 µL, 2.0 mM in water, 2 eq), CuSO4 (1.0 µL, 2.0 mM in water, 2 eq), 
tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) (1.0 µL, 10 mM in water, 10 eq) and 
sodium ascorbate (5.0 µL, 0.10 M in water, 500 eq) were added in series to bioconjugate 
17 (20 µL, 2.4 mg/mL, 50 µM) in BBS (25 mM sodium borate, 25 mM NaCl, pH 8.0). The 
reaction mixture was stored at 21 °C for 1.5 h. The excess reagents were then removed by 
repeated diafiltration into fresh PBS with 2 mM EDTA (to remove residual copper ions) 
using VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO). Following this, the 
buffer salts were removed by repeated diafiltration into deionised water using VivaSpin 
sample concentrators (GE Healthcare, 10,000 MWCO). The samples were analysed by 
SDS-PAGE gel (see Figure S43. [lane 3]) and UV-vis spectroscopy was used to determine 
a PAR of 4.0. PAR was calculated according to that previously described.84 
 
Figure S42.  UV-vis data for bioconjugate 18. 
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SDS-PAGE gel for Herceptin modification with pyridazinedione 15 and Dox-azide 
 
Figure S43. Distribution of bioconjugates 17 and 18 against unmodified native 
Herceptin. M) Molecular weight marker. 1) Untreated Herceptin. 2) Reaction of 
Herceptin mAb with pyridazinedione 15 at 4 °C (8 eq.) (i.e. bioconjugate 17). 3) 
bioconjugate 18. 
ELISA for Her-PD7-Dox bioconjugate 18 against native Herceptin 
Carried out according to procedure detailed for conjugates 16a-c. 
 
Figure S44. Binding activity of bioconjugate 18 against native unmodified Herceptin. 
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5.2 Experimental for Chapter 3 
 
General Experimental  
All reagents were purchased from Aldrich, AlfaAesar, Sino Biologial Inc or Lumiprobe and 
were used as received. Where described below Pet. refers to petroleum ether (40–60 °C). 
All reactions were monitored by thin-layer chromatography (TLC) on pre-coated SIL 
G/UV254 silica gel plates (254 m) purchased from VWR. Flash column chromatography 
was carried out with Kiesegel 60M 0.04/0.063 mm (200–400 mesh) silica gel. 1H and 13C 
NMR spectra were recorded at ambient temperature on a Bruker Avance 300 instrument 
operating at a frequency of 300 MHz for 1H and 75 MHz for 13C, a Bruker Avance 500 
instrument operating at a frequency of 500 MHz for 1H and 125 MHz for 13C, and a Bruker 
Avance 600 instrument operating at a frequency of 600 MHz for 1H and 150 MHz for 13C 
in CDCl3 or CD3OD (as indicated below). The chemical shifts () for 1H and 13C are quoted 
relative to residual signals of the solvent on the ppm scale. 1H NMR peaks are reported as 
singlet (s), doublet (d), triplet (t), quartet (q), doublet of doublets (dd), triplet of doublets 
(td), doublet of triplets (dt), triplet of triplets (tt) m (multiplet) and br (broad). Coupling 
constants (J values) are reported in Hertz (Hz) and are H-H coupling constants unless 
otherwise stated. Signal multiplicities in 13C NMR were determined using the 
distortionless enhancement by phase transfer (DEPT) spectral editing technique. Infrared 
spectra were obtained on a Perkin Elmer Spectrum 100 FTIR Spectrometer operating in 
ATR mode with frequencies given in reciprocal centimetres (cm-1). Melting points were 
measured with a Gallenkamp apparatus and are uncorrected. All bioconjugation reactions 
were carried out in triplicate. 
UV-Vis spectroscopy 
UV-Vis spectroscopy was used to determine protein concentrations, pyridazinedione to 
antibody ratios (PDAR), fluorophore to antibody ratios (FAR) and drug to antibody ratios 
(DAR) using a nanodrop ND-1000 spectrophotometer and a Varian Cary 100 Bio UV-
Visible spectrophotometer operating at 21 °C. Sample buffer was used as blank for 
baseline correction with extinction coefficients; ε280 = 225,000 M-1 cm-1 for Herceptin™, 
ε335 = 9,100 M-1 cm-1 for pyridazinedione scaffolds, ε493 = 75,000 M-1 cm-1 for Alexafluor 
488™ (AF488) and ε495 = 8,030 M-1 cm-1 for doxorubicin. The correction factors for 
pyridazinedione scaffolds, AF488 and doxorubicin at 280 nm are 0.25, 0.11 and 0.72, 
respectively. Calculations are performed according to that previously described.84 
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SDS-PAGE gels 
Non-reducing glycine-SDS-PAGE at 12% acrylamide gels were performed following 
standard lab procedures, unless stated otherwise. A 6% stacking gel was used and a 
broad-range MW marker (10–250 kDa, Prestained PagerulerPlus Protein Standards, Bio-
Rad) was co-run to estimate protein weights. Samples (15 μL at ~12 μM construct) were 
mixed with loading buffer (3 μL, composition for 6 × SDS: 1 g SDS, 3 mL glycerol, 6 mL 0.5 
M Tris buffer pH 6.8, 2 mg bromophenol blue in 10 mL) and heated at 75 °C for 3 min. The 
gels were run at 30 mA for 50 min in 1 × SDS running buffer. The gels were stained with 
Coomassie dye. 
Protein LC-MS 
Full Herceptin™ mAb conjugate 7 and Herceptin™ mAb were prepared for analysis by 
repeated diafiltration into ammonium acetate buffer (50 mM ammonium acetate, pH 6.9) 
using VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO) to a concentration 
of 6.6 µM (1.0 mg·ml-1). Following this, PNGase F (1 µL, 15,000 units·mL-1, in 20 mM Tris-
HCl, 50mM NaCl, 5 mM EDTA, pH 7.5) (purchased from New England BioLabs Inc.) was 
added and the resultant solution was incubated at 37 °C for 16 h. After this time the 
solution was diluted to 0.7 µM (1.0 mg·ml-1) in water and submitted to the UCL Chemistry 
Mass Spectrometry Facility at the Chemistry Department, UCL for analysis of antibody 
conjugates on the Agilent 6510 QTOF LC-MS system (Agilent, UK). 10 µL of each sample 
was injected onto a PLRP-S, 1000A, 8 µM, 150 mm x 2.1 mm column, which was 
maintained at 60 °C. The separation was achieved using mobile phase A (5% MeCN in 
0.1% formic acid) and B (95% MeCN, 5% water 0.1% formic acid) using a gradient elution. 
The column effluent was continuously electrosprayed into capillary ESI source of the 
Agilent 6510 QTOF mass spectrometer and ESI mass spectra were acquired in positive 
electrospray ionisation (ESI) mode using the m/z range 1,000−8,000 in profile mode. The 
raw data was converted to zero charge mass spectra using maximum entropy 
deconvolution algorithm over the region 12.3 – 16.8 min with MassHunter software 
(version B.07.00). 
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5.2.1 Synthesis of compounds for Chapter 3 
 
Tri-tert-butyl 2-methylhydrazine-1,1,2-tricarboxylate (22) 
 
To a solution of methylhydrazine 21 (1.00 g, 1.14 mL, 21.7 mmol), NEt3 (4.34 g, 6.04 mL, 
43.4 mmol) and DMAP (260 mg, 2.17 mmol) in CH2Cl2 (75 mL) was added Boc2O (18.9 g, 
86.6 mmol), and the reaction mixture stirred at 20 °C for 72 h. After this time, the reaction 
mixture was diluted with H2O (80 mL), extracted with EtOAc (3 × 60 mL), and the 
combined organic layers dried (MgSO4) and concentrated in vacuo. The crude residue was 
purified by flash column chromatography (20% EtOAc/petrol) to afford tri-tert-butyl 2-
methylhydrazine-1,1,2-tricarboxylate 22 (7.43 g, 21.5 mmol, 99%) as a yellowish oil: 1H 
NMR (600 MHz, CDCl3) (major rotamer) δ 3.05 (s, 3H), 1.51–1.43 (m, 27H); 13C NMR (150 
MHz, CDCl3) (major rotamer) δ 154.0 (C), 150.1 (C) 83.4 (C), 81.4 (C), 35.7 (CH3), 28.3 
(CH3), 28.1 (CH3); LRMS (ES+) 369 (100, [M+Na]+). 
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Figure S45. 1H and 13C NMR data for tri-tert-butyl 2-methylhydrazine-1,1,2-
tricarboxylate 22. 
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Di-tert-butyl 1-methylhydrazine-1,2-dicarboxylate (23) 
 
 
To a solution of tri-tert-butyl 2-methylhydrazine-1,1,2-tricarboxylate 22 (2.0 g, 5.8 mmol) 
in dry MeCN (15 mL) was added Mg(ClO4)2 (0.27 g, 1.21 mmol), and the reaction mixture 
stirred at 20 °C for 1 h. After this time, the reaction mixture was diluted with 10% aq. 
citric acid (20 mL) and Et2O (15 mL), extracted with Et2O (3 × 20 mL), and the combined 
organic layers were dried (MgSO4) and concentrated in vacuo. The crude residue was 
purified by flash column chromatography (15% EtOAc/petrol) to afford di-tert-butyl 1-
methylhydrazine-1,2-dicarboxylate 23 (1.3 g, 5.2 mmol, 89%) as a white solid: m.p. 54–
55 °C; 1H NMR (600 MHz, CDCl3) (major rotamer) δ 6.40 (br. s, 1H), 3.11 (s, 3H), 1.48–1.45 
(m, 18H); 13C NMR (150 MHz, CDCl3) (major rotamer) δ 155.9 (C), 155.3 (C) 81.3 (C), 81.1 
(C), 37.6 (CH3), 28.3 (CH3), 28.1 (CH3); IR (solid) 3316, 2978, 2932, 1701 cm−1; LRMS (ES+) 
269 (100, [M+Na]+); HRMS (ES+) calcd. for C11H22N2O4Na [M+Na]+ 269.1477, observed 
269.1476. 
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Figure S46. 1H and 13C NMR data for di-tert-butyl 1-methylhydrazine-1,2-dicarboxylate 
23. 
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Di-tert-butyl 1-(2-(tert-butoxy)-2-oxoethyl)-2-methylhydrazine-1,2-dicarboxylate 
(24) 
 
 
To a solution of di-tert-butyl 1-methylhydrazine-1,2-dicarboxylate (0.94 g, 3.8 mmol) in 
DMF (20 mL) was added caesium carbonate (1.86 g, 5.7 mmol) and then tert-butyl 
bromoacetate (1.1 g, 0.84 mL, 5.7 mmol), and the reaction mixture stirred at 20 °C for 16 
h. After this time, the reaction mixture was diluted with H2O (50 mL), extracted with Et2O 
(4 × 50 mL), the combined organic layers washed with sat. aq. LiCl (2 × 30 mL), dried 
(MgSO4), and concentrated in vacuo. Purification by flash column chromatography (10% 
Et2O/petrol) yielded di-tert-butyl 1-(2-(tert-butoxy)-2-oxoethyl)- 2-methylhydrazine-
1,2-dicarboxylate 24 (1.3 g, 3.7 mmol, 98%) as a colourless oil: 1H NMR (600 MHz, CDCl3) 
δ 4.73–4.04 (m, 2H), 3.68–3.10 (m, 3H), 1.54–1.39 (m, 27H); 13C NMR (150 MHz, CDCl3) 
(major rotamer) δ 169.2 (C), 155.2 (C), 81.9 (C), 81.6 (C), 81.1 (C), 52.7 (CH2), 36.8 (CH3), 
28.4 (CH3), 28.3 (CH3), 28.2 (CH3); IR (thin film) 2978, 1748 cm−1; LRMS (ES+) 361 (100, 
[M+H]+); HRMS (ES+) calcd for C17H33O6N2 [M+H]+ 361.2339, observed 361.2333. 
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Figure S47. 1H and 13C NMR data for di-tert-butyl 1-(2-(tert-butoxy)-2-oxoethyl)-2-
methylhydrazine-1,2-dicarboxylate 24. 
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2-(4,5-Dibromo-2-methyl-3,6-dioxo-3,6-dihydropyridazin-1(2H)-yl)acetic acid 
(20)84 
 
 
To a solution of di-tert-butyl 1-(2-(tert-butoxy)-2-oxoethyl)-2-methylhydrazine-1,2-
dicarboxylate 24 (1.0 g, 2.8 mmol) in CH2Cl2 (10 mL) was added TFA (10 mL), and the 
reaction mixture stirred at 20 °C for 2 h. After this time, all volatile materials were 
removed in vacuo. The crude residue was added to a solution of 2,3-dibromomaleic 
anhydride (0.75 g, 2.8 mmol) in glacial AcOH (40 mL), and the reaction mixture stirred at 
20 °C for 16 h before raising the temperature to 130 °C for 16 h. After this time, the 
reaction mixture was concentrated in vacuo, and purification of the crude residue by flash 
column chromatography (3% MeOH/CH2Cl2 with 1% AcOH) yielded 2-(4,5-dibromo-2-
methyl-3,6-dioxo-3,6-dihydropyridazin-1(2H)-yl)acetic acid 20 (0.65 g, 1.9 mmol, 73%) 
as a white solid: m.p. 210–214 °C; 1H NMR (600 MHz, MeOD) δ 4.96 (s, 2H), 3.62 (s, 3H); 
13C NMR (150 MHz, MeOD) δ 170.2 (C), 154.8 (C), 154.0 (C), 137.4 (C), 135.7 (C), 49.5 
(CH2), 35.0 (CH3); IR (solid) 3023, 2969, 1731, 1662 cm−1; LRMS (ES−) 341 (50, 
[M81Br81Br-H]−), 339 (100, [M81Br79Br-H]−), 337 (50, [M79Br79Br-H]−); HRMS (ES−) calcd 
for C7H5N2O4Br2 [M79Br79Br-H]− 336.8538, observed 336.8540. 
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Figure S48. 1H and 13C NMR data for 2-(4,5-dibromo-2-methyl-3,6-dioxo-3,6-
dihydropyridazin-1(2H)-yl)acetic acid 20. 
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Di-tert-butyl-1-(prop-2-yn-1-yl)hydrazine-1,2-dicarboxylate(25) 
 
To a solution of di-tert-butyl hydrazine-1,2-dicarboxylate 1 (2.00 g, 8.62 mmol) in a 
mixture of toluene (10 mL) and 5% aq. NaOH (10 mL) were added tetra-n-
butylammonium bromide (87 mg, 0.26 mmol) and then propargyl bromide (3.08 g, 25.86 
mmol). The reaction mixture was stirred at 20 °C for 16 h. After this time, H2O (20 mL) 
was added and the mixture was extracted with EtOAc (3 × 15 mL). The combined organic 
layers were washed with brine (15 mL), dried (MgSO4), and concentrated in vacuo. 
Purification of the crude residue by flash column chromatography (20% EtOAc/petrol) 
yielded di-tert-butyl 1-(prop-2-yn- 1-yl)hydrazine-1,2-dicarboxylate 25 (1.93 g, 7.14 
mmol, 83%) as a white solid: m.p. 101–103 °C; 1H NMR (500 MHz, CDCl3) δ 6.47 (br. s, 
0.78H), 6.18 (br. s, 0.22H,), 4.27 (s, 2H), 2.24 (t, J = 2.4 Hz, 1H), 1.48 (s, 18H); 13C NMR 
(150 MHz, CDCl3) δ 155.0 (C), 82.2 (C), 81.7 (C), 79.0 (C), 77.7 (C), 72.5 (CH), 39.5 (CH2), 
28.5 (CH3), 28.5 (CH3); IR (solid) 3310, 2109, 1703 cm−1.  
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Figure S49. 1H and 13C NMR data for di-tert-butyl-1-(prop-2-yn-1-yl)hydrazine-1,2-
dicarboxylate 25. 
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Di-tert-butyl 1-(2-(tert-butoxy)-2-oxoethyl)-2-(prop-2-yn-1-yl)hydrazine-1,2-
dicarboxylate (26) 
 
To a solution of di-tert-butyl 1-(prop-2-yn-1-yl)hydrazine-1,2-dicarboxylate 25 (1.45 g, 
5.36 mmol) in DMF (20 mL) were added caesium carbonate (3.56 g, 10.92 mmol) and then 
tert-butyl bromoacetate (1.57 g, 2.8 mmol), and the reaction mixture stirred at 20 °C for 
16 h. After this time, the reaction mixture was diluted with H2O (50 mL), extracted with 
EtOAc (4 × 50 mL), the combined organic layers washed with sat. aq. LiCl (2 × 30 mL), 
dried (MgSO4), and concentrated in vacuo. Purification of the crude residue by flash 
column chromatography (10% EtOAc/petrol) yielded di-tert-butyl 1-(2-(tert-butoxy)-2-
oxoethyl)-2-(prop-2-yn-1- yl)hydrazine-1,2-dicarboxylate 26 (2.00 g, 5.20 mmol, 97%) 
as a colourless oil: 1H NMR (600 MHz, CDCl3) δ 4.58–4.35 (m, 2H), 4.16–4.01 (m, 1H), 
3.67–3.64 (m, 1H), 2.18 (t, J = 2.3 Hz, 1H), 1.53–1.41 (m, 27H); 13C NMR (150 MHz, CDCl3) 
(major rotamer) δ 168.1 (C), 166.3 (C), 153.9 (C), 83.0 (C), 81.9 (C), 81.8 (C), 79.4 (C), 71.9 
(CH), 53.5 (CH2), 40.1 (CH2), 28.3 (CH3), 28.3 (CH3), 28.1 (CH3); IR (thin film) 3265, 2108, 
1714 cm− ; LRMS (CI) 385 (55, [M+H]+), 329 (65), 273 (100); HRMS (CI) calcd for 
C19H33O6N2 [M+H]+ 385.2333, observed 385.2319.  
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Figure S50. 1H and 13C NMR data for di-tert-butyl 1-(2-(tert-butoxy)-2-oxoethyl)-2-
(prop-2-yn-1-yl)hydrazine-1,2-dicarboxylate 26. 
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2-(4,5-Dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)-2,3-dihydropyridazin-1(6H)-yl) 
acetic acid (27)83 
 
To a solution of di-tert-butyl 1-(2-(tert-butoxy)-2-oxoethyl)-2-(prop-2-yn-1-
yl)hydrazine- 1,2-dicarboxylate 26 (0.50 g, 1.30 mmol) in CH2Cl2 (10 mL) was added TFA 
(10 mL), and the reaction mixture stirred at 20 °C for 2 h. After this time, all volatile 
materials were removed in vacuo. The crude residue was added to a solution of 2,3-
dibromomaleic anhydride (0.40 g, 1.57 mmol) in glacial AcOH (40 mL), and the reaction 
mixture stirred at 20 °C for 16 h before raising the temperature to 130 °C for 2 h. Then 
the reaction mixture was concentrated in vacuo, and purification of the crude residue by 
flash column chromatography (3% MeOH/CH2Cl2 with 1% AcOH) yielded 2-(4,5-
dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)- 2,3-dihydropyridazin-1(6H)-yl)acetic acid 27 
(0.31 g, 0.85 mmol, 65%) as a white solid: m.p. 108–110 °C; 1H NMR (600 MHz, MeOD) δ 
4.93 (s, 2H), 4.79 (d, J = 2.5 Hz, 2H), 2.46 (t, J = 2.5 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ 
168.1 (C), 153.9 (C), 152.6 (C), 136.3 (C), 135.9 (C), 77.3 (C), 75.4 (CH), 48.4 (CH2), 37.1 
(CH2); IR (solid) 3444, 3287, 2109, 1729, 1631 cm−1; LRMS (CI) 369 (50, [M81Br81Br+H]+), 
367 (100, [M81Br79Br+H]+), 365 (50, [M79Br79Br+H]+); HRMS (CI) calcd for C9H7N2O4Br2 
[M79Br79Br+H]+ 364.8767, observed 364.8762.  
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Figure S51. 1H and 13C NMR data for 2-(4,5-dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)-2,3-
dihydropyridazin-1(6H)-yl) acetic acid 27. 
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tert-Butyl (3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)carbamate (28)139 
 
To a stirring solution of 3,3'-((oxybis(ethane-2,1-diyl))bis(oxy))bis(propan-1-
amine) (8.10 g, 37.1 mmol) in 1,4-dioxane (60 mL) was added dropwise di-tert-
butyl dicarbonate (1.00 g, 4.60 mmol, pre-dissolved in 1,4-dioxane (25 mL)) over 
2 h, ensuring that the temperature did not exceed 21 °C. After this time, the 
reaction mixture was stirred at 21 °C for a further 30 mins. Following this, the 
reaction mixture was concentrated in vacuo, the crude residue dissolved in water 
(50 mL), and the organics extracted into EtOAc (5 × 30 mL). The organics were 
combined, dried (MgSO4) and concentrated in vacuo to give tert-butyl (3-(2-(2-(3-
aminopropoxy)ethoxy)ethoxy)propyl)carbamate 28 (1.1 g, 34 mmol, 75%) as a 
colourless oil. 1H NMR (600 MHz, CDCl3) δ 5.11 (br s, 1H), 4.99 (d, J = 1.9 Hz, 4H), 
4.93 (s, 4H), 3.65-3.61 (m, 12H), 3.24-3.19 (m, 2H), 2.79 (t, J = 6.7 Hz, 2H), 1.72 (tt, 
J = 6.5 Hz, 4H), 1.43 (s, 9H); 13C NMR 151 MHz, CDCl3) δ 156.2 (C), 79.0 (C), 70.7 
(CH2), 70.7 (CH2), 70.4 (CH2), 70.3 (CH2), 69.7 (CH2), 69.6 (CH2), 39.8 (CH2), 38.6 
(CH2), 33.5 (CH2), 29.7 (CH2), 28.6 (CH3); IR (thin film) 3360, 2928, 2865, 1696, 
1521, 1102 cm-1.  
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Figure S52. 1H and 13C NMR data for tert-butyl (3-(2-(2-(3-
aminopropoxy)ethoxy)ethoxy)propyl)carbamate 28. 
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tert-Butyl (1-(4,5-dibromo-2-methyl-3,6-dioxo-3,6-dihydropyridazin-1(2H)-yl)-2-
oxo-7,10,13-trioxa-3-azahexadecan-16-yl) (29) 
 
To a solution of 2-(4,5-dibromo-2-methyl-3,6-dioxo-3,6-dihydropyridazin-1(2H)-
yl)acetic acid 20 (350 mg, 1.02 mmol) in DMF (30 mL) was added CDI (165 mg, 
1.02 mmol), and the reaction mixture stirred at 21 °C for 15 mins. After this time, 
to the reaction mixture was added tert-butyl (3-(2-(2-(3-
aminopropoxy)ethoxy)ethoxy)propyl)carbamate) (362 mg, 1.13 mmol), and the 
mixture left to stir at 21 °C for a further 12 h. The reaction mixture was then 
diluted with EtOAc (50 mL) and washed with saturated sodium bicarbonate 
solution (1 × 20 mL), deionised water (4 × 20 mL) and brine (2 × 20 mL). The 
organic phase was then dried (MgSO4) and concentrated in vacuo, and the 
resultant crude residue purified by flash column chromatography (0-20% 
MeOH:EtOAc). The appropriate fractions were combined and concentrated in 
vacuo to afford tert-butyl (1-(4,5-dibromo-2-methyl-3,6-dioxo-3,6-
dihydropyridazin-1(2H)-yl)-2-oxo-7,10,13-trioxa-3-azahexadecan-16-
yl)carbamate 29 (50 mg, 0.08 mmol, 8%) as a yellow gum. 1H NMR (600 MHz, 
CDCl3) δ 7.12 (br. s, 1H), 4.96 (br. s, 1H), 4.74 (s, 2H), 3.69 (s, 3H), 3.66-3.58 (m, 
10H), 3.53 (t, J = 6.1 Hz, 2H), 3.42 (dd, J = 11.9, 5.7, 2H), 3.22-3.19 (m, 2H), 1.82-
1.78 (m, 2H), 1.76-1.72 (m, 2H), 1.43 (s, 9H); 13C NMR 151 MHz, CDCl3) δ 165.3 
(C), 156.2 (C), 153.5 (C), 152.5 (C), 136.9 (C), 134.9 (C), 79.2 (C), 70.5 (CH2), 70.4 
(CH2), 70.2 (CH2), 70.2 (CH2), 69.9 (CH2), 69.5 (CH2), 50.7 (CH2), 38.9 (CH2), 38.4 
(CH2), 34.9 (CH3), 29.9 (CH2), 28.6 (CH3), 28.5 (CH2); IR (thin film) 3347, 2921, 
2866, 1685, 1634, 1282, 1054 cm-1; LRMS (ES+) 647 (50, [M81Br81Br+H]+), 645 
(100, [M81Br79Br+H]+), 643 (50, [M79Br79Br+H]+); HRMS (ES+) calcd for 
C22H37Br2N4O8 [M81Br79Br+H]+ 643.0973, observed 643.0954. 
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Figure S53. 1H and 13C NMR data for tert-butyl (1-(4,5-dibromo-2-methyl-3,6-dioxo-3,6-
dihydropyridazin-1(2H)-yl)-2-oxo-7,10,13-trioxa-3-azahexadecan-16-yl)carbamate 29. 
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2-(4,5-Dibromo-2-methyl-3,6-dioxo-3,6-dihydropyridazin-1(2H)-yl)-N-(1-(4,5-
dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)-3,6-dihydropyridazin-1(2H)-yl)-2-oxo-
7,10,13-trioxa-3-azahexadecan-16-yl)acetamide (19) 
 
To a solution of 2-(4,5-dibromo-2-methyl-3,6-dioxo-3,6-dihydropyridazin-1(2H)-
yl)-N-(1-(4,5-dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)-3,6-dihydropyridazin-
1(2H)-yl)-2-oxo-7,10,13-trioxa-3-azahexadecan-16-yl)acetamide 29 (50.0 mg, 
0.08 mmol) in CH2Cl2 (5 mL) was added TFA (5 mL), and the reaction mixture 
stirred for 30 mins at 21 °C. After this time, the reaction mixture was concentrated 
in vacuo and the residue dissolved in CH2Cl2 (5 mL). The resultant solution was 
added to a pre-mixed (20 mins at 21 °C) solution of 2-(4,5-dibromo-3,6-dioxo-2-
(prop-2-yn-1-yl)-3,6-dihydropyridazin-1(2H)-yl)acetic acid 27 (27.3 mg, 0.08 
mmol), HATU (28.4 mg, 0.08 mmol) and N-ethyldiisopropylamine (21.2 mg, 0.16 
mmol, 30 µL) in CH2Cl2 (10 mL). The reaction mixture was then stirred for 16 h at 
21 °C. Following this, the reaction mixture was washed with water (3 × 10 mL) 
and the resultant aqueous washes extracted with CH2Cl2 (10 mL). The organic 
phases were combined, dried (MgSO4) and concentrated in vacuo, and the crude 
residue purified by flash column chromatography (0-15% MeOH:EtOAc). The 
appropriate fractions were combined and concentrated in vacuo to afford 2-(4,5-
dibromo-2-methyl-3,6-dioxo-3,6-dihydropyridazin-1(2H)-yl)-N-(1-(4,5-
dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)-3,6-dihydropyridazin-1(2H)-yl)-2-oxo-
7,10,13-trioxa-3-azahexadecan-16-yl)acetamide 19 (20 mg, 0.02 mmol, 30%) as 
a yellow gum. 1H NMR (600 MHz, CDCl3) δ 7.25 (t, J = 5.4 Hz, 1H), 7.21 (t, J = 5.2 
Hz, 1H), 4.99 (d, J = 2.0 Hz, 2H), 4.93 (s, 2H), 4.79 (s, 2H), 3.68 (s, 3H), 3.67-3.57 
(m, 14H), 3.40 (td, J = 12.3, 5.9, 4H), 2.46 (t, J = 2.0 Hz, 1H), 1.82-1.76 (m, 4H); 13C 
NMR 151 MHz, CDCl3) δ 165.4 (C), 165.3 (C), 153.7 (C), 153.6 (C), 152.5 (C), 152.4 
(C), 137.0 (C), 136.6 (C), 135.8 (C), 134.8 (C), 76.3 (C), 75.0 (CH), 70.3 (CH2), 69.8 
(CH2), 69.7 (CH2), 69.6 (CH2), 69.6 (CH2), 50.6 (CH2), 50.5 (CH2), 38.4 (CH2), 38.3 
(CH2), 37.4 (CH2), 34.9 (CH3), 28.5 (CH2), 28.5 (CH2); IR (thin film) 3305, 2924, 
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2870, 1636, 1571, 1287 cm-1; LRMS (ES+) 895 (55, [M81Br81Br81Br79Br +H]+), 893 
(100, [M81Br81Br79Br79Br+H]+), 891 (55, [M81Br79Br79Br79Br+H]+); HRMS (ES+) 
calcd for C28H32Br4N6O9 [M79Br79Br79Br79Br+H]+ 888.9037, observed 888.9039. 
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Figure S54. 1H and 13C NMR data for 2-(4,5-dibromo-2-methyl-3,6-dioxo-3,6-
dihydropyridazin-1(2H)-yl)-N-(1-(4,5-dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)-3,6-
dihydropyridazin-1(2H)-yl)-2-oxo-7,10,13-trioxa-3-azahexadecan-16-yl)acetamide 19. 
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N,N'-(((Oxybis(ethane-2,1-diyl))bis(oxy))bis(propane-3,1-diyl))bis(2-(4,5-
dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)-3,6-dihydropyridazin-1(2H)-yl)acetamide) 
(33) 
 
To a solution of 2-(4,5-dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)-3,6-
dihydropyridazin-1(2H)-yl)acetic acid 27 (200 mg, 0.60 mmol) in DMF (5 mL) 
was added DCC (120 mg, 0.58 mmol), and the reaction mixture stirred at 21 °C for 
15 mins. After this time, to the reaction mixture was added 3,3’-((oxybis(ethane-
2,1-diyl))bis(oxy))bis(propan-1-amine) (26 µL, 0.12 mmol), and the resultant 
mixture stirred at 21 °C for 12 h. After this time, the reaction mixture was diluted 
with EtOAc (20 mL) and washed with deionised water (4 × 10 mL) and brine (2 × 
10 mL). The organic phase was then dried (MgSO4), concentrated in vacuo and the 
crude residue purified by flash column chromatography (0-10% MeOH:CH2Cl2), 
which yielded N,N’-(((oxybis(ethane-2,1-diyl))bis(oxy))bis(propane-3,1-
diyl))bis(2-(4,5-dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)-3,6-dihydropyridazin-
1(2H)-yl)acetamide) 33 (20 mg, 0.02 mmol, 18%) as a yellow gum. 1H NMR (600 
MHz, CDCl3) δ 7.22 (t, J = 5.4 Hz, 2H), 4.99 (d, J = 1.9 Hz, 4H), 4.93 (s, 4H), 4.99 (d, 
J = 1.9 Hz, 4H), 3.68–3.62 (m, 4H), 3.62–3.56 (m, 8H), 3.39 (dd, J = 12.1, 5.9, 4H), 
2.46 (t, J = 2.4 Hz, 2H), 1.79 (dt, J = 12.1, 5.9, 4H); 13C NMR 151 MHz, CDCl3) δ 165.4 
(C), 153.8 (C), 152.4 (C), 136.5 (C), 135.8 (C), 76.3 (C), 75.0 (CH), 70.3 (CH2), 69.8 
(CH2), 69.7 (CH2), 50.5 (CH2), 38.4 (CH2), 37.3 (CH2), 28.5 (CH2); IR (thin film) 
3299, 2928, 2052, 1643, 1285 cm-1; LRMS (ES+) 917 (50, 
[M81Br81Br81Br79Br+H]+), 915 (100, [M81Br81Br79Br79Br+H]+), 913 (50, [M81Br79Br 
79Br79Br+H]+); HRMS (ES+) calcd for C28H32Br4N6O9 [M81Br79Br 79Br79Br+H ]+ 
912.9042, observed 912.9048. 
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Figure S55. 1H and 13C NMR data for N'-(((Oxybis(ethane-2,1-
diyl))bis(oxy))bis(propane-3,1-diyl))bis(2-(4,5-dibromo-3,6-dioxo-2-(prop-2-yn-1-yl)- 
3,6-dihydropyridazin-1(2H)-yl)acetamide) 9. 
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5.2.2 Bioconjugation reactions for Chapter 3 
 
In situ reduction of Herceptin™ mAb and reaction with bis-diBrPD 1 at 4 °C (16 
eq.) for the formation of conjugate 30   
 
TCEP.HCl (10 µL, 20 mM in deionised water, 80 eq.) was added to a solution of Herceptin™ 
(50 µL, 7.5 mg/mL, 50 µM) in BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 
8.0) which had been pre-treated with bis-diBrPD 19 (2.0 µL, 20 mM in DMSO, 16 eq.) and 
stored at 4 °C for 1 h previously. The reaction mixture was then stored at 4 °C for 15 h. 
Excess reagents were removed by repeated diafiltration into deionised water using 
VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO). The samples were 
analysed by SDS-PAGE gel and UV-Vis spectroscopy, which was used to determine a PDAR 
of 4.0. This reaction was repeated on 7 separate occasions with remarkable 
reproducibility; PDARs in the range of 3.9-4.1 were observed. A TCEP reduction control 
was also conducted on conjugate 30: TCEP.HCl (10 µL, 20 mM in deionised water, 80 eq.) 
was added to conjugate 30 (50 µL, 7.5 mg/mL, 50 µM) in BBS (25 mM sodium borate, 25 
mM NaCl, 0.5 mM EDTA, pH 8.0), the reaction mixture was then incubated at 37 °C for 1 
h. The sample was then analysed by LCMS. Expected mass: 146,320 Da. Observed mass: 
146,328 Da. The sample was analysed further by SDS-PAGE gel (lane 3, below). As there 
was no fragmentation observed (going from lane 2 to lane 3) it was concluded that no 
accessible inter-chain disulfide bonds were present in conjugate 30 (control Herceptin™ 
reduction below, Figure S20). This experiment, combined with the lack of any fragments 
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being observed in the SDS-PAGE gel in lane 2+3 and the UV-Vis data, confirmed that all 
accessible disulfides bonds were functionally re-bridged with PD molecules.  
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Figure S56a.  (Left) UV-Vis data for conjugate 30. (Right) SDS-PAGE gel; M.) Molecular 
weight marker; 1) Unmodified Herceptin™; 2) Conjugate 30; 3) Conjugate 30 treated 
with TCEP.HCl; 4) Herceptin™ reduced with TCEP.HCl displaying heavy chain and light 
chain fragments. 
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Figure S56b. (a) non-deconvoluted and (b) deconvoluted MS data for native Herceptin™ 
(deglycosylated). 
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Figure S56c. (a) non-deconvoluted and (b) deconvoluted MS data for conjugate 30 
(deglycosylated). 
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Reaction of conjugate 30 with AlexaFluor 488®-azide for the formation of conjugate 
31 
 
AlexaFluor 488®-azide (5.0 µL, 10.0 mM in DMSO, 20 eq.), CuSO4 (1.0 µL, 20.0 mM in 
water, 8 eq.), tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) (1.0 µL, 100 mM in 
water, 40 eq.) and sodium ascorbate (5.0 µL, 0.10 M in water) were added in series to 
conjugate 30 (50 µL, 7.5 mg/mL, 50 µM) in BBS (25 mM sodium borate, 25 mM NaCl, pH 
8.0). The reaction mixture was stored at 21 °C for 1.5 h. The excess reagents were then 
removed by repeated diafiltration into fresh PBS with 2 mM EDTA (to remove residual 
copper ions) using VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO). 
Following this, the buffer salts were removed by repeated diafiltration into deionised 
water using VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO). The samples 
were analysed by SDS-PAGE gel and UV-Vis spectroscopy, which was used to determine a 
FAR of 2.0. This reaction was repeated on 7 separate occasions with remarkable 
reproducibility; FARs in the range of 1.9-2.1 were observed. 
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Figure S57.  (Left) UV-Vis data for conjugate 31. (Right) SDS-PAGE gel; M.) Molecular 
weight marker; 1) Unmodified Herceptin™; 2) Conjugate 31. 
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Reaction of conjugate 30 with Doxorubicin-azide83 for the formation of conjugate 
32 
 
Doxorubicin-azide (5.0 µL, 10.0 mM in DMSO, 20 eq.), CuSO4 (1.0 µL, 20.0 mM in water, 8 
eq.), tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) (1.0 µL, 100 mM in water, 40 
eq.) and sodium ascorbate (5.0 µL, 0.10 M in water) were added in series to conjugate 30 
(50 µL, 7.5 mg/mL, 50 µM) in BBS (25 mM sodium borate, 25 mM NaCl, pH 8.0). The 
reaction mixture was stored at 21 °C for 1.5 h. The excess reagents were then removed by 
repeated diafiltration into fresh PBS with 2 mM EDTA (to remove residual copper ions) 
using VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO). Following this, the 
buffer salts were removed by repeated diafiltration into deionised water using VivaSpin 
sample concentrators (GE Healthcare, 10,000 MWCO). The samples were analysed by 
SDS-PAGE gel and UV-Vis spectroscopy was used to determine a DAR of 2.0. 
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Figure S58.  (Left) UV-Vis data for conjugate 32. (Right) SDS-PAGE gel; M.) Molecular 
weight marker; 1) Unmodified Herceptin™; 2) Conjugate 32. 
In situ reduction of Herceptin™ mAb and reaction with bis-diBrPD 33 at 4 °C (16 eq.) 
for the formation of conjugate 34 
 
TCEP.HCl (10 µL, 20 mM in deionised water, 80 eq.) was added to a solution of Herceptin™ 
(50 µL, 7.5 mg/mL, 50 µM) in BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 
8.0) which had been pre-treated with bis-diBrPD 33 (2.0 µL, 20 mM in DMSO, 16 eq.) and 
stored at 4 °C for 1 h previously. The reaction mixture was then stored at 4 °C for 15 h. 
Excess reagents were removed by repeated diafiltration into deionised water using 
VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO). The samples were 
analysed by SDS-PAGE gel and UV-Vis spectroscopy was used to determine a PDAR of 3.9. 
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Figure S59. (Left) UV-Vis data for conjugate 34. (Right) SDS-PAGE gel; M) Molecular 
weight marker; 1) Untreated Herceptin™; 2) Conjugate 34. Artefact in SDS-PAGE gel 
observed in both samples (ca. 35 kDa). 
Reaction of conjugate 34 with AlexaFluor 488™-azide for the formation of conjugate 
35 
 
AlexaFluor 488®-azide (10.0 µL, 10.0 mM in DMSO, 40 eq.), CuSO4 (1.0 µL, 20.0 mM in 
water, 8 eq.), tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) (1.0 µL, 100 mM in 
water, 40 eq.) and sodium ascorbate (5.0 µL, 0.10 M in water) were added in series to 
conjugate 34 (50 µL, 7.5 mg/mL, 50 µM) in BBS (25 mM sodium borate, 25 mM NaCl, pH 
8.0). The reaction mixture was stored at 21 °C for 1.5 h. The excess reagents were then 
removed by repeated diafiltration into fresh PBS with 2 mM EDTA (to remove residual 
copper ions) using VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO). 
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Following this, the buffer salts were removed by repeated diafiltration into deionised 
water using VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO). The samples 
were analysed by SDS-PAGE gel and UV-Vis spectroscopy was used to determine a FAR of 
3.9. 
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Figure S60. (Left) UV-Vis data for conjugate 35 modified with AlexaFluor 488™-azide. 
(Right) SDS-PAGE gel; M) Molecular weight marker; 1)Unmodified Herceptin™; 2) 
Conjugate 35. 
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Reduction of Herceptin™ mAb control for elucidation of accessible disulfides 
 
TCEP.HCl (10 µL, 20 mM in deionised water, 80 eq.) was added to Herceptin™ (50 µL, 7.5 
mg/mL, 50 µM) in BBS (25 mM sodium borate, 25 mM NaCl, 0.5 mM EDTA, pH 8.0). The 
reaction mixture was then incubated at 37 °C for 1 h. The sample was analysed by SDS-
PAGE gel revealing light chain and heavy chain fragments. 
 
Figure S61. SDS-PAGE gel; M) Molecular weight marker; 1) Unmodified Herceptin™; 2) 
Herceptin™ reduced with TCEP.HCl displaying heavy chain and light chain fragments. 
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Activity of Conjugates by enzyme-linked immunosorbent assay (ELISA) 
A 96-well Maxisorp plate was coated overnight at 4 °C with HER2 (0.25 µg⋅mL−1 in 50 mM 
sodium carbonate buffer pH = 9.6, 100 µl). As a negative control one row was coated with 
only buffer. The solutions were removed and each well washed (2 × PBS with 0.05% 
Tween). The wells were subsequently coated with a 1% BSA solution in PBS for one hour 
at room temperature. After this the wells were emptied and washed (4 × PBS with 0.05% 
Tween). Solutions of Native Herceptin™, Herceptin™ DiEt, conjugate 31, and conjugate 35 
in PBS pH = 7.4 were prepared in the following dilutions: 60.0 nM, 15.0 nM, 3.75 nM, 0.938 
nM, 0.234 nM and 0.00586 nM. The dilutions were placed into the wells, each in triplicate, 
and incubated for two hours at room temperature. As negative controls sodium carbonate 
buffer only and the antibodies at 60 nM in the absence of HER2 were also subjected to the 
same protocol. The solutions were removed and the wells washed (4 × PBS with 0.05% 
Tween). Detection antibody (100 µL of anti-human IgG, Fab-specific-HRP solution, 4 µL 
of a 1:5000 solution diluted further in 20 ml of PBS) was added and left for one hour at 
room temperature. The solutions were removed and the wells washed (4 × PBS with 
0.05% Tween). Finally, a TMB solution (1 × TMB Solution, eBioscience, 100 µL) was added 
to each well. After five minutes the reaction was stopped through addition of 0.2 M 
sulfuric acid (50 µL). Absorbance was measured at 450 nm and corrected by subtracting 
the average of negative controls. Protocol was adapted from a literature procedure. 
 
Figure S62. Binding activity of conjugates 31, 35 and Her-DiEt against unmodified 
Herceptin™. 
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Cell internalisation with confocal microscopy 
Cells on cover slips at 70% confluency were incubated with AlexaFluor-488™-conjugated 
constructs at 10 µg/ml for 1 h at 4 °C. Cells were extensively washed with PBS to remove 
unbound antibodies and incubated at 37 °C in growth media. Internalisation was allowed 
for 1 h, followed by extensive washing and fixation with 4% formaldehyde for 10 min at 
4 °C. Cover slips were then blocked with 5% goat serum in 0.3% Triton-X100 (Sigma). 
Actin was detected with phalloidin-568 (Invitrogen) and Hoechst trihydrochloride 
(Invitrogen) was used to stain cell nuclei. Unconjugated antibody was detected using 
Alexa-Fluor-488 Donkey anti-rabbit IgG. Cover slips were mounted on slides using 
ProLong Gold antifade (Invitrogen) and examined using a Zeiss LSM880 Confocal Plus 
microscope. 
  
Figure S63. Cell inernalisation visualised with confocal microscopy of Herceptin™ 
bioconjugates 31 (FAR2) and 35 (FAR4) compared with Herceptin™ positive control. 
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A mild TCEP-based para-azidobenzyl cleavage
strategy to transform reversible cysteine thiol
labelling reagents into irreversible conjugates†
Antoine Maruani, Shamim Alom, Pierre Canavelli, Maximillian T. W. Lee,
Rachel E. Morgan, Vijay Chudasama* and Stephen Caddick
It has recently emerged that the succinimide linkage of a maleimide
thiol addition product is fragile, which is a major issue in fields
where thiol functionalisation needs to be robust. Herein we deliver
a strategy that generates selective cysteine thiol labelling reagents,
which are stable to hydrolysis and thiol exchange.
Advances in proteinmodification by chemical means have led to the
development of a range of protein bioconjugation methodologies.1
These methodologies have been successfully applied to a number of
fields such as the fluorescent tagging of proteins,2 and the develop-
ment of therapeutic protein conjugates3,4 to treat indications such as
HIV,5 cancer,6 and malaria.7 Chemically modified proteins are also
utilised as diagnostics.8
The use of synthetic methodology to modify proteins has to
overcomemanymajor obstacles, the most significant of which is the
need for high selectivity, i.e. modifying only one amino acid type by
discriminating against the other natural amino acids in a protein.9
As free cysteines are extremely rare in proteins10 and the thiol side
chain has the highest nucleophilicity of all proteinogenic groups at
physiological conditions,11 it is a very popular target for the selective
and site-specific modification of proteins.12 Moreover, with the
possibility of facile cysteine introduction by site-directed mutagen-
esis, cysteine modification is a leading approach. The most popular
strategy for labelling the thiol moiety of cysteine residues is by
alkylation with maleimides to form thioether-succinimides.12,13
However, it has recently come to light that such an appendage is
sub-optimal owing to issues of hydrolysis, and thiol exchange with
reactive thiols in the blood (e.g. albumin).14 This has major implica-
tions for biologics that employ a maleimide motif to functionalise a
protein thiol for in vivo applications. For example, in antibody-drug
conjugates (ADCs), where an antibody delivers a toxic payload to
cancerous tissue selectively, the use ofmaleimides to attach cytotoxic
drugs to an antibody is not ideal as thiol exchange onto human
serum albumin in the blood results in oﬀ-site toxicity.14
Although recent advances have been made in this area through
the use of hydrolysedmaleimides and succinimides,14,15 a strong
drive to develop novel reagents for reliable, chemoselective,
stable and irreversible thiol labelling remains, and particularly
for the construction of ADCs.16
Recently, we have described a novel, reversible approach to
cysteine bioconjugation through the use of bromomaleimides
and bromopyridazinediones.17 To date, our approach has provided
access to complex bioconjugates in high yields, without prior
activation of reagents with reliable, reversible conjugation. Owing
to the demand for hydrolytically stable and thiol irreversible
bioconjugates that react in a chemoselective manner, we naturally
sought to explore the use of reagents that wouldmeet these criteria.
During the course of developing bromopyridazinediones for rever-
sible cysteine bioconjugation, we became intrigued by the prospect
of pyridazinediones (PDs) as irreversible cysteine functionalisation
reagents. Previously we have shown that if one of the nitrogen
atoms on the PD core is unsubstituted the molecule does not react
with thiols at physiological pH or higher.17a We postulate that this
is a consequence of such a structure existing as its enol tautomer,
which is likely to be significantly deprotonated under physiological
Fig. 1 A novel strategy for developing thiol-stable pyridazinedione
bioconjugates.
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pH (or higher), based on the reported pKa of 1-methyl-3,6-(1H,2H)-
pyridazinedione being B5.7 in H2O and the calculated pKa of its
thioether analogue,‡ 1-methyl-4-(methylthio)-3,6-(1H,2H)-pyridazine-
dione, being B5.9.18 Thiol reactivity will therefore be greatly
reduced as the electrophilicity of the resulting PD-core moiety
will be tuned down considerably. As such, we set about developing
a strategy where we could generate a mono-alkylated-PD species
post-bioconjugation to a cysteine thiol to aﬀord a thiol stable
construct (see Fig. 1).
Our study began with the reaction of model protein GFP-S147C 1
with pyridazinediones 2 and 3 to confirm our previous observations
when using protein Grb2-L111C (see Fig. 2).17a These results were
consistent with our previous work and confirmed that a mono-
alkylated-PD is unreactive to thiol (or other nucleophilic functional
groups on amino acid side-chains).
These initial studies paved the way for us to appraise the use of a
novel strategy for developing thiol-stable pyridazinedione bioconjugates
(see Fig. 1). To do so, we needed to develop a selective method for
cleavage of R2 from the PD core. There are many strategies that could
be applied, however, at this juncturewe took the opportunity to develop
a novel, mild and simplemethod based on an azide trigger. Our desire
to use an azide-based cleavable handle originates from the bioortho-
gonality of the azide functional group. Taking inspiration from thewell-
documented work on p-aminobenzyloxycarbonyl (PABC) linkers,19 we
set about using a p-azidobenzyl cleavage strategy (see Fig. 3).
We initially evaluated our p-azidobenzyl cleavage strategy in
a small molecule study through the use of cysteine derivative 6,
formed by reaction of N-(tert-butoxycarbonyl)-L-cysteine methyl
ester andmono-bromo PD 5 (see ESI† for details on synthesis). The
use of an alkyne handle, which would conceptually be retained post
p-azidobenzyl cleavage, would allow for the resulting construct
to be readily functionalised by a Cu(I)-catalyzed Azide-Alkyne
Cycloaddition (CuAAC). To our delight, treatment of derivative
6 with TCEP led to clean conversion to derivative 7, thus
providing proof of concept for our novel cleavage strategy.
Moreover, incubation of derivatives 6 and 7 with 15 equivalents
of 1-hexanethiol in THF/PBS buﬀer (pH 7.4) only led to thiol
exchange in the case of derivative 6. This provided encourage-
ment for our hypothesis of a mono-alkylated-PD being thiol
unreactive under physiological pH or higher (Fig. 4).
Following these encouraging results on a small molecule study,
we appraised our strategies on amodel protein with a single cysteine
mutation, GFPS147C 1. Initially, GFPS147C 1 was incubated with
mono-bromo-PD 5 in sodium phosphate buﬀer (pH 8.0) for 1 h at
37 1C. As expected, this proceeded with complete conversion and
aﬀorded GFP-derivative 8. We next applied our TCEP cleavage
strategy, by incubation of this derivative with 10 equivalents of
TCEP in phosphate buﬀer at pH 8.0. Satisfyingly, clean conversion
to bioconjugate 9 was observed, which is consistent with our small
molecule study. It is also noteworthy that no hydrolysis occurred
under these conditions, which is consistent with our previous
observations on the PD core being hydrolytically stable.17a
Fig. 2 Incubation of GFPS147C 1 with pyridazinediones 2 and 3.
Fig. 3 Use of a p-azidobenzyl cleavage strategy to generate a thiol-stable
pyridazinedione bioconjugate.
Fig. 4 Use of TCEP in our p-azidobenzyl cleavage strategy to generate
pyridazinedione derivative 7 from derivative 6, and the thiol stability of
each construct.
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Having established, using mass spectrometry, that our cleavage
strategy is applicable on a protein, we next compared the thiol
stability of 8 and 9 by incubation with glutathione (0.5 mM) for 72 h
at pH 7.4 and 37 1C. Gratifyingly, GFP-derivative 9 was completely
stable under the reaction conditions, whereas derivative 8 showed
complete thiol exchange with glutathione. This therefore established
proof of concept for both our strategies on a model protein scaﬀold.
Moreover, this work also highlights the versatility of the PD platform
with a facile shift from reversible to irreversible constructs achieved
under mild conditions (Fig. 5).
Following our work on developing a novel p-azidobenzyl
cleavage strategy and obtaining a thiol stabile construct, we set
about functionalising protein scaﬀold 9 by the use of ‘click’
chemistry. If successful, this would result in a facile method for
functionalising the thiol-stable bioconjugate. A number of ‘click’
conditions were trialled using benzyl azide as our model azide.
The most promising conditions were the use of Cu(I)Br as copper
source and THPTA as ligand. These conditions gave complete
conversion of starting material alkyne 9 to triazole bioconjugate
10a. Moreover, these conditions also allowed for clean reaction
of the alkyne derivative with a dansyl azide and a sulfo-cyanine5
azide to aﬀord 10b and 10c, respectively (Fig. 6).
In conclusion, we have developed, via a novel p-azidobenzyl
cleavage strategy, a route to thiol stable cysteine-bioconjugates that
has a clear advantage over conventional maleimide chemistry.
The strategy has been demonstrated on both a small molecule
system and on a model protein, GFPS147C. Owing to the plethora
of fields where thiol functionalisation needs to be robust and
irreversible, e.g. in antibody-drug conjugates (ADCs), imaging and
theranostics, we believe this work will find use in a variety of
domains. We hope to deliver on the application of our platform
in a range of contexts, including ADCs, in the near future.
The authors gratefully acknowledge the EPSRC, Ramsay
Memorial Trust and UCL for support of our programme.
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functional re-bridging all in one†
Maximillian T. W. Lee, Antoine Maruani, James R. Baker, Stephen Caddick
and Vijay Chudasama*
Herein we present a signiﬁcant step towards next-generation disulﬁde stapling reagents. A novel class of
reagent has been designed to eﬀect both disulﬁde reduction and functional re-bridging. The strategy has
been applied to great success across various peptides and proteins. Moreover, application to a multi-
disulﬁde system resulted in functional re-bridging without disulﬁde scrambling.Advances in protein modication by chemical means have led
to the development of a range of protein bioconjugation
methodologies.1 These methodologies have been successfully
applied to a number of elds such as the uorescent tagging of
proteins,2 the development of therapeutic protein conjugates3,4
to treat indications such as HIV,5 cancer6 and malaria,7 and for
use as diagnostic tools.8
Whilst a large number of reagents and protocols have been
developed to modify proteins, novel strategies for site-specic
conjugation continue to attract considerable interest in view of
the increasingly stringent requirements in the development of
biologics.1 Several amino acid side-chains have been targeted
for site-selective modication over the past few decades, e.g.
tryptophan, histidine, tyrosine and, in particular, lysine and
cysteine. However, the modication of native disuldes through
functional re-bridging, pioneered by Brocchini et al., has
attracted signicant interest in recent years with various
approaches being developed.9–13
Recently, Chudasama, Caddick et al. have shown dibromo-
pyridazinediones to be viable candidates for disulde stapling
and that the resulting bisthioether is stable in blood plasma-
mimicking conditions.9j Whilst this approach, as well as others,
oﬀer advances in this growing eld of disulde labelling, a
common limitation is the requirement for reduction and re-
bridging in distinct steps. This is mainly due to the incompat-
ibility of the bridging and reducing agents. This introduces
ineﬃciencies in terms of cost, time and practicality. Whilst one-
pot in situ methods have been employed, this is only at the
expense of using a vast excess of reducing and bridging agents
to compensate for the reaction between the two reagents.9jge London, 20 Gordon Street, London,
asama@ucl.ac.uk; Tel: +44207 679 2077
ESI) available: 1H and 13C NMR spectra
GE gels and UV-Vis analysis (where
: 10.1039/c5sc02666k
hemistry 2016In view of the above, we set about designing a reagent that
could incorporate both reducing and re-bridging functions
(Fig. 1). During the course of our previous studies, we observed
dithiophenolpyridazinediones to be unreactive towards
commonly used disulde reducing agent tris(2-carboxyethyl)
phosphine (TCEP). In light of this, TCEP moieties were a logical
choice for incorporation into a dithiophenolpyridazinedione.
More specically, the TCEP functional moieties were to be
tethered onto the thiophenol groups of the dithiophenolpyr-
idazinedione since these groups would be extruded post-bio-
conjugation with a reduced disulde.
A suitable route to a dithioaryl(TCEP)pyridazinedione was
conceived (Scheme 1). Initially, TFA cleavage of the Boc groups
of di-Boc-diethylhydrazine 1, followed by reaction with dibro-
momaleic anhydride under reux in AcOH, aﬀorded diethyl
dibromopyridazinedione 2. This dibromopyridazinedione was
reacted with 4-aminothiophenol to form dithioarylpyr-
idazinedione 3, which was nally coupled to mono-acid TCEP
derivative 4 to form target dithioaryl(TCEP)pyridazinedione 5.
With dithioaryl(TCEP)pyridazinedione 5 in hand, we
appraised its suitability as a bioconjugation reagent for both
disulde reduction and functional re-bridging. To do this,Fig. 1 Illustration highlighting previous strategies towards disulﬁde
stapling and the novel strategy described in this manuscript.
Chem. Sci., 2016, 7, 799–802 | 799
Scheme 1 Synthesis of dithioaryl(TCEP)pyridazinedione 5. Reagents
and conditions: (i) TFA, CH2Cl2, 21 C, 1 h; (ii) dibromomaleic anhy-
dride, AcOH, reﬂux, 2 h; (iii) 4-aminothiophenol, NEt3, CH2Cl2, 21 C,
2 h; (iv) acid 4, DMF, HATU, DIPEA, 21 C, 12 h.
Scheme 3 Pre-incubation of Fab fragment of Herceptin™ with pyr-
idazinedione 6, followed by addition of 5 aﬀords product derived from
reagent 5 only.
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View Article Onlinepyridazinedione 5 was incubated with a selection of biologically
relevant disulde containing peptides and proteins, i.e.
somatostatin, octreotide and a Fab (fragment antigen-binding)
arm of Herceptin™. To our delight, in each and every case,
pyridazinedione 5 was shown to reduce and functionally re-
bridge the singly accessible disulde (see Scheme 2 and ESI for
further details†). Moreover, only a small excess of “2-in-1”
reagent 5, 1.25 equivalents, was required to eﬀect complete
conversion. Another favourable property of pyridazinedione 5 is
that it is a solid which can be stored with complete stability over
a protracted period at 18 C under argon.
At this stage we rationalised that a molecule with both
reducing and re-bridging functions would minimise the resi-
dency time of the cysteines liberated from disulde reduction.
This is especially in view of no reduced protein being observed
upon incubation of the above peptides and proteins with
reagent 5 (see ESI for details†). To appraise this further, we
incubated the Fab fragment of Herceptin™ with 1, 2 and 5
equivalents of dipropyl-pyridazinedione 6 prior to incubation
with 2 equivalents of diethylpyridazinedione 5 (Scheme 3).
Validating our hypothesis, re-bridging was only observed with
the TCEP-bearing diethylpyridazinedione. The control reaction
of reducing the Fab prior to adding a mixture ofScheme 2 Functionally re-bridged somatostatin, octreotide and a Fab
of Herceptin™ using dithioaryl(TCEP)pyridazinedione 5.
800 | Chem. Sci., 2016, 7, 799–802pyridazinedione 5 and 6 aﬀorded a mixture of bioconjugates
(see ESI for details†).
With the knowledge of the use of dithioaryl(TCEP)pyr-
idazinedione 5 resulting in a high local concentration of the
specic pyridazinedione incorporated into the “2-in-1” scaﬀold,
we appraised the use of the reagent in the context of a multi-
disulde system. To do this, we chose to use Herceptin™ – an
antibody comprising four disulde bonds – whose disulde
bonds can be scrambled on attempted functional disulde re-
bridging.9h Although this scrambling can be minimised, the
leading strategy is reagent specic.9j We rationalised that the
use of pyridazinedione 5 would ensure minimisation ofFig. 2 Appraisal of the use of pyridazinediones 3 (in situ 4 C (pre-
reduced, portion-wise reduction), 37 C) and 5 for functional re-
bridging of Herceptin™.
This journal is © The Royal Society of Chemistry 2016
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View Article Onlinedisulde scrambling in a general sense. To this end, pyr-
idazinediones 3 (with no internal reducing agent function) and
5 (with reducing agent function) were reacted with Herceptin™
under the appropriate reaction conditions, i.e. reaction with
pyridazinedione 3 required reduction of Herceptin™ with
TCEP. Gratifyingly, no disulde scrambling was observed by
SDS-PAGE for reagent 5, with complete re-bridging of all
disuldes conrmed by UV-Vis (Fig. 2, lane 4). Analogous
reagent 3, with no inherent reducing capability, aﬀorded a
disulde scrambled product (Fig. 2, lane 2). Even when dithio-
pyridazinedione 3 was used in excess and TCEP was added in
small portions multiple times (6 0.33 eq per disulde every 30
min), i.e. to minimise the number of open disuldes at any
given time, disulde scrambling was still observed (Fig. 2, lane
3). Although scrambling was far less pronounced, the reaction
protocol is highly cumbersome and ineﬃcient. Reaction of
dithiopyridazinedione 3 at 37 C also aﬀorded a mixture of
products (Fig. 2, lane 5). Furthermore, reaction of pyr-
idazinedione 2 at 4 C and 37 C also aﬀorded a mixture of
correctly and incorrectly re-bridged modied Herceptin™
conjugates (see ESI for details†).
Providing a reagent that can functionally re-bridge the
disulde bonds of Herceptin™ without disulde scrambling is
a major contribution in view of the desire to create homogenous
conjugates in the eld of antibody–drug conjugates.14 Use ofScheme 4 Application of alkyne bearing pyridazinedione 7 for disul-
ﬁde reduction and re-bridging as well as “click” functionalisation of the
product with various azides to form bioconjugates 9a–c.
This journal is © The Royal Society of Chemistry 2016Herceptin™, in view of its clinical validation alone and as the
antibody component of FDA-approved ADC Kadcyla™,15
provides direct applicability of the chemistry to this exciting
area of targeted therapy.
To make this approach modular and expand its scope, we
synthesised an analogue of pyridazinedione 5, which contained
an alkyne handle for “click” functionalisation, in alkyne-pyr-
idazinedione 7 (see Scheme 4). An analogous route to that
described in Scheme 1 was followed (see ESI for further
details†). The appraisal of this molecule was carried on the Fab
fragment of Herceptin™ as this would allow extensive analysis
by UV-Vis, MS, SDS-PAGE and ELISA (for binding). The opti-
mised conditions for the insertion of dithioaryl(TCEP)pyr-
idazinedione 5, was applied to the alkyne bearing analogue for
the functional re-bridging of the Fab fragment of Herceptin™
to form conjugate 8. The eﬃciency of reduction and re-bridging
was translated cleanly from reagent 5 to alkyne analogue 7 by
MS, SDS-PAGE and UV-Vis (see Scheme 4 and ESI for further
details†).
Finally, conjugate 8 was functionalised by “click” modica-
tion using doxorubicin, AlexaFluor488™ and sulfo-cyanine5
azides (see Scheme 4). In all cases, complete conversion was
observed to aﬀord functionalised conjugates 9a–c, thus
demonstrating how the platform may be used for eﬃcient
introduction of functional modalities as well as reduction and
re-bridging. Moreover, the binding of the Fab protein was not
compromised, by ELISA analysis (see ESI for details†), through
the chemistry applied. Pyridazinedione 7 was also shown to
successfully re-bridge the full antibody system of Herceptin™
and be amenable to “click” functionalisation with doxorubicin
azide (see ESI for details†).Conclusions
In conclusion, we have provided an important step towards
delivering on next-generation disulde stapling. This rst-in
class technology allows for reduction and functional re-bridging
by the use of a single reagent. Moreover, this strategy has been
shown to result in a high local concentration of bridging agent,
which has been exploited for the functional re-bridging of a
multi-disulde system (i.e. Herceptin™) without disulde
scrambling. Finally, facile “click” functionalisation and reten-
tion of binding aﬃnity, using our strategy, has been demon-
strated on a Fab of Herceptin™.Acknowledgements
The authors gratefully acknowledge the EPSRC and UCL for
funding. MTWL and AM funded by EPSRC (164255). VC funded
by UCL Excellence Fellowship.Notes and references
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conjugates with a loading of two modules without
antibody engineering†
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Stephen Caddick and Vijay Chudasama*
The generation of antibody conjugates with a loading of two modules is desirable for a host of reasons.
Whilst certain antibody engineering approaches have been useful in the preparation of such constructs,
a reliable method based on a native antibody scaﬀold without the use of enzymes or harsh oxidative
conditions has hitherto not been achieved. The use of native antibodies has several advantages in terms
of cost, practicality, accessibility, time and overall eﬃciency. Herein we present a novel, reliable method
of furnishing antibody conjugates with a loading of two modules starting from a native antibody scaﬀold.Antibody conjugates play an important role in a variety of
applications, particularly in the eld of diagnostics and
therapeutics.1,2 In recent years, there has been signicant
interest in the area of antibody-drug conjugates (ADCs).2 ADCs
comprise antibodies covalently attached to highly potent drugs
using a linker conjugation technology.2 As therapeutics, they
conceptually combine the specicity of antibodies, i.e. enabling
discrimination between healthy and diseased tissue, with the
cell-killing ability of cytotoxic drugs. This powerful and exciting
class of targeted therapy has shown considerable promise
in the treatment of various cancers with two US Food and
Drug Administration approved ADCs currently on the market
(Adcetris™ and Kadcyla™)3,4 and approximately 40 currently
undergoing clinical evaluation.5 However, most of these ADCs
exist as heterogeneous mixtures, which can result in a narrow
therapeutic window and have major pharmacokinetic implica-
tions.2,6 In order for ADCs to achieve their full potential,
sophisticated site-specic conjugation technologies to connect
the drug to the antibody are increasingly being developed.2
Whilst a large number of reagents and strategies have been
developed to create these next generation ADCs, novel strategies
for site-specic conjugation continue to attract considerable
interest.2 This is especially important as it is coming to light that
specic requirements are essential for each particular ADC to
operate at its optimum.2 Whilst engineered antibodies have
worked well in meeting the demand for these tailor-made anti-
body conjugates, e.g. by using engineered cysteine residues,
unnatural amino acids, selenocysteine or enzymatic conjugation,7ge London, 20 Gordon Street, London,
c.uk; Tel: +44 (0)207 679 2077
ESI) available: 1H and 13C NMR spectra
GE gels and UV-vis analysis (where
: 10.1039/c6sc03655dthere is a requirement for methods that are based on native
antibody modication. This is to ensure that technologies to
make these “designer” ADCs are more accessible and cost-eﬀec-
tive; engineered approaches oen require signicant optimisa-
tion on each antibody scaﬀold they are applied, as well not being
accessible to a broad range of scientists.
It has recently come to light that in various tailor-made ADCs
one of the most desirable ratios of drugs to antibody is two. The
reason for this is that for certain hydrophobic drugs, e.g. pyr-
rolobenzodiazepines (PBDs), a loading of two is preferable as it
provides a good balance between eﬃcacy and pharmacokinetic
prole (higher payload loading tends to result in too rapid
clearance and lower loadings reduce eﬃcacy). This argument is
supported by the PBD-based ADCs that are currently in clinical
trials.2,8 Whilst this particular challenge has to some extent
been addressed by antibody engineering approaches, e.g. THI-
OMAbs for homogeneous DAR 2 conjugates, they are not readily
accessible and there are issues associated with the methodology
(e.g. potential for disulde scrambling and the ineﬃciency of
having to reduce, carefully re-oxidise and then conjugate).2
Thus, there is a need for a reliable method of constructing
antibody conjugates with a loading of two entities starting from
a native antibody construct. This is especially in the context of:
(i) the rapid progression in the development of further hydro-
phobic drugs being used and developed in the eld;8a,b,9 and
(ii) the major attempts on native antibodies (i.e. based on the
selective reduction of the Fab or hinge disuldes of an IgG1)10g,11
proving to lack broad applicability, as evidenced by the lack of
uptake in the eld, or having to employ harsh oxidation
conditions or enzymes under specic conditions.12 Herein we
detail the realisation of a reliable and reproducible strategy
to make antibody conjugates with a loading of two starting
from a native scaﬀold. It has signicant advantages in terms ofThis journal is © The Royal Society of Chemistry 2017
Fig. 1 Illustration detailing the typical approach to functional disulﬁde
re-bridging conjugates.
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View Article Onlinecost, practicality, accessibility, time and overall eﬃciency when
compared to existing methods.
Recently, we have shown dibromopyridazinediones
(diBrPDs) and dibromo/dithio-maleimides to be excellent
candidates for the functional re-bridging of inter-chain disul-
des in antibodies (Fig. 1). Moreover, the resulting bisthioether
conjugates have been shown to be stable in blood plasma-
mimicking conditions and retain activity plus selectivity in
vitro.10 The dibromomaleimide platform has also been shown to
be eﬀective in vivo by Jackson and co-workers.13 Whilst this
approach, as well as others,10,13,14 oﬀer advances in terms of
providing homogeneous DAR 4 conjugates starting from a non-
engineered antibody scaﬀold, there has as yet been no trans-
lation of the technologies to form controlled DAR 2 conjugates.
Nonetheless, we set out to explore if we could exploit the eﬃ-
cient functional re-bridging of disuldes with diBrPDs as
a conduit to realise the goal of controlled DAR 2 conjugate
formation starting from a native antibody scaﬀold. We envis-
aged that conjugation of two bis-dibromopyridazinediones
(containing a single functional modality) with an appropriate
linker length could “tie up” two pairs of the 4 disuldes on an
IgG1 to allow the formation of a conjugate with an overall
loading of two functional modules (see Fig. 2).
Our study began with the synthesis of an appropriate spaced
bis-dibromopyridazinedione, bis-diBrPD 1. As we were aiming
to react a pair of disuldes using bis-diBrPD 1 it was rational-
ised from the outset that the linker length would be key. If too
short, the bis-PD could not react with a pair of disuldes as it
could not span the appropriate length; too long and it wouldFig. 2 Illustration detailing a novel approach to achieving antibody
conjugate with a loading of two. Each pair of red and purple stars per
linker molecule are independently interchangeable, and other disulﬁde
pairs (e.g. Fab–Fab, hinge–hinge) may be functionally re-bridged.
This journal is © The Royal Society of Chemistry 2017increase the likelihood of undesirable intermolecular reac-
tion(s) by losing the high local concentration eﬀect – thus
resulting in ineﬃcient bridging of bis-diBrPD 1 across a pair of
disuldes. In an eﬀort to avoid these issues we designed a linker
based on the spacing of the disuldes on an IgG1 for which
a crystal structure has been obtained (16.7 A˚ ¼ maximum
linear distance).14,‡ To ensure exibility, and improve water
solubility of the bis-dibromopyridazinedione, a PEG spacer
was used to link together the PD bioconjugation sites. We
installed a single alkyne on the bis-PD scaﬀold so as to even-
tually allow a loading of two modules, through the use of click
chemistry, post-conjugation of bis-diBrPD 1 on a full antibody.
The click handle was also positioned by design to be close to
a PD-disulde bridging site to minimise exposure of the clicked
entity.
Compound 1 was synthesised by the route described in
Scheme 1; in view of the maximum linear distance between
inter-chain disuldes being 16.7 A˚ in the crystal structure of
the IgG1, 25 A˚ was anticipated to be a suitable separation
between the bridging sites when taking into account the reso-
lution of the measurement,15 the exibility of this region of the
antibody and the PEG chain not being structurally linear.
Initially, protected hydrazine 2 was formed via alkylation of
diboc-hydrazine (see ESI for further details†). This species was
then deprotected using TFA, and reacted with dibromomaleic
anhydride under reux in AcOH to aﬀord methyl-PD 3. Amide
coupling of this PD with a mono-boc protected bis-amine
resulted in the formation of PD linker reagent 4. Finally, this
species was deprotected and reacted with alkyne-PD 6 (prepared
in an analogous manner to methyl-PD 3) to aﬀord target
compound bis-diBrPD 1. Whilst the overall yield for theScheme 1 Synthesis of bis-diBrPD 1. Reagents and conditions: (i) TFA,
CH2Cl2, 21 C, 1 h; dibromomaleic anhydride, AcOH, reﬂux, 2 h; (ii)
tert-butyl (3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)carba-
mate, CDI, DMF, 21 C, 12 h; (iii) TFA/DCM, 21 C, 30 min; (iv) HATU,
DIPEA, DMF, acid-alkyne PD 6 21 C, 16 h.
Chem. Sci., 2017, 8, 2056–2060 | 2057
Fig. 3 Illustration of bis-diBrPD her conjugate 7. Each pair of red and
purple stars per linker molecule are independently interchangeable,
and other disulﬁde pairs (e.g. Fab–Fab, hinge–hinge) may be func-
tionally re-bridged.
Fig. 4 Structure of conjugate 8 (each pair of green and purple stars
per linker molecule are independently interchangeable, and other
disulﬁde pairs (e.g. Fab–Fab, hinge–hinge) may be functionally re-
bridged); ELISA and SDS-PAGE gel (M: molecular weight marker; 1:
native Herceptin™; 2: conjugate 8) of conjugate 8 with native
Herceptin™ control.
Scheme 2 Synthesis of bis-diBrPD 9.
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View Article Onlinesynthesis was low (<5%) we do highlight that the chemistry is
straightforward to carry out and that none of the steps were
optimised as we were more interested in exploring the novel
chemical biology methodology.
Following the successful synthesis, the conjugation of 1 on
a full antibody was appraised on Herceptin™, a clinically
improved immunoglobulin used for the treatment of breast
cancer and the antibody component of FDA-approved ADC
Kadcyla™.4 On account of pyridazinediones having a signi-
cant extinction coeﬃcient at a distinct wavelength to other
entities in the corresponding antibody conjugate, UV-vis was
considered to be an appropriate method to analyse PD loading
on the antibody. To our delight, aer minimal optimisation,
reaction of Herceptin™ with bis-diBrPD 1 gave a pyr-
idazinedione-to-antibody ratio (PDAR) of 4.0 with complete
functional re-bridging conrmed by SDS-PAGE (including
under TCEP reducing conditions). This result supported our
hypothesis, as it suggested each bis-diBrPD had re-bridged two
disuldes; i.e. only such a result could have yielded the observed
SDS-PAGE prole and PDAR. Despite the challenges of using
mass spec for characterisation of antibody conjugates,16 espe-
cially for disulde modied conjugates,13 we obtained mass
spec data for conjugate 7 (see ESI for details†), which further
veried our observation; i.e. we observed two additions of bis-
diBrPD 1 to Herceptin™ (see representation in Fig. 3).
With conjugate 7 in hand, we next appraised what the
loading would be if we were to click on a uorophore-azide.
Owing to its favourable optical properties and our previous
experience with the azide,10i we chose to click on Alexa Fluor®
488 azide. To ensure that all available pendant alkynes on
conjugate 7 would be reacted, an excess of Alexa Fluor® 488
azide was used in the click reaction (20 eq.). Gratifyingly, these
conditions resulted in the formation of a conjugate where the
loading of the Alexa Fluor® 488 dye on the antibody conjugate
was 2.0. Furthermore, the result was highly reproducible with
the click reaction not aﬀecting PDAR or promoting antibody
degradation by SDS-PAGE. In addition to this, pre-click modi-
cation (i.e. carrying out the click reaction prior to bio-
conjugation) aﬀorded similar results (see ESI for details†).
It is also noteworthy that the nal conjugate retained
binding activity by ELISA (Fig. 4), even when compared to2058 | Chem. Sci., 2017, 8, 2056–2060classical diBrPD conjugation (see ESI for details†).10c,iMore than
this, the reactions were highly reproducible, with as many as
seven attempts showing PDARs in the range of 3.9–4.1 and Alexa
Fluor® 488 loadings in the range of 1.9–2.1. Finally, an ADC with
a DAR of 2.0, based on the “click” conjugation of an azide
functionalised doxorubicin10i to conjugate 7, was prepared in
a facile manner owing to the modular nature of the chemistry.
These results thus provide the rst examples of forming
a conjugate with a controlled loading of 2.0 on a native antibody
scaﬀold in a facile and reliable manner.
Not content with providing conjugates with a controlled
loading of two modules, we next turned our attention to the
synthesis of an antibody conjugate with a loading of four to
showcase the exibility of our strategy. This would also serve as
further proof of our disulde pair functional re-bridging
hypothesis as well as provide a novel conjugation strategy for
making antibody conjugates with a loading of four. To this end,This journal is © The Royal Society of Chemistry 2017
Fig. 5 Structure of conjugate 10 (other disulﬁde pairs (e.g. Fab–Fab,
hinge–hinge) may be functionally re-bridged); ELISA and SDS-PAGE
gel (M: molecular weight marker; 1: native Herceptin™; 2: conjugate
10) of conjugate 10 with native Herceptin™ control.
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View Article Onlinewe synthesised bis-diBrPD 9 in a similar manner to which bis-
diBrPD 1 was formed (see Scheme 2).
Pleasingly, application of the optimised conditions for
functional re-bridging, in the formation conjugate 7, to reagent
9 on Herceptin™ aﬀorded a conjugate with a PDAR 3.9 with all
disuldes of the antibody functionalised (Fig. 5, see ESI for
further details†). Moreover, reaction with an excess of Alexa
Fluor® 488 azide resulted in a uorophore loading of 3.9 (Fig. 5,
see ESI for details†). This, in combination with the SDS-PAGE
data, further veries the bridging mode of these rst-in-class
reagents, and ELISA data again showed binding to be unaf-
fected by the strategy. Moreover, it showcases how this novel
class of reagent can act as a branch point for the construction of
antibody conjugates with distinct and controlled module load-
ings of two and four.Conclusions
In conclusion, we have provided a rst-in-class strategy for
enabling the controlled, reproducible loading of two modules
onto a native antibody scaﬀold. This was enabled by the
successful synthesis and application of an entity, containing
one “click” handle, which functionally re-bridges two pairs of
disulde bonds on an IgG1. Subsequent reaction of the formed
conjugate with an azide-uorophore and azide-drug showed
that the controlled loading of two modules was feasible and
reproducible. The strategy, starting from the same branch
point, was also readily adapted for the formation of a conjugate
with a loading of four modules. Furthermore, all nal conju-
gates were shown to retain binding by ELISA and antibody-PD
conjugates have previously been shown to be biologically
functional and stable.10i–k We believe this simple yet elegantThis journal is © The Royal Society of Chemistry 2017approach to facilitate the loading of two modules starting from
a native antibody scaﬀold will nd application in multiple elds
where the controlled loading of lower than four entities is
desirable (e.g. antibody conjugates bearing highly hydrophobic
modules) and especially in laboratories where antibody engi-
neering techniques are not accessible, too expensive or not
practical.
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